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Abstract 
Colorectal cancer (CRC) screening aims to reduce mortality by detecting cancer at an earlier 
stage. The National Health Service Bowel Cancer Screening Programme (BCSP) offers faecal 
occult blood screening followed, in positive cases, by colonoscopy to screen for CRC. 
Participants diagnosed with colorectal adenomas then undergo surveillance according to 
the British Society of Gastroenterology guidelines. 
 
Data obtained from the BCSP database from June 2006 to June 2012 were studied to 
evaluate the magnitude of the detection of advanced neoplasia, and identify the predictive 
factors that influence the presence of carcinoma in adenomas and the proportions of 
advanced neoplasia detected in different segments of the colon. The outcome of first 
surveillance procedures was evaluated to assess the validity of the current risk stratification 
guidelines for BCSP participants. The appropriateness and safety of the time interval used in 
surveillance for high- (HR) and intermediate-risk (IR) groups were analysed. 
 
The majority of adenomas (59.75%) detected in the BCSP were non-advanced adenomas 
(NAAs). Advanced neoplastic features were more prevalent in larger adenomas. Increasing 
size and distal location were significantly associated with the presence of carcinoma in 
adenomas. The current surveillance strategy is effective in risk-stratifying BCSP participants 
as the HR group had a significantly higher proportion of adenomas (60.24 vs. 40.14%; 
P<0.001) at first surveillance; the majority of the IR group did not have any colorectal 
neoplasia at first surveillance compared to the HR group (59.98 vs. 39.06%; P<0.001). The 
proportion of HR participants who had their surveillance after one and half years instead of 
one year, did not demonstrate any increased likelihood of advanced colorectal neoplasia. 
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Adenoma size and segmental location were the important factors associated with the 
presence of advanced neoplasia in adenomas. The current guidelines are effective in risk-
stratifying BCSP participants; however, the surveillance interval can be safely prolonged for 
HR and IR patients. 
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Chapter 1: Introduction 
Colorectal cancer (CRC) is the fourth most common cancer and second most common 
cause of cancer-related mortality in men and women in the United Kingdom (UK) [1]. The 
disease causes significant impact and burden on society due to its high mortality and 
morbidity. The disability-adjusted life years (the number of years lost due to ill-health, 
disability or early death) related to CRC are significant. In England and Wales, 8 605 362 
disability-adjusted life years were lost in the period from 2002 to 2006 due to all cancers, 
and CRC ranked as the third major cause among men and women in this league table [2], 
demonstrating the disease burden on the population . 
If CRC is diagnosed early, mortality and morbidity can be prevented with curative surgical 
resection, when the tumour is still confined to the bowel [3–5]. Various population-based 
screening programmes have been developed to identify CRC at its earlier stages; they have 
shown a reduction in mortality from CRC because curative surgery is offered following early 
detection [5, 6].  
The majority of CRCs develop from pre-cancerous adenomas. The progression from 
adenoma to early invasive cancer takes years and this time window provides an 
opportunity to detect pre-cancerous adenomas along with early CRC at screening [7, 8]. In 
fact, a colorectal adenoma is the most common neoplasm found during CRC screening [9]. 
Detection and removal of adenomas reduce future incidence and therefore CRC mortality 
[10]. Individuals with adenomas are at increased risk of developing metachronous 
colorectal neoplasia compared to individuals without adenomas; therefore, they require 
surveillance colonoscopy after initial detection and removal of adenomas. 
18 
 
A successful population-based screening programme for CRC should therefore have a 
strategy and framework to deliver a widespread, population-based surveillance programme 
for patients with colorectal adenomas detected at screening. 
Delivering an effective adenoma surveillance programme needs an appropriate, safe and 
cost-effective use of colonoscopic examination, a resource-intensive and invasive 
procedure, to be performed in such a way that patients with the highest risk of developing 
advanced colorectal neoplasia (ACN) (>=1 cm or HGD)  would benefit the most. Such 
surveillance programmes in turn require a skilled endoscopic workforce, a well-organized 
service framework and a valid and effective risk stratification strategy that could identify a 
cohort of patients with colorectal adenomas at the highest risk of developing future ACN. 
These concepts led to the development of population-based screening programmes and 
guidelines for adenoma surveillance. Depending on the resources available, various 
invasive and non-invasive modalities were adopted as screening tools in different parts of 
the world [7], and national and international guidelines for adenoma surveillance were 
created. 
In England and Wales, the National Health Service (NHS) Bowel Cancer Screening 
Programme (BCSP) was launched in 2006. The screening tool chosen for bowel cancer 
screening was the faecal occult blood test (FOBT), which had been validated in a prior 
randomized controlled trial (RCT) [11] and was also shown to be cost-effective [12] in the 
NHS setting. In the BCSP, patients who have a positive FOBT test and then agree undergo a 
screening colonoscopy. Those who are diagnosed with CRC are referred for treatment; 
patients with colorectal adenomas take part in a subsequent colonoscopy-based adenoma 
surveillance programme after adenoma removal at the screening colonoscopy. 
19 
 
The surveillance guidelines for colorectal adenomas after polypectomy were published by 
the British Society of Gastroenterology (BSG) in 2002 and then updated in 2010 [13, 14] 
(Figure 1.1); they provide the framework for surveillance in the BCSP. Patients are stratified 
into different risk groups according to their increasing likelihood of developing 
metachronous ACN depending on the number and size of the adenomas found during the 
screening colonoscopy and therefore undergo surveillance colonoscopy at different 
intervals. The three risk groups are low (LR), intermediate (IR) and high (HR); they undergo 
their first surveillance colonoscopy after one, three and five years after screening, 
respectively. In the BCSP, the LR group undergoes a biennial FOBT test rather than a 
surveillance colonoscopy every five years. 
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Figure 1.1 Adapted from the BSG adenoma surveillance guidelines. 
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The available evidence behind the current BSG surveillance guidelines was derived from 
RCTs and cohort studies. The study population in these studies consisted of individuals with 
an average risk of having colorectal neoplasia; the colonoscopies were performed by 
independent practitioners in a hospital-based setting, but were not performed within the 
setting of a screening service. 
The overall picture of the adenoma surveillance guidelines loses its uniformity if we 
consider guidance followed in Europe and in the USA also derived from population-based 
studies; yet, UK guidelines differ from those adopted in Europe and the USA, and there is 
heterogeneity among risk stratifications strategies and surveillance intervals among 
English, European and American guidelines. 
The American Gastroenterology Association (AGA) guidelines stratify patients to undergo 
surveillance colonoscopies at four different time intervals according to the number and size 
of adenomas; they also consider the presence of sessile serrated polyps, villous adenomas 
and high-grade dysplasia (HGD) as determinants of risk stratification. The surveillance 
interval varies from 1 to 10 years according to baseline risk at screening [9]. The AGA 
guidelines are summarized in Table 1.1. 
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Table 1.1 Outline of the AGA guidelines 
Baseline colonoscopy: most advanced findings Surveillance 
interval (years) 
No polyps/small (<10-mm) hyperplastic polyps in rectum/sigmoid 
colon 
10 
1–2 (<10-mm) tubular adenomas (TAs) 5–10 
3–10 TAs; one or more TAs ≥10 mm; one or more villous 
adenomas; adenomas with HGD; sessile serrated 
polyp(s) ≥10 mm/sessile serrated polyp(s) with 
dysplasia/traditional serrated adenoma 
3 
>10-mm adenomas <3 
Serrated polyposis syndrome 1 
Note: AGA = American Gastroenterology Association; HGD = high-grade dysplasia. 
The European guidelines for CRC screening and adenoma surveillance were first published 
in 2010. They stratified patients into three different risk categories and considered villous 
adenomas and HGD along with the number and size of adenomas  
as determinant factors for risk stratification [15]. The guidelines recommended surveillance 
colonoscopy to be performed at three different intervals for LR, IR and HR groups. The 
recommendations are outlined in Figure 1.2. 
23 
 
 
Figure 1.2 Adapted from the 2010 European guidelines for CRC screening and 
surveillance. 
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The European post-polypectomy surveillance guidelines published in 2013 (Figure 1.3) take 
into account the value of high-quality colonoscopy, stratify patients into HR and LR groups 
and recommend first surveillance at the third and 10th year, respectively. The guidelines 
also identify villous adenomas and HGD as high-risk features [16]. The high-quality 
colonoscopy outlined in the European guidelines was defined as ‘complete colonoscopy 
with a meticulous inspection of adequately cleaned colorectal mucosa. Neoplastic lesions 
have also been completely removed and retrieved for histological examination’ [16]. 
 
Figure 1.3 Adapted from the ESGE 2013 post-polypectomy surveillance guidelines. 
Note: ESGE = European Society of Gastrointestinal Endoscopy. 
In my personal journey as a trainee gastroenterologist, I came across the BSG guidelines 
while performing procedures in patients with colorectal adenomas. With the 
commencement of the BCSP, I was intrigued to find out that the BCSP adopted population-
based adenoma surveillance; patients were different from the general population, and only 
colonoscopists accredited to perform a screening colonoscopy performed the procedures. 
The screened population consists of men and women aged 60–74 years of age who have a 
positive FOBT test; they do not represent a population at an average risk of having 
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colorectal neoplasia. The prevalence of CRC and colorectal adenomas is much higher in this 
FOBT-positive cohort compared to the general population. 
The colonoscopies performed in the BCSP are high-quality colonoscopies. The procedures 
are performed in screening centres accredited by the Joint Advisory Group on GI 
Endoscopy (JAG); the endoscopists involved are certified through an accreditation process 
and have to demonstrate achievement of a certain pre-defined practice standard (that is, 
completion rate and adenoma detection, which are performance indicators for a 
colonoscopist) in their own colonoscopy practice. Once accredited, they undergo an 
ongoing performance audit and quality assurance checks during their participation in the 
BCSP. 
With the evolving European adenoma surveillance guidelines against the backdrop of high-
quality colonoscopy, it seems clear that the adenoma surveillance interval could be safely 
prolonged and this could prove to be more cost-effective.  
Since a population-based risk stratification strategy is currently being used in the BCSP for 
FOBT-positive patients of a defined age group, it is essential to examine the outcome of 
adenoma surveillance in the BCSP, evaluate the appropriateness and validity of the current  
screening strategy for the FOBT population and also assess whether the surveillance 
interval could be increased. Since various determinant factors were used in the different 
guidelines, the important factors that could predict clinical outcomes in a screened 
population need to be identified. 
This thesis provided the opportunity to examine the outcomes of adenoma surveillance in 
the BCSP and also evaluate a valid design for risk stratification. 
The current chapter provides the general background and explains the purpose of the 
study. Chapter 2 describes the current evidence from the literature relevant to this work 
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and Chapter 3 describes the methodology followed. The aims and objectives of the study 
are described in Chapter 4. 
The results of the study are discussed in Chapters 5, 6 and 7 with the specific relevant 
discussions integrated in each chapter. 
Chapter 5 examines all the colorectal adenoma data identified in the BCSP at screening and 
surveillance; it also evaluates and determines the distributions of advanced histological 
features in the different size categories, important predictor factors that determine the 
presence of carcinoma in adenomas, and the differences between proximal and distal 
adenomas. The distribution of ACN in different bowel segments is estimated and the 
importance of location in determining the presence of ACN in adenomas is determined. 
Chapter 6 evaluates the outcome of continuous surveillance of IR and HR groups over the 
six-year study period and evaluates whether the current BSG guidelines are effective in 
stratifying the screened population depending on the surveillance outcomes. It also 
highlights that, within the setting of high-quality colonoscopy performed in the BCSP, one 
can safely prolong the surveillance interval for the IR group. 
Chapter 7 examines the different relevant patient- and adenoma-specific characteristics 
seen during screening; these may, in turn, predict any adverse outcomes at first 
surveillance and hence throw light on the re-stratification risk. 
Chapter 8 highlights the important conclusions and discussions derived from this work. 
This thesis comprises a retrospective study, but provided the unique opportunity to 
examine data from the BCSP, which was collected contemporaneously; hence, it is a 
retrospective study of prospectively collected data that allows us to revisit the adenoma 
surveillance guidelines in the context of screening and provides stimulus for future RCTs 
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safely performed in the light of the outcomes of this study. Thus, it can change the way 
adenoma surveillance is currently performed.
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Chapter 2: Literature review 
2.0 Strategy for the literature review 
This review is based on evidence contained in relevant articles published in the medical 
literature and is divided into nine sections. 
The aim of the first part of the literature review is to provide an overview of the: 
 magnitude of the burden of CRC and its demographics;  
 natural history of CRC; 
 concept of bowel cancer screening; 
 the BCSP. 
This is not an exhaustive overview of all aspects of CRC, but it focuses on those aspects 
pertaining to the basis for CRC screening and the evidence supporting population-based 
screening programmes. 
In the second part, a detailed review of the following key areas was carried out: 
 surveillance of patients with colorectal adenoma; 
 risk stratification for surveillance: relationship between the number and size and 
advanced histological features of adenomas at index screening colonoscopy and the 
number, size and advanced histology at surveillance. 
In this section of the literature review, a detailed review of the available evidence and a 
perspective of current opinions on this are provided. Areas in which ongoing research for 
this thesis is relevant are then identified. 
29 
 
Research was performed to evaluate the detection of advanced neoplasia in BCSP by 
T.J.W.Lee and the strategy and part of the knowledge in this literature review was adopted 
from that work.  
PubMed (http://www.ncbi.nlm.nih.gov/pubmed) was interrogated for relevant publications  
between 1990 and 2014. This time period was chosen because it reflects modern and 
current clinical practice. Articles from earlier than 1990 were included if they proved 
relevant to the patient and did not contain outdated information. The following MeSH 
subject headings were used: colonic polyps; colonoscopy; colorectal neoplasms; early 
detection of cancer. Logical operators were used where relevant. Terms from the U. S. 
National Library of Medicine’s controlled vocabulary used for indexing articles for 
MEDLINE/PubMed were selected. MeSH terminology provides a consistent way to retrieve 
information that may use different terminology for the same concepts. These concepts were 
selected because they pertained to the aims of the literature review (17). 
Abstracts were reviewed and articles were excluded if they were in a language other than 
English or if they were not of sufficient relevance to the stated aims of the literature review. 
Full-text articles were then obtained. The reference lists of selected articles were scrutinized 
for additional articles (not restricted by year of publication). Because of the wide range of 
topics covered by this literature review, a single quality assessment protocol or data 
extraction process could not be applied to all the papers (17).  
Part 1 
2.1 Colorectal cancer: the current magnitude 
Cancer is among the leading causes of morbidity and mortality worldwide, with 
approximately 14.1 million new cases diagnosed and 8.2 million cancer-related deaths 
occurring in 2012 [18]. In 2012, globally 1.67 million new cases of CRC were diagnosed, 
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making CRC the third most common cancer and the fourth most common cause of cancer-
related death worldwide, causing 694 000 deaths worldwide in 2012 [19]. 
Bowel cancer was the second most common cancer in Europe, with around 447 000 new  
cases diagnosed in 2012 (13% of all newly diagnosed cancers) [20].  
In 2011, in the UK, 41 581 new cases of bowel cancer were diagnosed and it became the 
third most common cancer among men and women [21]. Prostate and lung cancer were 
more common among men and the incidence of breast and lung cancer preceded that of 
bowel cancer in women. Bowel cancer became the fourth most commonly detected cancer 
in the combined population including both sexes (incidence 13%), preceded by breast, lung 
and prostate cancer [1]. Figures 2.1 and 2.2 show cancer incidence in men and women in 
2011 (England). 
 
Figure 2.1 Cancer incidence in men in 2011 (England). 
Source: Cancer Research UK, Office for National Statistics. Cancer Statistics Registrations, England 
(Series MB1). 
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Figure 2.2 Cancer incidence in women in 2011 (England). 
Source: Cancer Research UK, Office for National Statistics. Cancer Statistics Registrations, England 
(Series MB1). 
In 2012, bowel cancer contributed to 16 187 deaths in the UK, making it the third most 
common cause of cancer-related death in men and women, and the second most common 
cause of cancer-related mortality (10%) in the combined male and female population [1]. It 
was preceded only by lung cancer in the mortality league table (Figure 2.3). 
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Figure 2.3 Cancer-related mortality in 2012 (UK). 
Source: Cancer Research UK. Cancer Statistics Report: Cancer Incidence and Mortality in the UK, 
January 2014. 
In an average year as per the data available in 2007, 35 000 people are diagnosed with 
cancer in the UK and more than 15 000 people die every year, making bowel cancer the 
second most common cause of death from cancer [22]. 
The national cancer survival data for December 2014 showed that the 10-year survival rate 
from bowel cancer among men and women was 56 and 57%, respectively. There has been a 
35% overall improvement in the 10-year survival rate over the last 40 years [23]. However, 
the survival rate can be improved further by detecting more bowel cancer cases at an earlier 
stage, when a curative treatment can be offered. 
2.2 The demographics of colorectal cancer 
Over 100 cases of CRC are diagnosed in the UK each day. The lifetime risk of CRC is 1 in 16 
for men and 1 in 20 for women [24]. The incidence of CRC increases with age and 83% of 
CRC cases are diagnosed in individuals aged ≥60. CRC is more common in men, with an 
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overall age-standardized male to female ratio of 1.6:1 [24]. This preponderance in men is 
most marked between the ages of 60 and 80 years; however, over the age of 80, CRC is 
numerically more prevalent in women than men. This is a result of women living longer than 
men and thus forming the numerical majority in that age group. 
Across the UK and Ireland, small geographic variations in the incidence of bowel cancer have 
been recorded, with higher rates noted in Scotland, Northern Ireland and Ireland and lower 
rates found in South East England [25].  
2.3 The natural history of colorectal cancer 
The term CRC comprises cancer in two distinct locations of the large bowel. The large bowel 
is the portion of the digestive tract that connects the small bowel to the exterior of the 
body. The colon is the large bowel proximal to the rectum. The rectum can reach up to 
15 cm proximal to the anal verge. The location of a cancer with regard to the colon and 
rectum has important implications from both diagnostic and therapeutic perspectives. 
The majority of cancers of the large bowel arise in the left side of the bowel; this holds true 
for the cases diagnosed in the UK (Figure 2.4) [26]. 
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Figure 2.4 Percentage distribution of CRC cases by site, England 1997–2000. 
Note: CRC = colorectal cancer. 
One of the major breakthroughs in understanding the natural history of CRC was the 
establishment of the ‘adenoma–carcinoma’ model. Cancer development is a neoplastic 
process, with epithelial cells going through progressive phases of genetic alteration leading 
to the loss of the normal control mechanism of cellular growth and proliferation [27]. In the 
large bowel, these phases of aberrant proliferation lead to the development of adenomas; 
these represent the morphologically categorized precursor of the vast majority of CRCs [8]. 
Morson [28] was the first to describe this evolution of CRC from a precursor lesion. It is now 
recognized as the major pathway for the development of CRC in the general population and 
in HR patients with a family history of adenomatous polyposis or hereditary non-polyposis 
CRC [28–30]. Later on, Vogelstein and colleagues [31] studied and described the genetic 
alterations detected in these precursor lesions and the adenoma–carcinoma model became 
known as ‘Vogelstein’s hypothesis’. 
Colorectal adenomas start as small, superficial, protruding lesions, morphologically known as 
polyps, although by definition they are neoplastic lesions. Polyps are any protruding 
superficial   mucosal   pathology   and   can   be   neoplastic   or  non-neoplastic.  Examples  of 
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non-neoplastic polyps are inflammatory and hyperplastic polyps. This distinction is made 
here because these terms will be used later in this thesis.  
In the model of tumour progression proposed by Vogelstein et al. [31], epithelial cells 
undergo genetic alterations leading to the development of a neoplastic clone, which in turn 
leads to the emergence of adenomas with a progressively aggressive phenotype. Therefore, 
this mechanism illustrates the occurrence of adenomas varying in size and dysplasia extent. 
The progression from adenoma to invasive cancer is a slow process and can vary from five to 
more than 20 years [30]. Research has shown that only few adenomas transform into 
invasive cancer (0.25% per year) [32]. Although every adenoma has a malignant potential, 
not  all  of  them  will  progress  to  cancer;  some  stabilize  while  others  may  even  regress  
 [33–35]. Non-progression or regression of adenomas is supported by the fact that, although 
adenoma prevalence in the Western world varies from 15 to 40%, only 3% of people with 
adenomas go on to develop carcinomas [36–45]. 
A different pathway of serrated neoplasia has been identified, where dysplasia can affect the 
serrated epithelium of hyperplastic polyps, featuring mainly right-sided colonic neoplastic 
polyps, the serrated adenomas. This tumour genetic pathway parallels therefore the classical 
adenoma–carcinoma sequence of the large bowel, in which metaplastic epithelium 
undergoes progressive steps of architectural and nuclear dysplasia, to colorectal cancer. 
Such polyps, are noted to occur in large number in hyperplastic polyposis and in attenuated 
familial adenomatous polyposis (43). 
Another alternative pathway of adenomatous transformation was noted where due to DNA 
microsatellite instability, hyperplastic polyps develop atypical or adenomatous feature and 
show progression to carcinoma (44) 
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Various factors determine the progression of benign adenomas to carcinomas; some of 
these factors have been identified. The development of CRC from an adenoma depends on 
size, growth pattern and dysplasia extent [8]. For individuals with adenomas, the annual 
conversion rate to malignant adenomas has been given as 3, 17 and 37% when large 
adenomas, villous (VH) or tubulovillous histology, and HGD are present, respectively [32]. 
Generally adenomatous growth is progressive and the increase in size parallels the extent of 
dysplasia [10]. Adenoma size is the major independent factor for the development of VH and 
HGD; this, in turn, is the most important factor determining malignant transformation of a 
benign adenoma [46]. 
This has led to the identification  of advanced adenomas (AAs) that are at high risk of 
developing into malignant lesions [47]. These adenomas have one or more of the following 
characteristics, described in different studies as risk factors for an adenoma to be malignant: 
 size ≥10 mm [48]; 
 VH in ≥25% of the mass [49]; 
 HGD [50]. 
These are neoplastic lesions that progress at a higher rate (up to 5% a year) towards cancer 
[50]. Adenomas missing these features are described as non-advanced adenomas (NAAs) in 
this thesis. Adenomas with the features of AAs and adenomas where cancer has developed 
are collectively described as ACNs in the subsequent sections of this work. 
Once an adenoma develops into a cancer, it can then progress further into different stages 
depending on: 
1. the depth of invasion of the bowel wall; 
2. the presence or absence of lymph node invasion; 
3. the presence or absence of distant metastases. 
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Dukes devised this staging classification in the 1930s, though it is still widely in use [3]. It was 
originally used for staging rectal cancer, but also proved useful in staging CRC. The original 
Dukes’ staging system was based solely on pathological findings and did not take into 
account distant metastases. A modified Dukes’ classification that also includes stage D 
(distant metastases (liver, lung, bones)) has therefore been widely adopted (Table 2.1). 
 
 
Table 2.1 Modified Dukes’ staging of colorectal tumours: pathological criteria, five-year 
survival and case distribution 
Stage Pathological criteria Five-year 
survival 
(%) [48] 
Cases 
(%) [48]  
A Tumour is confined to the bowel wall with no lymph 
node metastases 
93.2 8.7 
B Tumour has penetrated the bowel wall to the serosa 
or perirectal fat with no lymph node metastases 
77.0 24.2 
C Lymph node metastases present 47.7 23.6 
D Distant metastases (for example, in the liver, lungs or 
bones) present 
6.6 43.5 
 
The reason for the five-year survival rate being reported as an outcome measure of CRC is 
because at least 90% of disease-related events (cancer recurrence or death) will occur within 
five years of diagnosis. If diagnosed at an earlier stage, patients can be offered a curative 
resection. 
Slow progression of adenomas into cancer and the increased survival of early-stage CRC 
provide a window of opportunity to detect pre-malignant adenomas and early cancers. 
Removal with endoscopic and surgical resection respectively can thereby decrease both CRC 
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incidence and mortality. The endoscopic procedure used to resect adenomas is generally 
called a polypectomy. 
It is clear that early CRC diagnosis and treatment provide considerable survival advantages to 
the patient. If a patient is diagnosed with Dukes’ A cancer, they have approximately a 90% 
chance of surviving for five years. If, however, they are diagnosed at Dukes’ stage C, their 
five-year survival drops to approximately 50% [24]. The main aim of a screening programme 
for CRC is therefore to diagnose cancers earlier to confer these survival benefits. 
The evidence for the protective benefit of adenoma removal is largely based on historical 
studies and observational data. Prospective RCTs of polypectomy for adenomas with 
watchful waiting as the control are not feasible for ethical reasons. However, data regarding 
different surveillance strategies following polypectomy are available from RCTs. The 
available evidence is discussed later on in this literature review. 
2.4 Bowel cancer screening   
The UK National Screening Committee defined screening as ‘a process of identifying 
apparently healthy people who may be at increased risk of a disease or condition. They can 
then be offered information, further tests and appropriate treatment to reduce their risk 
and/or any complications arising from the disease or condition.’ For a disease to be 
amenable to screening it should fulfil the criteria laid out by Wilson and Jungner for the 
World Health Organization (WHO) in 1968 [52]. These criteria are shown in Table 2.2 [52]; 
details relevant to CRC are shown in the right-hand column. 
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Table 2.2 Criteria for a disease to be suitable for screening 
 
Criteria Relevance to CRC 
Wilson and Jungner [52] Evidence supporting CRC screening 
The condition is an important 
health problem 
CRC is the fourth most common cancer in the UK 
[1] 
Its natural history is well 
understood 
Adenoma–carcinoma sequence [31] 
Recognition at an early stage is 
possible 
Pre-malignant lesion is an adenoma 
An acceptable treatment exists Polypectomy or surgery is the acceptable 
treatment 
A suitable test exists FOBT shows a 50–70% sensitivity for CRC (the 
proportion of people with the target condition 
who have a positive test result) [53] 
An acceptable test exists FOBT is accepted by approximately 50% of those 
invited for the test 
Adequate facilities exist to cope 
with any abnormalities detected 
Colonoscopy and surgical services are 
adequately equipped to cope with demand [54] 
Screening is carried out at 
repeated intervals when onset is 
insidious 
FOBT trials have used a biennial FOBT strategy 
Risk–benefit ratio is favourable FOBT is safe  
Cost is balanced against benefit Similar cost-effectiveness to breast cancer 
screening in the short term. Possibly superior in 
the long term [12] 
Note: CRC = colorectal cancer; FOBT = faecal occult blood test. 
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In light of these criteria suggesting that CRC should be amenable to screening, numerous 
studies have examined various approaches to screening. Colonoscopy is the current ‘gold 
standard’ for adenoma and CRC detection because it provides opportunities for optical 
diagnosis and histological sampling. Mass population screening in the UK using colonoscopy 
is not economically or logistically viable because manpower and financial resources could 
not currently allow every adult of a specific age to undergo colonoscopy. In addition, the 
potential risks of colonoscopy would need to be taken into account. The use of colonoscopy 
for mass population screening, however, is used in the USA where guidelines recommend 
that average-risk adults should undergo colonoscopy at 50 years of age and subsequently 
every 10 years [55].  
In the UK an alternative, cost-effective approach for mass population screening is required, 
and one that is also safe and acceptable to patients. The most widely studied test that fulfils 
these criteria is the FOBT; it is based on the peroxidase-like activity of haematin in faeces on 
guaiac (a phenolic compound derived from a wood resin extracted from trees of the genus 
Guaiacum). When hydrogen peroxide is mixed with guaiac and faecal material that contains 
blood, the peroxidase activity of haemoglobin and haematin oxidizes guaiac, turning it from 
a neutral to a blue colour. The reaction is very slow and takes minutes, but the 
pseudoperoxidase activity of haematin (if present in blood in stool) catalyses the reaction so 
that it takes place in seconds. 
FOBT relies on the fact that adenomas, particularly AAs and CRC, tend to bleed. This 
bleeding is intermittent and occurs at a slow rate; it occurs because of the hypervascular 
structure of adenomas/CRC and trauma from passing faeces. The peroxidase-like activity of 
haematin diminishes as it passes through the gastrointestinal tract, reducing the chance that 
upper gastrointestinal bleeding will cause false-positive results. Ingestion of animal 
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haemoglobin or peroxidase-containing vegetables (for example, cabbage, leeks, potatoes, 
onions and green beans), however, may also cause false-positives; therefore, dietary 
restrictions should be recommended, particularly if the FOBT result is equivocal [56]. 
2.5 The faecal occult blood test 
In 1967, Greecor [38] first described the usefulness of the FOBT in the detection of 
asymptomatic colon cancer. Over a three-and-a-half-year period, 900 adult patients were 
administered the FOBT; 5% of them had a positive test results and then underwent barium 
enema examination, while 1% of the entire cases had CRC and 1% had a non-malignant 
polyp; this illustrated the effectiveness of the FOBT in identifying asymptomatic CRC. 
Three large prospective RCTs of FOBT have been conducted in Minnesota (USA) [57], 
56Denmark [58] and Nottingham (UK) [11], respectively. In the Minnesota study, 46 551 
participants were randomized into control, annual FOBT and biennial FOBT groups and 
followed up for a period of 13 years. The 13-year cumulative mortality (per 1000 
participants) from CRC was 5.88 (95% confidence interval (CI) = 4.61–7.15), 
 8.33 (95% CI = 6.82–9.84) and 8.83 (95% CI = 7.26–10.4) in the annual, biennial and control 
groups, respectively. The difference between the control and the group screened annually 
was statistically significant. 
Mandel et al. [59] followed up the same Minnesota group for a period of 18 years and 
showed that the biennial group had a 21% reduction in CRC mortality rate compared to the 
control group, thus establishing the effectiveness of biennial screening. In this 18-year 
follow-up period, they demonstrated that the cumulative incidence ratios for CRC in the 
screened groups compared with the control group were 0.80 (95% CI = 0.70–0.90) for the 
annual group and 0.83 (95% CI = 0.73–0.94) for the biennial group [60]. Their findings 
illustrated that the use of annual or biennial FOBT significantly reduced CRC incidence. 
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In the landmark study carried out by Kronborg et al. [58] in Denmark, 61 933 participants 
were followed up for a 10-year period after randomization into biennial FOBT and control 
groups. The study revealed that CRC mortality, including deaths attributable to 
complications from CRC treatment, was significantly lower in the screened group compared 
to the control group (mortality ratio 0.82, 95% CI = 0.68–0.99; P = 0.03). They also 
demonstrated that Dukes’ A CRCs were less common and Dukes’ stage C CRCs were more 
common in the control group compared to the screened group; the cumulative survival of 
patients was higher in the screen-detected CRC than in the control group. 
In the UK, the Nottingham study consisted of a RCT of FOBT; the authors recruited 152 850 
participants after performing a pilot study. Their results were similar to those of Kronborg et 
al. [58]. There were more Dukes’ A and fewer Dukes’ C CRCs in the screening-detected group 
compared to the control group and there was a significant survival advantage in the 
screening-detected group. The study also showed that the detection rates for adenoma and 
CRC after a positive FOBT were higher in individuals aged ≥65 years at the entry point [11]. 
The results from these studies laid the foundations for the BCSP. 
2.6 The NHS Bowel Cancer Screening Programme 
The screening programme in England consists of five national programme hubs across the 
country, operating a national call and recall system that sends out FOBT kits to eligible 
individuals (Figure 2.5). Adults aged between 60 and 69 years were screened initially.  
43 
 
 
 
Figure 2.5 The five BCSP hubs. 
Note: BCSP = Bowel Cancer Screening Programme. 
 
Later on, the screening programme was extended to include 70–74-year-old adults and was 
rolled out across England (Figure 2.6).  
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Figure 2.6 National coverage of the BCSP in June 2011 including roll out of the age 
extension. 
Note: BCSP = Bowel Cancer Screening Programme. 
  The FOBT was performed according to a protocol designed to optimize the sensitivity and 
specificity of the test. (Specificity is the proportion of people without the target condition 
who have a negative test result.) No dietary restrictions are recommended before test 
completion. Individuals receive the kit by post and, after completion, return it by post to the 
screening hub within 14 days. Participants are provided with a WHO-approved, postage-paid 
envelope. When repeat testing is required, this is performed within 13 weeks of the previous 
test. Trained individuals based at the hub assess all FOBT kits on the day they are received. 
Quality assurance consists of continuous internal and external assessment of both FOBT kits 
and kit readers to ensure that standards remain high.  A survey to assess the uptake of FOBT 
All screening centres offering 
coverage of age range  
covering of age range 
 
Some centres offering coverage 
of the extended age range 
covering of age range 
 
No centres offering coverage of 
the extended age range 
covering of age range 
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screening in March 2015 revealed that the FOBT screening programme has been rolled out 
covering the entire population in the country (61). 
Table 2.3 shows how FOBTs are interpreted and when repeat testing is necessary. 
Table 2.3 Classification of FOBT results  
Test result Criteria Action 
Normal No positive windows Discharge to next screening 
round in two years 
Unclear 1–4 positive windows Patient given up to two 
further FOBT kits. 
If either subsequent FOBT is 
unclear or abnormal, patient 
is referred for colonoscopy. 
These are classified as a ‘weak 
positive’ result. 
If both subsequent FOBT kits 
are normal, discharge to next 
screening round 
Abnormal 5 or 6 positive windows Patient referred for 
colonoscopy 
Technical failure 
or spoilt kit 
Lab processing problem or 
unreasonable kit due to incorrect 
use 
Further FOBT kit sent 
Source: Adapted from [62]. 
Note: FOBT = faecal occult blood test. 
Screening centres (up to 20 per hub; see Figure 2.7) then provide endoscopy services and 
specialist screening nurse clinics to individuals as necessary. For instance, if a patient had a 
positive FOBT at the hub, they would then be invited to attend a screening centre closer to 
their home for assessment and colonoscopy. Patients found to have cancer are managed 
and followed up through the colorectal multi-disciplinary meeting at the patient’s local 
hospital. The screening programme, in line with the current BSG guidelines, coordinates 
adenoma management and surveillance [13, 14]. 
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Figure 2.7 Predicted outcomes of Bowel Cancer Screening. 
Source: Population screening programmes: NHS bowel cancer screening (BCSP) programme. Available 
from: http://www.cancerscreening.nhs.uk/bowel/#screening-work (accessed 21 September 2016). 
Note: FOBT = faecal occult blood test. 
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Based on data from the pilot studies, around 98 in 100 people will receive a normal FOBT 
result and will be returned to routine screening. They will be invited for bowel cancer 
screening every two years if still within the eligible age range. 
Around two in 100 people will receive an abnormal result. They will be referred for further 
investigation and usually offered a colonoscopy. Around 40–50% of patients who go on to 
have a colonoscopy will be found to have one or more adenomas; approximately 10% will be 
found to have bowel cancer. This is illustrated in Figure 2.8. 
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Figure 2.8 Adapted from the BSG guidelines for adenoma surveillance. 
Note: BSG = British Society of Gastroenterology. 
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Part 2 
2.7 Surveillance of patients with colorectal adenoma 
2.7.1 The need for adenoma surveillance 
Colorectal adenomas are common findings in repeat examinations after index colonoscopy 
and polypectomy. Findings of metachronous or recurrent adenomas during follow-up 
colonoscopy,   after  initial   colonoscopy   and   polypectomy,   are   a   widely   reported  and 
well-known phenomenon. 
In one study, 227 patients had all their adenomas removed during the initial colonoscopy; 
when they were re-examined after one year, 56% were detected to have further adenomas 
and 9% had adenomas larger than 10 mm [63]. 
In the National Polyp Study (NPS) (UK), a total of 27.5 and 32.0% of patients were found to 
have adenomas after one and three years, respectively, following their index colonoscopy 
(87). In another prospective case-control study with 36 months of follow-up, the cumulative 
incidence rate and cumulative recurrence rate of colorectal adenomas detected were 16 and 
42% respectively [50].  
In the study by Kronborg et al. [58], the cumulative risk of a patient developing new 
adenomas was 35.0% (28.7–41.4%) after 24 months and 35.5% (28.4–42.7%) after 
48 months of surveillance [51] after removal of all colorectal adenomas at the index 
colonoscopy. 
In a further prospective study, 785 patients were followed up for 10 years. Individuals were 
categorized following their index colonoscopy into LR and HR groups according to the 
number and size of the adenomas detected. Patients were then randomized into annual, 
three-yearly or five-yearly surveillance colonoscopy. During follow-up, 48% of the HR and 
36% of the LR patients had at least one adenoma detected [64]. 
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In a pooled analysis, Martínez et al. [65] 64analysed data from eight prospective studies 
involving 9167 patients and showed that during a median follow-up of 47.2 months ACN was 
detected in 1082 (11.8%) of which 58 (0.62%) had invasive cancer. 
Thus, it is evident that patients with colorectal adenomas are at greater risk of developing 
adenomas with ACN (adenomas ≥10 mm, unfavourable histology) in the future. Similar 
findings have been replicated in more recent studies [66–69]. 
These studies highlight the fact that patients with colorectal adenomas can develop new 
metachronous lesions after the initial colonoscopy and removal of all existing adenomas. A 
proportion of those metachronous adenomas will contain advanced neoplasia. Therefore, 
patients with adenomas require surveillance procedures to detect and remove new 
adenomas to reduce the chance of developing future CRC. 
2.7.2 Missed synchronous lesions are common in colonoscopy 
Colonoscopy provides the opportunity to detect and resect all colorectal adenomas. By 
removing all potential pre-malignant lesions, it also reduces the subsequent incidence and 
mortality from CRC. 
The correlation between missed adenomas and future development of advanced neoplasia 
is well established. In a population-based study, 126 851 patients underwent colonoscopies 
and 159 of them developed interval cancer within 6–60 months of their initial colonoscopy. 
A significantly higher proportion of patients with interval cancer had adenomas during their 
index colonoscopy (57.2 vs. 26%; P<0.001) compared to patients without interval cancer 
[70]. In this particular series, the cohort with interval cancer had a higher proportion of 
patients with adenomas ≥10 mm in size and underwent polypectomies. This signifies that 
the cohort with interval cancer developed new adenomas, had incomplete resection or had 
missed synchronous adenomas. 
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In another study, 163 patients with multiple adenomas were followed up by colonoscopy 
within nine months after their initial procedure and polypectomy. Additional adenomas 
were detected in almost one quarter of all patients resulting in ‘missed rates’ for adenomas 
<5 mm, ≥5 mm and AAs of 17.7, 3.2 and 0.9%, respectively [67].70 
Several risk factors that increase the chance of an adenoma being missed during 
colonoscopy were identified. Several studies identified poor bowel preparation, morphology, 
size and right sided location of the adenomas, proficiency of the colonoscopist, withdrawal 
time and patient age as factors affecting adenoma detection and hence determining missed 
adenoma rates [72–74]. Smaller size and flat nature and inadequate bowel preparations 
have been identified as contributing factors for missed right sided adenomas. These factors 
can lead to increased detection of interval cancer in the right side of the colon which is 
reported in literature. In a population based study Interval CRCs were associated with the 
proximal colon, earlier-stage cancer, lower risk of death, higher rate of adenoma, and family 
history of CRC (75). In another population based study among the subjects who underwent 
surgical resection for right-sided colon cancer, the miss rate of colonoscopy for detecting 
cancer was noted to be 4.0% (76). These facts illustrate the evidence of interval cancer and 
right sided location of the pathology, which could result from missed right sided colonic 
lesions. 
High-quality colonoscopy overcomes some of the risk factors for missed lesions and reduces 
the chance of undetected synchronous adenomas during the initial colonoscopy. This in turn 
reduces the risk of developing advanced metachronous neoplasia during follow-up. These 
key findings were noted in studies performed with demonstrable high-quality colonoscopy 
[10, 46, 77]. However, no test is 100% accurate and even with meticulous colonoscopy 
lesions can go undetected [72, 78].  
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In 1997, in a landmark study of back-to-back colonoscopies, Rex et al. [78] showed that the 
overall miss rate for adenomas was 24%. With regard to size, the miss rate was 27% for 
adenomas <6 mm, 13% for adenomas 6–9 mm in size and 6% for adenomas >9 mm. 
Experienced physician endoscopists performed all the colonoscopies in this particular study; 
all of them had performed at least 500 colonoscopies previously (range of experience: from 
500 to >10 000 colonoscopies). 
In another study colonoscopy was performed in 1233 patients by a single experienced 
endoscopist following virtual colonoscopy. The incidence of undetected adenomas ≥10 mm 
in size was 12% during colonoscopy [72].  
Therefore, colonoscopies, even when performed in quality-controlled settings, cannot 
overcome all the factors that affect adenoma detection. Evidence of missed adenomas and 
high-risk lesions were also reported in patients with inadequate bowel preparation on initial 
colonoscopy, when performed in the setting of a BCSP. In one study, patients who attended 
for a screening colonoscopy and had poor bowel preparation underwent a repeat 
colonoscopy. Of these, 33.8% had at least one adenoma detected and 18% had HR lesions 
(three adenomas, one adenoma of 1 cm, or any adenoma with villous features or HGD) [73]. 
Similar findings were noted in another study where the missed rate of colorectal adenomas 
was measured after adjustment of the colonoscopy quality indicators [79]. The overall miss 
rate of polyps, adenomas and AAs measured was 16.8, 17 and 5.4%, respectively. 
In a systematic review of studies that included tandem colonoscopies, the pooled miss rate 
for the adenomas ≥10 mm was 2.1% (95% CI = 0.35–7.3). The pooled miss rate for adenomas 
between 5 and 10 mm and below 5 mm was 13% (95% CI = 8.0–18) and 26% (95% CI = 27–
35), respectively [80]. 
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These studies show that a small but significant proportion of patients with colorectal 
adenomas will have a missed adenoma during their initial colonoscopy; this justifies the 
need to have a follow-up procedure to detect and resect synchronous AAs and NAAs and to 
prevent the development of future CRC. 
2.7.3 Colonoscopy and polypectomy reduce the risk of colorectal cancer 
Colorectal adenomas are well established as precursor lesions for CRC and have been 
described as a ‘good epidemiologic indicator of colon cancer risk’ [81]. Removal of these 
precursor lesions has been shown to reduce the incidence and mortality associated with 
CRC. 
In the NPS, a cohort of 1418 patients who underwent colonoscopic polypectomy was 
followed up for an average period of 5.9 years to determine the true and expected incidence 
of CRC on the basis of the findings of three well-defined reference groups. Two of the 
reference groups contained patients where polyps were not removed (Mayo Clinic cohort 
from the USA and St Mark’s cohort from the UK), and one was a group from the population-
based Surveillance, Epidemiology, and End Result Program of the National Cancer Institute 
(USA). The study population was examined with one (examination in the third year) or two 
colonoscopies (examination in the first and third year) for each individual during follow-up; 
all patients were also offered an examination at the end of a six-year follow-up period. Only 
five asymptomatic early-stage CRCs were detected in the study group, whereas the number 
of expected cases on the basis of the reference groups were 48.3, 43.4 and 20.7, suggesting 
a 90, 88 and 76% reduction in the incidence of CRC [46]. 
Zauber et al. [10] followed up the NPS cohort for a further period and showed a reduction in 
CRC-related mortality in the polypectomy group. In this particular study, 2602 patients who 
had their adenomas removed by polypectomy were followed up for a median period of 
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15.8 years. The standardized incidence-based mortality ratio from CRC was 0.47 (95% CI = 
0.26–0.80) in the group with polypectomy suggesting a 53% reduction in mortality from CRC 
(25.4 expected deaths from CRC in the non-adenoma group vs. 12 deaths from CRC in the 
polypectomy group).  
In a population-based case-control study in Germany, colonoscopy with polypectomy was 
found to be associated with significant risk reduction from developing CRC in both men and 
women [82]. In this particular study, colonoscopy and polypectomy in the preceding 
10 years was associated with a 77% lower risk for CRC. The strong risk reduction was noted 
for   CRC   in  all   stages  and   in   all  ages,   except  for  right-sided   cancer  in  persons  aged  
50–59 years. 
Another recent large population-based study from Norway used data from the Cancer 
Registry and the Cause of Death Registry, revealing that CRC mortality was lower during the 
follow-up period among patients who had LR adenomas removed at their first colonoscopy 
[83]. In this study, the investigators followed up 40 826 patients diagnosed with colorectal 
adenomas over a median follow-up period of 7.7 years. This study showed that the 
standardized mortality ratio (SMR) from CRC was low in patients who had LR adenoma at the 
onset (expected deaths = 189; observed deaths = 141; SMR = 0.75; 95% CI = 0.63–0.88) but 
higher in patients who initially had HR adenomas (expected deaths = 209; observed deaths = 
242; SMR = 1.16; 95% CI = 1.02–1.31). The higher SMR in patients with HR adenomas could 
be explained by the fact that the Norwegian guidelines recommended colonoscopy after 
10 years for patients with HR adenomas (adenomas with HGD, a villous component or 
≥10 mm) and after five years for patients with three or more adenomas. 
All of these studies show that colonoscopy and polypectomy performed during initial and 
subsequent colonoscopy reduce the incidence and mortality from CRC during the follow-up 
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period. The fact that a missed colorectal adenoma (synchronous lesion) during the index 
colonoscopy and newly developed metachronous adenomas in patients with multiple 
adenomas could develop into advanced neoplasia, makes a strong argument for 
surveillance. 
2.8 Risk stratification strategy and surveillance interval 
Although surveillance colonoscopy is a rational way to follow up patients with colorectal 
adenomas, a skilled workforce and a structured framework are required to organize and 
deliver such a service nationally within the quality-controlled setting of bowel cancer 
screening practice. It is also not a risk-free procedure.  
Diagnostic colonoscopy carries a small chance of significant adverse events and that 
probability increases with therapeutic procedures undertaken to remove adenomas. The 
overall complications reported in the UK National Colonoscopy Audit showed that bleeding, 
bowel  perforation  and  cardiorespiratory   adverse  event  rates  (with a 95% CI)  were  0.26  
(0.2–0.36), 0.04 (0.02–0.08) and 0.02% (0.01–0.05), respectively [84]. 
The majority of complication data from colonoscopy were derived from practices in the 
secondary or tertiary care sector. Studies from community-based practices also showed 
complications from diagnostic and therapeutic colonoscopy. In one study looking into 
community-based practices in the USA, data were collected from an extensive electronic 
database of the integrated healthcare delivery system (Kaiser Permanente, Northern 
California). This study included 16 318 patients who had their colonoscopies between 
January 1994 and July 2002 [85]. Serious complications occurred in 0.8 per 1000 diagnostic 
colonoscopies and in 7.0 per 1000 colonoscopies with biopsy or polypectomy. Perforations 
occurred in 0.9 per 1000 colonoscopies (95% CI = 0.5–1.5 per 1000 colonoscopies), 0.6 per 
1000 diagnostic procedures and 1.1 per 1000 colonoscopies with biopsy or polypectomy. 
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Adverse events from colonoscopies carried out in the BCSP have also been studied. The 
overall bleeding rate was 0.65% and the rate of bleeding requiring transfusion was 0.04%. 
The  overall   perforation   rate   was   0.06%.   Polypectomy   increased  the  risk  of  bleeding  
11.14-fold and the perforation risk 2.97-fold [86]. 
A population-based adenoma surveillance programme needs a skilled endoscopy workforce 
and appropriate support services, incurring significant costs to the health service.  
Consequently, surveillance colonoscopy should be targeted at the population who will 
benefit   most  from  it,  accepting   that  adverse  events   will  be  balanced  in  terms  of  the  
risk–benefit ratio towards the positive side and will be cost-effective. An effective and 
continuing surveillance programme in turn needs the establishment of an effective and 
skilful workforce with an appropriate support service and a valid strategy to identify people 
with colorectal adenomas who have a higher probability of developing advanced 
metachronous colorectal neoplasia, including AA and CRC. Targeted surveillance will identify 
this cohort and, by removing pre-malignant adenomas in this HR group, it will reduce the 
future incidence and mortality from CRC. 
The NPS addressed these issues when it was launched in 1980 and sponsored by the AGA. 
This study was a multicentre, prospective, randomized trial designed to evaluate follow-up 
surveillance strategies in patients with colorectal adenoma with the aim of preventing future 
occurrence of CRC [87]. The study recruited 9112 patients who had their colonoscopy 
examinations in seven participating centres. A total of 1418 patients with adenomas were 
randomized into two arms, one arm having colonoscopy one year after the index procedure 
and the other arm having colonoscopy at the first and third year after their index procedure. 
A six-year colonoscopy was offered to patients in both arms of the study. The randomization 
of patients into different arms was performed by stratifying them using three variables to 
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ensure a balance of these variables between the follow-up treatment arms (that is, groups 
with different surveillance intervals): geographic location (each of the seven centres); 
number of adenomas (single vs. multiple); and adenoma histology (tubular vs. villous). 
Patients for this study were mainly referred for colonoscopy because of positive findings on 
barium enema examination (27%), sigmoidoscopy (15%), FOBT (11%) or other tests (10%), or 
because of symptoms (32%) or a family history (5%) of CRC [87]. The mean age of patients 
participating in this study in all seven centres varied from 56 ± 13 (mean and standard 
deviation) years to 64 ± 13 years. Interestingly, only 11% of patients were referred after a 
positive FOBT. 
There was a significant difference in the proportion of patients having an adenoma detected 
during surveillance colonoscopy. The group with two examinations had a higher proportion 
(41.7 vs. 32.0%; P = 0.006) of adenomas, but the proportion of patients with adenomas 
exhibiting advanced pathological features was the same (3.3%) in both groups. The 
researchers concluded that the first surveillance colonoscopy could be performed at year 3 
in the majority of patients diagnosed with colorectal adenoma on initial examination. They 
also showed that age, number of adenomas and size of the largest adenoma at enrolment 
were independent risk factors for predicting any adenoma detected during the first 
surveillance colonoscopy, but the only factor predicting the detection of adenomas with 
advanced pathological features was  the  number  of  adenomas  at  onset  (≥3  adenomas;  
odds  ratio  (OR) =  6.9; 95% CI  = 2.6–18.3; P<0.001) [48]. 
Noshirwani et al. [88] performed a retrospective study using the data from the Cleveland 
Clinic Foundation Adenoma Registry. They identified 697 patients eligible for the study who 
were seen in the period between 1979 and 1989, had one or more adenomas removed at 
colonoscopy and completed a surveillance examination within 10–42 months (mean = 
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18 months). Overall, 9% of their patients had an adenoma with advanced pathological 
features (advanced adenoma or adenoma containing a focus of cancer). Their findings 
showed that the number and size of baseline adenomas were significantly associated with 
clinical outcome (having four or more adenomas or any adenoma with advanced 
pathological features; P<0.001). Age, sex, pathology of baseline adenomas and time interval 
between colonoscopies were not significantly associated with clinical outcome. This study 
showed that patients with one or two sub-centimetre adenomas had a very low probability 
of having significant pathology at first surveillance colonoscopy and that their first 
surveillance examination could be delayed beyond three years. 
Martínez et al. [65] performed a pooled study of 9167 patients (aged 22–80 years) from 
eight different prospective trials and a median follow-up period of 47.2 months. They 
showed that the risk of a metachronous AA was higher among patients with ≥5 adenomas 
(24.1%; standard error (SE) = 2.2) and those with an adenoma ≥20 mm (19.3%; SE = 1.5). 
Their multivariate analysis identified male sex, increasing age, number and size of 
adenomas, proximal location and villous architecture at baseline as independent risk factors 
for metachronous advanced neoplasia.  
Saini, Kim and Schoenfeld [89] performed a meta-analysis to address the issue of AA 
incidence in LR and HR patients at the three-year surveillance colonoscopy to support the 
risk categorization strategy. They included 15 prospective studies; of these only five 
stratified their patients according to the findings at the index colonoscopy. The final result of 
this meta-analysis showed that the presence of ≥3 adenomas was associated with an 
increased risk of having AAs compared to patients with one or two adenomas (relative risk 
(RR) = 2.52; 95% CI = 1.07–5.97). Presence of HGD at the index colonoscopy was also 
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significantly associated with an increased risk of having AAs at follow-up (RR = 1.84; 95% CI = 
1.06–3.19). 
A recent study from Japan analysed the relationship between the number of surveillance 
colonoscopies and CRC prevention, using the detection of AAs at surveillance as the end 
point. They divided 2391 patients into LR (having one or two sub-centimetre adenomas) and 
HR (having ≥ 3 adenomas) groups and analysed data regarding their surveillance 
colonoscopy after their index colonoscopy over a period of five years. The results showed 
that comparing patients who had infrequent colonoscopies (once or not at all within the 
previous five years) with those who had two or three colonoscopies within five years 
resulted in a 67 and a 52% reduced risk for AAs in the LR and HR groups, respectively. 
However, for cases undergoing colonoscopy very frequently (≥ four times within five years), 
the additional risk reduction for AAs was relatively small [90]. 
In a polyp prevention trial, van Stolk et al. [91] evaluated the predictive effects of the 
number of adenomas, and their size, type and degree of atypia in 479 patients, using the 
same characteristics at follow-up (ORs with 95% CIs). Their study concluded that patients 
with one or two tubular adenomas constitute the LR group for whom follow-up might be 
safely extended beyond three years. Similar findings were reported in other studies [88, 92]. 
Lieberman et al. [77] conducted a study to measure the incidence of advanced neoplasia 
after five and a half years of an initial screening colonoscopy. In this study, 3121 
asymptomatic patients underwent a screening colonoscopy and, according to their baseline 
adenoma characteristics, underwent a surveillance colonoscopy once after five years or 
twice at the second and fifth year. Compared to patients with no neoplasia, patients with 
only one or two tubular adenomas <10 mm did not show a statistically significant incidence 
of advanced neoplasia during surveillance (4.6 vs. 2.4%; P = 0.13); hence they were 
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described as the LR group. Patients with three or more tubular adenomas <10 mm had a 
higher rate of AAs compared to patients without any neoplasia at screening (11.9 vs. 2.4%; 
P<0.001) or having just one or two small sub-centimetre adenomas (11.9 vs. 4.6%; P<0.001). 
Patients with one or two sub-centimetre adenomas have been described consistently as the 
LR group and the available evidence suggests that their surveillance colonoscopy could be 
safely performed after five years [64, 66, 88, 91, 92]. One study showed a higher incidence 
of  advanced  neoplasia  in  this  group  compared  to  controls  (hazard  ratio  = 2.6; 95% CI =  
1.6–4.2) [66]. Several other studies compared the incidence of advanced metachronous 
adenomas in control and LR groups; they did not find any significant difference during 
surveillance if this was performed  [93, 94] or 10 years after screening [95]. 
The long-term risk of developing CRC in patients with adenoma has been well demonstrated 
in several studies. In one retrospective study, 1618 patients whose adenomas were resected 
during the rigid sigmoidoscopy were followed up [49]. Patients who were stratified as the LR 
group showed a similar risk of developing CRC as the general population (standardized 
incidence  ratio  (SIR)   =  0.5;   95%  CI  =  0.1 – 1.3).    Similar  findings   were   reported  in  a  
registry-based study involving 5579 post-polypectomy patients and the SIR of CRC in the LR 
group was 0.68 (95% CI = 0.44–0.99), even when surveillance colonoscopy was not 
performed [68]. Case-control studies also showed a low risk of CRC during five years of 
follow-up in this group [96, 97]. 
The available evidence suggests that the risk of developing advanced metachronous 
neoplasia is smaller in patients who have one or two small (<10 mm) adenomas and they are 
referred to as the LR group in the literature. The risk was greater in patients who had ≥3 
adenomas or had a larger (≥10 mm) adenoma at the initial colonoscopy; they have been 
described consistently in different studies as the HR group. 
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The risk of developing CRC has been extensively studied in HR groups. In the epidemiological 
study performed by Atkin, Morson and Cuzick [49], the HR patients were followed up for up 
to 14 years without endoscopic surveillance and they showed a 3.6–6.6-fold increased risk of 
developing CRC compared to the general population. The registry-based study mentioned 
previously showed a 4.26-fold (95% CI = 2.89–6.04) increased risk of developing CRC 
compared  to  the  general  population  during  the  follow-up  period  [68].   Epidemiological  
case-control studies have shown that the HR group has a higher long-term risk of developing 
CRC compared to the general population after five years of surveillance following initial 
colonoscopy and polypectomy [96–98].  
The incidence of advanced metachronous neoplasia in HR populations was detected and was 
significantly higher compared to populations without adenomas and LR groups. In 
prospective cohort studies, the incidence of advanced metachronous neoplasia was 5–7 
times higher in HR groups compared to individuals without any adenomas [66, 77, 93]. In the 
pooled analysis study, the risk of advanced neoplasia in the HR group during surveillance was 
15.5% compared to 6.9% in the LR group [65]. The study from the Cleveland Clinic 
Foundation Adenoma Registry also showed that the risk of incidence of AAs at surveillance 
increased fivefold in patients who had ≥4 smaller (<10 mm) adenomas removed compared 
to the LR group, and the risk increased 10-fold if patients with multiple adenomas had one 
adenoma >10 mm at the onset [89]. In a pooled analysis, Martínez et al. [99] analysed the 
data from four prevention trials which performed surveillance colonoscopies after one year. 
Patients with five small (<10 mm) adenomas or with three adenomas, one of which was 
>10 mm, had an 18.7% absolute risk of having advanced neoplasia at year 1, showing the 
benefit of having surveillance at year 1 in that group. 
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Along with adenoma-specific factors (number and size), colonoscopy quality indicators at 
surveillance were also identified as important factors that influence the incidence of 
advanced neoplasia. In a community-based study, van Heijningen et al. [100] showed that 
large size, number, VH and proximal location of adenomas, as well as insufficient bowel 
preparation and poor ‘colonoscopy reach’ at the first colonoscopy were associated with AA 
detection at surveillance. This study showed that along with the number and size of 
adenomas detected, colonoscopy quality indicators also had a vital role in adenoma 
detection. The limitation of including the villousness in the histology is that it is a subjective 
assessment and widespread inter-observant variation is a possibility. 
Thus, the available evidence supports the idea of stratifying patients with colorectal 
adenomas into different risk groups depending on the number and size of adenomas at the 
onset and then continuing follow-up with colonoscopy at different time intervals depending 
on the projected risk of developing advanced metachronous colonic neoplasia. 
In the UK, the adenoma surveillance guidelines were based on the available evidence in 2002 
[13] and further updated in 2010 without any major changes [14]. The guidelines divide 
patients into three different risk categories depending on the number and the size of the 
adenomas detected at the initial colonoscopy; they suggest performing surveillance at 
different time intervals according to the risk of developing future advanced colonic 
neoplasia. Because of the paucity of evidence for future advanced neoplasia in the LR group, 
the guidelines suggest that patients could either be discharged or followed up after five 
years for surveillance purposes. The surveillance pathway is shown in Figure 2.8. 
The chosen cut-off age for surveillance is 75 years because the remaining life expectancy is 
less than the average time required for new adenomas to develop into advanced pathology 
or CRC. 
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These guidelines are widely used in the UK and form the basis of adenoma surveillance in 
the BCSP. The only variation is that the LR patients in the BCSP are returned to the biennial 
FOBT screening pool [101] (Figure 2.9). 
 
Figure 2.9 Adapted from the Adenoma surveillance NHS BCSP guidelines. 
2.9 High-quality colonoscopy on surveillance 
High-quality colonoscopy has been defined as ‘complete colonoscopy with a meticulous 
inspection of adequately cleaned colorectal mucosa. Neoplastic lesions have also been 
completely removed and retrieved for histological examination [16].’ Detection and removal 
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of all neoplastic lesions in the colon is important for screening efficacy; this can be achieved 
through  a  high-quality   colonoscopy  [96–98]. 101-103  If  complete  detection  and   
removal  of  all  
pre-malignant adenomas can be achieved during the index colonoscopy, then the proportion 
of advanced metachronous lesions that develop as a consequence of missed and 
incompletely removed pathology can be minimized; hence, the surveillance interval can be 
prolonged to detect future colorectal neoplasia that would develop de novo from a normal 
mucosa because of accelerated carcinogenesis in susceptible individuals who initially had 
multiple and larger adenomas. The degree of success with which colonoscopy detects 
adenomas depends on various factors. 
Atkin et al. [99] 104proposed several performance indicators that need to be monitored to 
assure a high-quality screening colonoscopy service. Key performance indicators included: 
withdrawal time; adenoma detection; incomplete polyp excision; complications; and missed 
cancers. The study also focused on various other key areas of quality improvement for a 
screening service. 
The importance of the adenoma detection rate (ADR) as a performance indicator has been 
studied in the context of bowel cancer screening. Kaminsky et al. [100]105 used Cox’s 
proportional hazards model to evaluate the influence of colonoscopy quality indicators on 
the risk of interval cancer. The study involved 186 colonoscopists and data about quality 
indicators were collected. This was done within the setting of a colonoscopy-based CRC 
screening programme and involved 45 026 patients who participated in the screening during 
the study period. The study showed that an endoscopist’s ADR was significantly associated 
with the risk of interval cancer. An ADR below 20% was associated with significant risk of 
interval cancer, compared to an ADR ≥20%. 
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The BCSP has aimed to develop and deliver a high-quality colonoscopy service from the 
onset. Performance quality control was well described by Logan et al. [107]. They suggested 
that all colonoscopies are undertaken at JAG-accredited screening centres 
(http://www.thejag.org.uk/) by screening-accredited colonoscopists, who have passed a 
formal assessment comprising a 12-month personal colonoscopy audit and multiple choice 
questionnaire, and have performed two directly observed colonoscopies assessed 
independently by two screening examiners. Ongoing quality assurance includes assessment 
of cecal intubation rate, ADR, polyp retrieval rate, colonoscopy withdrawal time, comfort 
score and complications. Screening colonoscopies are allocated 45-min time slots. A 
screening specialist practitioner accompanies the patient during the procedure and records 
a detailed data set onto the national Bowel Cancer Screening System (BCSS) database.  
Before becoming accredited and starting to practise in the BCSP, all colonoscopists are 
required to have performed at least 1000 colonoscopies with a cecal intubation rate >90% 
and an ADR >20% in the preceding 12 months. In addition, sedation levels have to be in 
keeping with National Patient Safety Agency recommendations and the BSG guidelines; the 
complication rate has to be reported and deemed acceptable [108]. 
In the BCSP, to ensure the delivery of high-quality colonoscopy, quality indicators, standards 
and auditable outcomes were identified in the quality assurance guidelines [109]. These 
indicators, their definitions and level of accountability are shown in Table 2.4. 
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Table 2.4 Quality indicators in the BCSP 
Quality indicator Accountability Definition 
ADR Colonoscopist Number of colonoscopies at which one or more 
histologically confirmed adenomas were found 
divided by the total number of colonoscopies 
performed in the same time period 
Polyp detection 
rate 
Colonoscopist Number of colonoscopies at which one or more 
polyps were found (regardless of histological type) 
divided by the total number of colonoscopies 
performed (in the same time period) 
Colonoscopy 
withdrawal time 
Colonoscopist Average time taken to withdraw the colonoscope 
from the caecal pole to the anus in complete, 
negative procedures 
Unadjusted cecal 
intubation rate 
Colonoscopist Proportion of all colonoscopic procedures in which 
the caecum, terminal ileum or anastomosis was 
reached (no adjustment made for poor bowel 
preparation or impassable strictures) 
Rectal 
retroversion rate 
Colonoscopist Proportion of procedures in which the colonoscope 
was retroverted in the rectum 
Polyp retrieval 
rate 
Colonoscopist Proportion of resected polyps that were retrieved 
and sent for histological analysis 
Sedation 
practices 
Colonoscopist Mean doses of pethidine, fentanyl and midazolam, 
when used 
Patient comfort assessed during colonoscopy using 
the modified Gloucester discomfort score to grade 
patient discomfort as none, mild, moderate or 
severe [110] 
Hyoscine 
butylbromide 
use 
Colonoscopist Proportion of procedures in which hyoscine 
butylbromide was administered 
Bowel 
preparation 
scores 
Screening centre Quality of bowel preparation assessed by 
colonoscopist at the time of colonoscopy using a 
four-point modified Likert scale 
Descriptors for quality of bowel preparation are: 
incomplete examination due to inadequate 
preparation; complete examination despite 
inadequate preparation; adequate or excellent 
preparation [110] 
Adverse events Colonoscopist/ 
screening 
centre/unit 
Data from BCSS, adverse event log and screening 
centres 
Note: BCSS = Bowel Cancer Screening System; ADR = adenoma detection rate. 
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Similar quality indicators are accepted worldwide and also mentioned in recently published 
American guidelines for colonoscopy quality indicators [111]. 
The impact of high-quality colonoscopy on post-polypectomy surveillance is discussed in the 
European guidelines [16]; they recommend that surveillance procedures should be done at 
longer intervals, which will be more cost-effective.  
In   the light   of   these   facts,   the   current   adenoma surveillance guidelines need to be  
re-examined to evaluate whether their effectiveness and appropriateness in stratifying the 
FOBT-positive screened  is adequate, as the population is of a specific age group (60 to 74 
years) in which the incidence of colorectal adenoma is high. Since high quality colonoscopy is 
currently being used in the NHS BCSP it is relevant to determine whether current 
surveillance intervals in the BCSP can be prolonged. 
The evidence presented in this literature review highlights that CRC is an important burden 
on society and health care, being one of the major causes of mortality in the UK and 
worldwide. If CRC could be detected at an earlier stage when localized to the bowel wall, 
then a curative treatment is feasible by providing curative resection, reducing both mortality 
and morbidity from the disease. The development of malignant bowel cancer from a benign, 
pre-malignant adenoma is slow, allowing time to make a diagnosis at this stage. Time is also 
needed for early-stage CRC to progress to an advanced stage. This time window, present 
during benign to malignant transformation of adenomas and progression from early-to 
advanced-stage CRC provides the opportunity to detect and remove adenomas with a 
consequent reduction in the future incidence of CRC. 
The FOBT is a valid tool for population-based screening of CRC and is being currently used in 
the BCSP. The current surveillance guidelines are based on population-derived studies rather 
than on a FOBT-positive cohort. If a high-quality colonoscopy service could be routinely 
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provided within a quality-controlled framework, then the intensity of surveillance could be 
optimally prolonged. The BCSP is providing a quality-controlled screening colonoscopy 
service delivered by accredited and experienced endoscopists. It also provides the evidence 
to prolong surveillance intervals. Assessing the surveillance outcome in the BCSP will 
validate the current guidelines for a screening cohort but can also be used to assess whether 
the surveillance interval can be safely prolonged in routine clinical practice. This will allow 
more efficient use of the current workforce in an era of finite financial resources in the NHS. 
2.10 Summary 
CRC is a common disease that imposes a significant burden on society, being the second 
most common cause of cancer-related death in the UK.  
Great advances in understanding the natural history of CRC have been made over the last 
40 years. This has led to the acceptance of the adenoma–carcinoma model being the origin 
for most CRCs. 
Fortunately, the transition from adenoma to cancer takes place over many years; this 
provides the ideal opportunity for a screening programme to detect and remove such lesions 
before they become malignant. 
Larger adenomas and CRCs tend to bleed intermittently. This means that the detection of 
blood in faeces (using a FOBT) may allow their detection. However, the FOBT only detects 
around 50% of such lesions due to the intermittent nature of bleeding. 
Early diagnosis of CRC confers significant survival advantages. Three large RCTs of biennial 
FOBT have shown a 13–21% reduction in CRC mortality. One of these studies showed a 17% 
reduction in CRC incidence after an 18-year follow-up. 
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On the basis of these large trials, the BCSP invites men and women aged 60–74 years to 
enter a biennial FOBT programme with colonoscopy recommended if the FOBT is positive. 
The BCSP aims to detect cancers at an earlier stage and detect and remove adenomas. 
Advanced metachronous adenomas are a common finding among patients with colorectal 
adenomas during follow-up. 
Colonoscopic polypectomy at the index colonoscopy and during continued surveillance 
reduced the incidence and mortality from CRC. Colonoscopic surveillance for patients with 
adenomas is best performed by targeting groups according to their risk of developing 
advanced metachronous adenomas. 
The available evidence for risk stratification is derived from population-based studies, 
including symptomatic patients and FOBT-positive patients. The current BSG adenoma 
surveillance was developed on the basis of this evidence and is the basis of the adenoma 
surveillance programme in the BCSP. 
Recent evidence suggests that with high-quality colonoscopy, surveillance intervals can be 
prolonged. 
Colonoscopies performed in the BCSP are carried out by accredited clinicians and are done 
within quality-controlled settings, thereby delivering high-quality colonoscopy. 
The appropriateness of the current adenoma surveillance guidelines needs to be validated 
for FOBT-positive patients in the BCSP population who have had a demonstrably high-quality 
colonoscopy. 
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Chapter 3: Methodology 
3.0 Introduction 
In this chapter, the general methodology followed in this thesis is discussed. The specific 
analytical methodologies used to obtain the results in different chapters are illustrated in 
each chapter: 
• the study location; 
• the study population; 
• the BCSP database; 
• ethical considerations and approval; 
• data transfer and storage; 
• aims and objective of the methodology; 
• general methodology. 
3.1 Study location and nature of the work 
The study took place at the Wolfson Research Institute for Health and Wellbeing, Durham 
University, and University Hospital of North Tees, Stockton on Tees, UK. The project involved 
analysing the data obtained from the BCSP national database based in Sheffield. There was 
no direct involvement or interaction with any of the study patients. The data obtained were 
anonymized and then used for analysis. 
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3.2 Aims and objectives 
The aims and objectives of this study included: 
 identifying the size of adenomas detected in the BCSP that contained advanced 
neoplasia (adenomas containing HGD, VH, carcinoma, adenoma ≥10 mm); 
 identifying the predictive factors that influence the presence or absence of advanced 
neoplasia in the adenomas of the FOBT-positive population and hence provide valuable 
information for endoscopists to enhance the ability to identify them; 
 evaluating the outcomes of the continuing screening of HR and IR patients; 
 determining the effects of continuous screening of HR and IR groups on the reduction of 
AAs at surveillance; 
 determining the predictive factors (adenoma- and patient-specific) at screening that can 
effectively determine outcome at surveillance and can provide further information and 
knowledge to create a more effective risk re-stratification strategy at screening; 
 determining an effective surveillance interval to better make use of the available 
workforce and resources needed to detect more AAs at surveillance without any 
significant increase in the detection of CRC at surveillance. 
3.3 The study population 
The individuals included in the study took part in the BCSP for the period from June 2006 to 
August 2012. The screening programme started in June 2006 and offered a guaiac-based 
FOBT to all men and women aged between 60 and 69 every two years. From February 2010, 
the age of participants was increased up to 75 years. The information relevant for use in this 
thesis included participants who had a positive FOBT test and who were subsequently 
examined with colonoscopy. 
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For the purpose of the objectives of this work, two separate data sets from the national 
databases were obtained, as described later in the chapter. 
For the analysis of factors predicting the presence of advanced neoplasia, data for all polyps 
detected and removed was obtained, as documented in the BCSP, from June 2006 up to 
June 2012. Adenomas occur as superficial mucosal lesions on the inner surface of the bowel 
and are classified as polyps. All lesions identified as polyps during the study period have 
been included in this study. The data set is described later on in the chapter. 
To analyse the surveillance outcomes of IR and HR participants, a separate data set 
containing the relevant participant-, procedure- and adenoma-specific information was 
obtained. All individuals identified as being in the IR and HR groups at their screening 
colonoscopy from June 2006 to September 2012 were included. The data set is described 
later in the chapter.  
3.4 The BCSP database 
The BCSP database contains the data for all patients entering the programme. Further data 
on patients undergoing colonoscopy were contemporaneously uploaded by specialist 
screening practitioners and administrative staff at screening centres around England, as 
patients followed the screening pathway. The data were entered with a graphical user 
interface (the BCSS) into an Oracle database. Data could be exported to a SQL server to allow 
specific queries to be written.  
The database is comprehensive and data were prospectively gathered. A wide range of 
parameters were recorded including: demographics (age, sex, postcode of address at the 
time of entry into the screening programme, relevant medication history, weight and 
height); FOBT results; colonoscopy results; histology outcomes; and subsequent 
management. 
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Access to the national database is restricted. Professor Matt Rutter is chair of the National 
BCSP Service Evaluation Group and acted as sponsor for this research. The body of work 
contained within this thesis was formally sanctioned by the evaluation group. As the 
author’s clinical supervisor, Professor Rutter facilitated access to the national database. 
Assistance in accessing the database was also provided by the BCSP National Office. 
Requests for specific data sets were made to the National Office who provided the data as a 
Microsoft Excel spreadsheet. 
The process of extracting the data from the main database was undertaken by the author 
and by Claire Nickerson (data analyst, BCSP). This involved defining the specific data that 
were required and writing the ‘query’ used to search the database to ensure that the correct 
data were obtained. The author developed the list of variables for the ‘query’ after a series 
of meeting with his supervisors and after identifying important relevant factors from the 
literature review. The author planned to interrogate the BCSP database from June 2006 to 
September 2012 to capture five years of up-to-date information available in the database. 
3.4.1 Data transfer and storage 
All the required data were gathered after interrogating the BCSP database. The data were 
initially in Microsoft Excel format; they were then transferred electronically using NHS mail 
accounts. These are entirely encrypted and could only be accessed from a NHS computer. 
The data were stored in a dedicated account on the North Tees and Hartlepool NHS 
Foundation Trust server. 
Initially, data were processed to eliminate the patient identifier variables (NHS number, 
patient ID), thereby allowing the data sets to be transformed into a pseudo-anonymized 
form and used for further analysis. 
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The anonymized data were stored in an encrypted external storage device, provided by the 
North Tees and Hartlepool NHS Foundation Trust and used for data transfer and analysis 
whenever required. For the purpose of analysis and data processing, the data sets were also 
stored in an encrypted and password-protected device, and kept at a safe location in the 
Wolfson Research Institute for Health and Wellbeing. Following completion of this work, the 
data would be stored only in the North Tees and Hartlepool NHS Foundation Trust server 
under the auspices of Professor Rutter. Caldecott approval was obtained from the Trust 
Information and Governance team to obtain and store NHS BCSP data and use it for analysis. 
Approval was obtained from the University to store pseudo-anonymized data and use that 
for analysis, which was followed throughout this work. 
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3.5 The data sets  
3.5.1 Data set for the analysis of advanced neoplasia in adenomas 
Information for each polyp detected during the study period was obtained (Table 3.1) 
Table 3.1 Characteristics of polyps detected during the study period 
Variable 
number 
Variable and information obtained 
1 NHS Number (unique patient identifier) 
2 Date of birth 
3 Sex 
4 Date of polypectomy (date when the procedure was performed) 
5 Patient ID in the BCSP (unique patient identifier) 
6 Polyp ID (unique ID for each polyp at endoscopic detection) 
7 Polyp location (segment of colon where the polyp was found) 
8 Estimated size of polyp in mm (polyp size estimated during 
endoscopy) 
9 Histological ID (unique ID for each polyp in the histology report) 
10 Polyp actual size in mm (polyp size measured during histology) 
11 Polyp architecture (histological types) 
12 Degree of dysplasia 
13 Presence of carcinoma (yes/no) 
14 Polyp morphology (sessile/pedunculated/flat) 
15 Excision completeness 
16 Centre ID (bowel cancer screening centre where colonoscopy was 
performed) 
Note: BCSP = bowel cancer screening programme. 
The methodology used to process and analyse the data is described in Chapter 5; the 
analysis of all adenomas is also described in Chapter 5. 
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3.5.2 Data sets for the analysis of surveillance outcome 
Data about the participants and their investigations for both screening and surveillance 
staging were obtained. In addition, information about the adenomas detected at both 
screening and surveillance was gathered. The data obtained are described in Tables 3.2 and 
3.3. 
Table 3.2 Patient- and procedure-specific information 
Variable 
number  
Variable and information obtained 
1 NHS number (unique patient identifier) 
2 Patient ID in the BCSP (unique patient identifier) 
3 Sex 
4 Date of birth 
5 Episode ID (unique ID for when a patient attends an investigation 
in the BCSP) 
6 Episode type (screening/surveillance) 
7 Confirmed date (date of the investigation) 
8 Patient height (in metres, when available) 
9 Patient weight (in kilograms, when available) 
10 Screening centre code (centre for colonoscopy) 
11 Greatest risk (outcome of the colonoscopy: normal or abnormal, 
LR/IR/HR adenoma, cancer) 
12 Outcome of the result (subsequent management: 
surveillance/discharge/treatment) 
Note: NHS = National Health Service; BCSP = Bowel Cancer Screening Programme; LR = low-risk; IR = 
intermediate-risk; HR = high-risk. 
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Table 3.3 Information about adenomas obtained at screening and surveillance 
Variable 
number 
Variable and information obtained 
1 NHS number (unique patient identifier) 
2 Date of birth 
3 Sex 
4 Date of polypectomy (date when the procedure was performed) 
5 Patient ID in the BCSP (unique patient identifier) 
6 Episode type (screening/surveillance) 
7 Episode ID (unique ID for an event when a patient attends an 
investigation, as recorded in the BCSP database) 
8 Polyp ID (unique ID for each polyp at endoscopy) 
9 Polyp location (segment of colon where the polyp was found) 
10 Polyp estimated size in mm (as estimated during endoscopy) 
11 Histological ID (unique ID for each polyp in the histology report) 
12 Polyp actual size in mm (polyp size measured during histology) 
13 Polyp architecture (histological types) 
14 Degree of dysplasia 
15 Presence of carcinoma (yes/no) 
14 Polyp morphology (sessile/pedunculated/flat) 
15 Excision completeness 
16 Centre ID (bowel cancer screening centre where colonoscopy was 
performed) 
Note: NHS = National Health Service; BCSP = Bowel Cancer Screening Programme. 
The patient and procedure data set was used to derive datasets for screening and 
surveillance procedures. The surveillance dataset were then arranged sequentially in a 
fashion so that surveillance episodes were arranged chronologically. The multiple 
procedures in a same episode were arranged chronologically as well. Following this when 
screening and surveillance datasets were merged using unique pseudo anonymised subject 
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identifier number a comprehensive dataset was obtained demonstrating the screening and 
subsequent surveillance procedures for participants in the NHS BSCP.  
The HR and the IR group subjects at screening were then only selected which generated two 
robust datasets demonstrating screening and surveillance episodes for these two groups. 
The polyp data set was used in different way for valid analysis. For the descriptive part of the 
study to evaluate the colorectal adenomas and the prevalence advanced neoplasia in them 
the entire polyp data set was used and then subsequently screened to include polyps with 
complete information available for all histological variables. The process of selection has 
been elaborately described in the figures 5.1 and 5.2 subsequently.  
For evaluation of the screening and surveillance outcome the polyp dataset was screened to 
derive separate screening and surveillance polyp data sets. For polyps detected in the same 
segment of the bowel in multiple sequential procedures in the same episode, with 
endoscopic mucosal resection being the procedure of polypectomy then it has been only 
counted once to avoid duplication in the data. The patient and procedure datasets for 
screening and surveillance then was merged with the screening and surveillance polyp 
datasets to derive four comprehensive datasets for HR and IR group subjects with screening 
and surveillance procedure and polyps to evaluate the outcome. These have been 
demonstrated in the figure 6.2 and 6.3 in chapter six. 
For risk stratification analysis subjects with complete histological datasets for all polyps at 
screening and surveillance are only used and the data processing and merging has been 
explained in figure 7.1 in chapter seven. 
After data merging at each step the a random ten percentage of the derived data was taken 
and checked with the pseudo-anonymized original data set obtained at source and to ensure 
absence of any mismatch before proceeding in to analysis. 
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The descriptive statistical outcomes have been documented with tables and figures. 
Proportions will be described in percentage up to two decimal points. Pearson’s chi-square 
tests were used to test for significant differences in frequency data and a Student’s t-test 
was used to compare adenoma size between pairs of different groups. After building valid 
models, binary logistic regressions were performed to determine the important predictor 
factors that determine the presence of advanced neoplasia in adenomas. Multinomial 
logistic regressions with valid models were performed to determine any important factors at 
screening that determine outcome at surveillance. The exact statistical analysis plans and 
models are discussed in the respective chapters. 
3.6 Analysis software 
Data were obtained in Microsoft Excel 2010 format. To process the data and merge the 
different sets of data, the Stata Statistical Software, Release 12 (Stata Corporation, College 
Station, TX, USA) was used. The statistical analyses were performed with IBM SPSS Statistics 
for Windows, Version 19.0 (IBM Corporation, Armonk, NY, USA). 
The analyses were carried out with supervision provided by Dr Douglas Wilson, a statistician 
based at the Wolfson Research Institute of Health and Wellbeing, University of Durham. The 
exact tests and analysis performed are described in the relevant chapters. 
3.7 Ethical considerations 
The work described in this thesis was an evaluation of the BCSP. As such it was termed 
‘service evaluation’ and prospective ethical approval was not necessary. Also, there was no 
allocation to intervention groups, nor was any randomization planned. Similar work within 
the field of breast cancer screening over the past 20 years had not necessitated prospective 
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ethical approval.  The research project was discussed verbally with the local Regional Ethics 
Committee of The Health Research Authority based in Jarrow and formal ethics approval was 
not needed as the project is of a service evaluation nature. Ethical approval was obtained 
from the University Ethics committee for this work (Appendix 1). The   use   of   BCSP   data   
in   this   thesis   has   been   sanctioned by the director of the NHS Screening Programmes 
and confirmation was obtained through electronic communication (Appendix 2). 
3.8 Summary 
By using the data sets obtained from the BCSP national database it was possible to evaluate 
the magnitude of advanced neoplasia detected by the BCSP. 
Binary and multinomial regression methods were used to determine important predictors 
for advanced neoplasia in colorectal adenomas and to evaluate important factors at 
screening that predict surveillance outcome; comprehensive data cleaning and consolidation 
created a workable database with which to perform the analysis.
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Chapter 4: Aims and objectives 
4.0 Aims and objectives for the study of all adenomas in the BCSP 
These included: 
 detecting the extent of advanced neoplasia in the adenomas detected in the BCSP 
(adenomas containing HGD, VH, carcinoma, adenomas ≥10 mm); 
 identifying the predictive factors that influenced the presence or absence of carcinoma 
in the adenomas of the FOBT-positive population; 
 evaluating whether the adenomas of all size categories with advanced neoplasia were 
more common in the left side of the colon; 
 identifying factors that predict the presence of advanced neoplasia in adenomas in 
different segments of the colon. 
4.1 Aims and objectives for the study of surveillance outcome 
These included: 
 detecting the proportion of patients diagnosed with CRC and adenomas at surveillance 
with particular emphasis on first surveillance; 
 determining the proportion of patients with AAs at screening and assessing for any 
significant difference in proportions between the IR and HR groups; 
 detecting the proportion of patients with adenomas ≥10 mm at screening and evaluating 
any significant difference in proportions in between the two groups; 
 assessing the difference in outcome between IR and HR groups at first surveillance and 
determining whether the difference was significant; 
 determining the yield of colorectal neoplasia at second and third surveillance for IR and 
HR groups; 
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 comparing the yield of the proportion of patients with AAs between screening and first 
surveillance and between first and second surveillance to demonstrate the changing 
pattern and determine whether the differences were statically significant.  
4.2 Aims and objectives for the study of surveillance risk re-stratification 
These included: 
 determining the magnitude of advanced neoplasia detected in IR and HR patients at 
screening; 
 determining the magnitude of advanced neoplasia detected at surveillance;  
 identifying the factors at screening that could predict the outcome at surveillance; 
 identifying the effects of alternative surveillance intervals on the outcomes of 
surveillance of HR patients. 
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Chapter 5: Adenoma characteristics in the BCSP 
5.0 Aims and objectives 
These included: 
 detecting the proportion of advanced neoplasia detected in the BCSP (adenomas 
containing HGD, VH, carcinoma, adenoma ≥10 mm); 
 identifying the predictive factors that influence the presence or absence of carcinoma in 
the adenomas of the FOBT-positive population; 
 evaluating whether adenomas with advanced neoplasia of all size categories were more 
common in the left side of the colon; 
 identifying the factors predicting the presence of advanced neoplasia in adenomas in 
different segments of the colon. 
5.1 Methodology 
5.1.1 Data processing 
During colonoscopy, polyps were assessed and data about each polyp was recorded in the 
BCSP database by the specialist nurse. The polyps were then resected, retrieved and sent for 
histological examination. The results of the histological examinations were then transcribed 
into the database. The BCSP national database was interrogated to capture all the lesions 
identified as polyps during colonoscopy for the period from June 2006 to May 2012. The 
information about each polyp is described in Chapter 3. 
The data set was processed (Figure 5.1 and Table 5.1) and cleaned to obtain a 
comprehensive database where all the variables for analysis were available for each of the 
adenomas (Figure 5.2). 
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Figure 5.1 Data processing flow chart. 
 
 
 
 
 
 
 
229 419 (100% data) 
polyps identified from 
June 2006 to June 2012 
Histology for 25 851 
polyps not available, 
hence these were 
excluded 
203 568 polyps 
  
Histological size for 20 582 
not available, hence these 
were excluded 
182 986 polyps  
Architecture for 9773 
polyps not available, 
hence they were 
excluded 
173 213 polyps suitable for analysis 
 
 
 
 
Lesions detected as 
superficial mucosal 
lesions/polyps during the 
study period were 
included, including 
screening and 
surveillance polyps 
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Table 5.1 Histological types recorded in the BCSP 
 
Polyp architecture Number % 
Tubular adenoma 96 980 55.99 
Tubulovillous adenoma 36 061 20.81 
Villous adenoma 2323 1.34 
Hyperplastic 33 480 19.33 
Serrated adenoma 1830 1.06 
Other polyp 1821 1.05 
Mixed HP/adenoma 430 0.25 
Lipoma 117 0.07 
Lymphoid 99 0.07 
Endocrine tumour (carcinoid) 49 0.03 
Stromal 23 0.01 
Total 173 213 100 
Note: HP = hyperplastic 
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Figure 5.2 Data cleaning flow chart. 
Note: NAA = non-advanced adenoma. 
33 589 Non-adenomas excluded 
137 624 adenomas included for 
analysis 
Degree of dysplasia not 
available for 471 adenomas, 
hence excluded 
 
137 139 adenomas included for 
analysis 
166 adenomas located in the 
anus, anastomosis, ileum and 
appendix, hence excluded 
136 973 (59.7% of the data at the start) colorectal adenomas 
included for final analysis, evaluated in relation to size, location 
and advanced histological features  
171 213 polyps with histology, including size, and 
architecture available 
14 adenomas >100 mm, hence 
excluded from analysis 
137 610 adenomas included for 
analysis 
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During the data processing, only colorectal adenomas with their complete histology data 
available were included and these led to inclusion of 59.7% of the total number of polyps to 
be included for the analysis leaving 40.3% of polyps being not included. These has been 
carefully thought off as statistical imputation to create corroborative value in comparison 
the polyps with complete data sets could not account for all biological and genetic 
variabilities that play in part in adenoma formation and progression. In comparison to the 
polyps with data set the polyps with missing data did not reveal any particular pattern, that 
could suggest a reason for missed information.   
Histological size for any analysis involving the adenomas was chosen because it is the most 
appropriate and true measure of adenoma size. Adenomas >100 mm were excluded because 
this may be due to error during data input and because superficial mucosal lesions >100 mm 
are not very common. Adenomas located in the anus and appendix were excluded as these 
locations do not involve the large bowel. Adenomas located in the anastomosis were 
excluded because their segmental location in the bowel was altered as a result of surgical 
procedure. The final data set contained 136 973 adenomas whose information was recorded 
and used.  
For analytical purposes, tubulovillous and villous adenomas were grouped together as 
villous. The large bowel was divided into six segments as shown in Table 5.2; all locations 
proximal to the splenic flexure (SF) were regarded as the right or proximal colon, and all 
locations distal to the transverse colon (TC) as the left or distal colon. For the purpose of 
segmental analysis, the SF and descending colon (DC) were considered as the same segment 
and the ascending colon (AC) and hepatic flexure (HF) as the same segment, because it was 
often anatomically difficult to distinguish between these adjacent parts in the colon.  
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The proportion of AAs and NAAs detected was measured and the AAs and adenomas with 
carcinoma were described together as adenomas with ACN for the purpose of segmental 
analysis.  
Table 5.2 Segmental order of the bowel 
 
Segmental number Location in the bowel 
Segment 1 Rectum 
Segment 2 Sigmoid colon 
Segment 3 DC and SF 
Segment 4 TC 
Segment 5 HF and AC 
Segment 6 Caecum 
Note: DC = descending colon; SF = splenic flexure; TC = transverse colon; HF = hepatic flexure; AC = 
ascending colon. 
 
5.2 Results 
5.2.1 Basic demography of patients with adenomas 
During the study period June 2006 – August 2012 the total number of adenomas included 
for analysis was 136 973, obtained from 58 334 patients during screening or surveillance 
procedures in the BCSP. The majority of patients were men (39 503, 67.72% men; 18 831, 
32.28% women) and the mean age at polypectomy was 66.22 years (range: 59.24–93.30; 
standard deviation (SD): 4.14). 
5.2.2 Adenoma location 
The segmental distribution of the adenomas is shown in Table 5.3 and Figure 5.3. 
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Table 5.3 Location of adenomas 
Location Number % 
Rectum 14 830 10.83 
Sigmoid colon 53 835 39.30 
DC and SF 16 973 12.39 
Transverse 18 580 13.56 
AC and HF 21 076 15.39 
Caecum 11 679 8.53 
Total 136 973 100 
Note: DC = descending colon; SF = splenic flexure; HF = hepatic flexure; AC = ascending colon. 
 
 
 
 
Figure 5.3 Segmental distribution of adenomas. 
Note: DC = descending colon; SF = splenic flexure; HF = hepatic flexure; AC = ascending colon. 
The majority of adenomas were located in the combined regions of the rectum and sigmoid 
colon (50.13%). The majority of adenomas were detected in the distal colon (62.52%). 
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5.2.3 Size distribution of adenomas 
Adenomas were divided into different size cohorts according to increasing size. The 
proportions of adenomas of different size groups are described in Figure 5.4. 
 
Figure 5.4 Size distribution of adenomas. 
 
The majority of adenomas detected by the BCSP were smaller adenomas <5 mm (53.2%) in 
size. Diminutive adenomas and sub-centimetre adenomas accounted for 69.8% of all 
adenomas removed. 
5.2.4 Advanced histological features in the different size categories 
To determine the prevalence of advanced histological features (HGD, VH, carcinoma), 
adenomas were divided into 5-mm size categories. Then, the proportion of adenomas in 
each category containing those features was estimated (Table 5.4 and Figure 5.5). 
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Table 5.4 Percentage of adenomas with an advanced histology 
 
Size (mm) Total number HGD 
N 
HGD 
% 
Villous 
N 
Villous 
% 
Cancer 
N 
Cancer 
% 
1–5 72 815 599 0.8 6489 8.9 79 0.1 
6–9 22 776 896 3.9 6406 28.1 182 0.8 
10–14 19 468 2320 11.9 9928 51.0 539 2.8 
15–19 11 152 2193 19.0 7198 64.5 598 5.4 
20–24 5737 1519 26.5 4119 71.8 389 6.8 
25 –29 2295 723 31.5 1773 77.3 200 8.7 
30–34 1358 483 35.6 1076 79.2 139 10.2 
35–39 397 154 38.8 334 84.1 50 12.6 
40–44 464 177 38.1 386 83.2 42 9.1 
45–49 111 50 45.0 94 84.7 10 9.0 
50–54 214 94 43.9 176 82.2 32 15.0 
55–59 33 15 45.5 27 81.8 4 12.1 
≥60 153 62 40.5 135 88.2 18 11.8 
Total 136 973 9285 6.8 38 141 27.8 2282 1.7 
Note: HGD = high-grade dysplasia. 
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Figure 5.5 Percentage of adenomas with advanced histology. 
Note: HGD = high-grade dysplasia. 
 
Adenomas containing the highest proportion of HGD were 55–59 mm in size. Adenomas 
containing the highest proportion of cancer were 50–54 mm in size. Adenomas containing 
the highest proportion of VH were of 50–54 mm in size (Figure 5.5). The proportion of 
adenomas containing advanced histological features increased with the increasing size of the 
adenoma up to 35 mm and then plateaued. 
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5.2.5 Magnitude of detection of advanced adenomas 
Table 5.5 shows the number and proportion of AAs (adenomas with HGD or VH, size 
≥10 mm) detected. The majority of adenomas were NAAs (81 846, 59.75%), while the 
remaining 55 127 (40.25%) were AAs. The majority of AAs (41 382, 75.06%) were ≥10 mm in 
size. Of the remaining sub-centimetre AAs, a significant proportion (12 895, 23.4%) were AAs 
due to a villous component. Only 850 (1.54%) were AAs due to the presence of HGD. 
Table 5.5 Detection of advanced adenomas 
Adenoma type Number % 
NAA 81 846 59.8 
AA 55 127 40.2 
Total 136 973 100 
Note: NAA = non-advanced adenoma; AA = advanced adenoma. 
In the BCSP, the majority of the adenomas detected and resected were NAAs. 
5.2.6 Analysis of adenomas containing cancer 
5.2.6.1 Analysis plan 
A total of 2282 adenomas containing cancer were included in the final data set used for 
analysis. These analyses were performed to obtain information about the location of 
malignant adenomas in the colon, their size and distribution between the sexes. The 
proportions of adenomas were analysed to see whether there were any differences between 
the proportions of adenomas with or without carcinoma in men and women, and between 
proximal and distal sites in the colon. 
Univariate and multivariate logistic regression analyses were carried out to determine the 
significant factors that could influence the development of carcinoma in adenomas; then, 
the OR with 95% CIs for these significant factors was calculated. 
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5.2.6.2Location of adenomas containing carcinomas 
Table 5.6 shows the location of adenomas that contained carcinomas. 
Table 5.6 Location of adenomas with cancer 
 
Location N % 
Sigmoid colon 1623 71.1 
Rectum 449 19.7 
DC 105 4.6 
TC 27 1.2 
SF 23 1.0 
AC 37 1.6 
HF 10 0.4 
Caecum 8 0.4 
Total 2282 100 
Note: DC = descending colon; TC = transverse colon; SF = splenic flexure; AC = ascending colon; HF = 
hepatic flexure. 
 
The majority (90.8%) of adenomas containing carcinomas were situated in the rectosigmoid 
region. The majority (95.6%) of adenomas containing carcinomas were located in the left 
side of the colon.  
5.2.6.3Size distribution of adenomas with carcinomas 
Malignant adenomas were divided into different size cohorts; the proportion of malignant 
adenomas in the different size cohorts is shown in Table 5.7. 
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Table 5.7 Size distribution of adenomas with carcinomas 
 
Size (mm) N % 
1–5  79 3.5 
6–9  182 8.0 
10–14 539 23.6 
15–19 598 26.2 
20–24 389 17.0 
25–29 200 8.8 
30–34 139 6.1 
35–39 50 2.2 
40–44 42 1.8 
45–49 10 0.4 
50–54 32 1.4 
55–59 4 0.2 
>60 18 0.8 
Total 2282 100 
The majority (66.8%) of adenomas containing carcinomas were 10–24 mm in size. 
 
5.2.6.4 Sex distribution of malignant adenomas 
Adenomas were categorized according to the sex of the participants; then, the proportion of 
adenomas containing carcinomas was measured for each sex (Table 5.8). 
A Pearson’s chi-square test was performed to assess the significance of the difference 
between proportions (Table 5.9). 
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Table 5.8 Proportion of malignant adenomas in men and women 
 
Adenoma type  Men 
N (%) 
Women 
N (%) 
Adenoma  99 665 (98.5) 35 026 (98.0) 
Adenoma with carcinoma 1562 (1.5) 720 (2.0) 
Total 101 227(100) 35 746 (100) 
 
 
Table 5.9 Pearson’s chi-square test results 
 
 
Test performed χ² df  Two-tailed P-value 
Pearson’s chi-square 35.794 1 <0.001 
Note: df = degrees of freedom. 
 
The proportion of adenomas containing carcinomas was higher in women and the difference 
was statistically significant.  
5.2.6.5Sex and location distribution analysis for adenomas with cancer 
Adenomas were categorized into groups according to their proximal or distal location. 
Location in the SF, DC, sigmoid colon and rectum was considered as distal; the remaining 
locations were considered as proximal. In each group, the proportion of adenomas with 
carcinomas and their distribution between the sexes were measured. Pearson’s chi-square  
tests were used to measure whether there was any significant difference in the proportion 
of adenomas with cancer between men and women, incorporating both proximal and distal 
locations. The results of the analysis are shown in Table 5.10. 
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Table 5.10 Location and sex distribution of AAs with and without carcinomas 
 
Location Sex Adenoma 
N (%) 
Adenoma 
with 
carcinoma 
N (%) 
χ² df P 
Distal Female 22 224 (97.0) 693 (3.0) 25.88 1 <0.001 
Distal Male 61 214 (97.6) 1507 (2.4)    
Proximal Female 12 802 (99.8) 27 (0.2) 2.75 1 0.097 
Proximal Male 38 451 (99.9) 55 (0.1)    
Total Female 35 026 (98.0) 720 (2.0)    
Total Male 99 665 (98.5) 1562 (1.5)    
  134 691 2282    
Note: df = degrees of freedom. 
 
Compared to adenomas detected in men, adenomas detected in women had a higher 
proportion of carcinoma in the distal colon, and this difference was statistically significant. 
There was no significant difference in the proportion of adenomas containing carcinomas in 
the proximal colon and between men and women. 
5.2.6.6Age group and sex distribution of adenomas with carcinomas  
Adenomas were divided according to the patient’s age at the time of the polypectomy. The 
proportion of adenomas with cancer was measured for both sexes in the four age groups. A 
Pearson’s chi-square test was performed to evaluate the significance in the different 
proportions of malignant adenomas between the two sexes in all four age group. The results 
are described in Table 5.11. 
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Table 5.11 Age group distribution of adenomas containing carcinomas 
 
Age, 
years 
Sex Adenoma  
N (%) 
Adenoma with 
carcinoma 
N (%) 
χ² df P 
60–65 Female 13 316 (98.0) 278 (2.0) 15.7 1 <0.001 
 Male 39 349 (98.5) 619 (1.5)    
66–70 Female 14 826 (98.0) 309 (2.0) 19.17 1 <0.001 
 Male 42 282 (98.5) 650 (1.5)    
71–75 Female 6326 (98.2) 118 (1.8) 2.14 1 0.14 
 Male 16 730 (98.4) 265 (1.6)    
>75 Female 557 (97.4) 15 (2.6) 0.41 1 0.52 
 Male 1276 (97.9) 28 (2.1)    
Note: df = degrees of freedom. 
 
In patients up to 70 years of age, adenomas detected in women had a higher proportion of 
malignancy than adenomas from men and the difference was statistically significant. 
There was no significant difference in the proportion of adenomas containing carcinomas 
between men and women above the age of 70 years. 
5.2.6.7Factors that predict the presence of carcinomas in adenomas 
The factors assessed in the model were patient- and adenoma-specific characteristics. 
Adenoma-specific factors included: the presence of VH, HGD, distal location and increasing 
size. Adenomas were divided into three size categories (<6 mm, 6–9 mm and >9 mm). 
Patient-specific factors included female sex and increasing age. 
The distribution of adenoma- and patient-specific factors is described in Table 5.12. 
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Table 5.12 Adenoma- and patient-specific factors 
Note: HGD = high-grade dysplasia; VH = villous histology. 
A univariate analysis was performed followed by a multivariate analysis to detect important 
predictive factors in logistic regression. The results are described in Tables 5.13 and 5.14. 
The Wald test calculates a z statistic for each coefficient in the logistic model, which is 
squared and has a chi-square distribution; the OR is a measure of the association between 
exposure and outcome; it represents the odds that an outcome will occur given a particular 
exposure, compared to the odds the outcome will produce in the absence of that 
exposure/reference. 
 
 
 
Adenoma-specific factors 
Number HGD  
N (%) 
VH 
N (%) 
Distal 
location 
N (%) 
<5 mm 
N (%) 
6–9mm 
N (%) 
>9mm 
N (%) 
136 491 (adenomas) 7258 
(5.4) 
36 621 
(27.3) 
83 438 
(61.1) 
72 736 
(54.0) 
22 594 
(16.5) 
39 361 
(29.3) 
2282 (adenomas 
with cancer) 
2027 
(88.8) 
1520 
(66.6) 
2200 
(96.4) 
79 
(3.5) 
182 
(8.0) 
2021 
(88.6) 
Patient-specific factors 
Number Men 
N (%) 
<66 
years 
N (%) 
66–70 
years 
N (%) 
71–74 
years 
N (%) 
>74 years 
N (%) 
136 491 (adenomas) 99 665 
(73.0) 
52 665 
(38.6) 
57 108 
(42.4) 
23 056 
(17.1) 
1833 
(1.3) 
2282 (adenomas 
with cancer) 
1562 
(68.4) 
897 
(39.3) 
959 
(42.0) 
383 
(16.8) 
43 
(1.9) 
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Table 5.13 Result of the univariate logistic regression for adenoma- and patient-specific 
factors determining cancer in adenomas 
Factors  Wald test OR  
(df = 1) 
Lower 95% CI Upper 95% CI P 
HGD 5347.87 139.5 122.2 159.3 <0.0001 
VH 1398.37 5.34 4.89 5.83 0.008 
Distal location 619.19 16.48 13.21 20.55 0.002 
Female sex 35.58 1.31 1.2 1.4 <0.001 
6–9 mm 220.46 7.41 5.69 9.66 <0.001 
>9 mm 1127.06 47.27 37.45 59.2 <0.001 
Note: OR = odds ratio; df = degrees of freedom; CI = confidence interval; HGD = high-grade dysplasia; 
VH = villous histology. 
 
The univariate analysis model for age alone is not significant in predicting the presence of 
cancer in adenomas in the three different age groups and hence it is not included. 
In univariate analysis, HGD, presence of VH, distal location, increasing size and female sex 
showed significant ORs for the presence of carcinomas in adenomas. 
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Table 5.14 Results of the multivariate logistic regression for adenoma- and patient-specific 
factors determining cancerous adenomas 
Factors for 
cancer 
B Wald P OR  Lower 95% 
CI OR 
Upper 95% 
CI OR 
HGD 4.175 3283.447 <0.001 65.049 56.39 75.03 
VH −0.018 0.125 0.724 0.982 0.88 1.08 
Distal location 1.141 91.285 <0.001 3.129 2.47 3.95 
Female 0.154 9.076 0.003 1.16 1.05 1.28 
60–64 years 
(Ref) 
      
65–69 years −0.045 0.744 0.388 0.956 0.863 1.059 
70–74 years 0.125 3.251 0.071 1.133 0.989 1.298 
>74 years 0.14 0.614 0.433 1.15 0.811 1.632 
<6 mm (Ref)       
6–9 mm 1.019 51.791 <0.001 2.771 2.099 3.657 
>9 mm 1.553 149.786 <0.001 4.728 3.687 6.063 
Note: OR = odds ratio; CI = confidence interval; HGD = high-grade dysplasia; VH = villous histology. 
 
Controlling for all other factors, the presence of HGD, distal location and increasing size had 
significantly higher ORs for malignant adenomas. 
An adenoma detected in a woman would be 1.1 times more likely to contain a carcinoma 
than an adenoma detected in a man. This higher OR for women was statistically significant 
(P = 0.003) but was not a very strong determining factor (95% CI = 1.05–1.28). 
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5.2.7 Adenomas with advanced neoplasia in the right (proximal) and left (distal) 
colon 
An adenoma with advanced neoplasia is described as one that contains any of the following 
characteristics: HGD, VH and carcinoma. All adenomas were categorized into three groups 
according to their size as determined by histological examination (<6 mm, 6–9 mm and 
>9 mm). 
5.2.7.1Are adenomas with advanced neoplasia more common in the left or right  
  colon? 
The number and proportion of advanced neoplasia for the different size categories and the 
two different locations were measured. A Pearson’s chi-square test was used for each size 
category to determine the significance of the differences in proportion between the right 
and left side of the colon (Table 5.15 and Figure 5.6).  
 
Table 5.15 Distribution of adenomas with advanced neoplasia in the three size categories 
and proximal and distal locations 
Size 
(mm) 
LA 
(N) 
LA 
(%) 
LAN 
(N) 
LAN 
(%) 
RA 
(N) 
RA 
(%) 
RAN 
(N) 
RAN 
(%) 
<6  29 926 89.1 3677 10.9 35 976 91.7 3236 8.3 
6–9 10 143 65.9 5238 34.1 5733 77.5 1662 22.5 
>9 11 706 31.9 24 948 68.1 2165 45.8 2563 54.2 
Note: LA = left-sided adenoma; RA = right-sided adenoma; LAN = left-sided advanced adenoma, RAN = 
right-sided advanced adenoma. 
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Figure 5.6 Distribution of ACN in all size categories. 
Note: ACN = advanced colorectal neoplasia. 
The proportion of adenomas with advanced neoplasia was greater in the left than the right 
side of the colon in all size categories. There was a statistically significant increased 
proportion of adenomas with advanced neoplasia in the left colon, in each size category, as 
shown by the chi-square test in Table 5.16. 
 
Table 5.16 Chi-square test statistics 
 
Note: LA = left-sided adenoma; LACN = left-sided advanced colorectal neoplasia; RA = right-sided 
adenoma; RAN = right-sided advanced colorectal neoplasia; df = degrees of freedom. 
 
R <6 mm R 6-9 mm R >9 mm L<6 mm L 6-9 mm L >9mm
91.7 
77.5 
45.8 
89.1 
65.9 
31.9 
8.3 
22.5 
54.2 
10.9 
34.1 
68.1 
Size 
(mm) 
LA  
N (%) 
LACN  
N (%) 
RA  
N (%) 
RACN  
N (%) 
χ² (df = 1) 
 
P 
<6 
29 926 
(89.1) 
3677 
(10.9) 
35 976 
(91.7) 
3236  
(8.3) 
152.06 <0.001 
6–9 
10 143 
(65.9) 
5238 
(34.1) 
5733 
(77.5) 
1662 
(22.5) 
316.59 <0.001 
>9 
11 706 
(31.9) 
24 948 
(68.1) 
2165 
(45.8) 
2563 
(54.2) 
360.1 <0.001 
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5.2.7.2Are adenomas with advanced neoplasia smaller in the right than left colon? 
The differences in size between right- and left-sided adenomas were measured with the 
Student’s t-test for all adenomas first and then for ACNs. The results of the t-test and the 
size distribution are shown in Tables 5.17 and 5.18, and Figures 5.7 and 5.8. 
 
Table 5.17 Difference in mean adenoma size between the left and right side for all 
adenomas 
Note: SD = standard deviation; MD = mean difference; CI = confidence interval. 
 
 
 
 
 
 
Location N Mean size 
(mm) 
SD  MD 95% CI of 
MD 
t  P 
Left 85 638 9.71 7.857 4.898 4.83–4.96 143.8
7 
<0.0001 
Right 51 335 4.81 4.743 – – – – 
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Figure 5.7 Box plot showing the size of left- and right-sided adenomas. 
The rectangle represents 50% of the cases, the line in the middle of the box represents the 
median value, the whiskers represent the maximum and minimum values and the dots 
above the whiskers represent the outliers, in this case larger adenomas. 
 
Table 5.18 Difference in mean size between left- and right-sided ACNs 
 
Location Number Mean 
Size 
(mm) 
SD  MD 95% CI of MD t P 
Left 33 863 14.54 8.66 5.29 5.07–5.50 47.55 <0.0001 
Right 7461 9.25 8.7 – – – – 
Note: ACN = advanced colorectal neoplasia; SD = standard deviation; MD = mean difference. 
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Figure 5.8 Box plot showing the size of left/distal and right/proximal ACN. 
Note: ACN = advanced colorectal neoplasia. 
All left-sided adenomas were larger than right-sided adenomas; any differences in size were 
statistically significant. 
 
5.2.7.3Relationship between adenomas with advanced neoplasia and their size, 
  location, patient sex and age when detected 
The distribution of the predictor factors for adenomas with and without advanced neoplasia 
was measured with univariate and multivariate logistic regression analyses to identify 
important predictors of ORs with a 95% CI (Tables 5.19 and 5.20). 
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Table 5.19 Distribution of patient- and adenoma-specific factors (sex, location and size) in 
adenomas with and without advanced neoplasia 
Number Men 
N (%) 
Women 
N (%) 
Right 
colon 
N (%) 
Left 
colon 
N (%) 
<6 mm 
N (%) 
6–9 mm 
N (%) 
>9 mm 
N (%) 
A = 95 649 71 624 
(74.9) 
24 025 
(25.1) 
43 874 
(45.9) 
51 775 
(54.1) 
65 902 
(68.9) 
15 789 
(16.6) 
13 871 
(14.5) 
ACN = 
41 324 
29 603 
(71.6) 
11 721 
(28.4) 
7461 
(18.1) 
33 863 
(81.9) 
6913 
(16.7) 
6900 
(16.7) 
27 511 
(66.6) 
Note: A = adenoma without advanced neoplasia; ACN = advanced colorectal neoplasia. 
 
 
Table 5.20 Results of univariate analysis showing the ORs of the predictor factors for CAN 
 
 
Factors Wald test OR (df = 1) Lower 95% CI 
of OR 
Upper 95% 
CI of OR 
P 
Female sex 157.44 1.18 1.15 1.21 <0.001 
Left colon 8822.6 3.84 3.73 3.73 <0.001 
6–9 mm 5494 4.14 3.99 4.3 <0.001 
>9 mm 32 209 18.9 18.31 19.52 <0.001 
Note: OR = odds ratio; df = degrees of freedom; CI = confidence interval. 
Increasing size and left-sided location were independently associated with a statistically 
significant increased risk for the presence of advanced neoplasia in adenomas (Tables 5.21 
and 5.22). 
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Table 5.21 Multivariate logistic regression result showing the determining factors for ACN 
 
Factors for ACN B Wald test P OR Lower 95% 
CI OR 
Upper 95% 
CI OR 
Left location 0.462 750.52 <0.001 1.58 1.53 1.64 
Right location (ref)       
Female sex 0.16 42.11 <0.001 1.10 1.07 1.14 
Male sex (ref)       
<6 mm (ref)       
6–9 mm 1.335 4713 <0.001 3.8 3.65 3.94 
>9 mm 2.766 25592 <0.001 15.89 15.36 16.44 
Note: ACN = advanced colorectal neoplasia; OR = odds ratio; CI = confidence interval. 
 
Controlling for all other factors, when adenomas were located in the left colon they were 1.5 
times more likely to show ACN compared to adenomas in the right colon. Controlling for all 
other factors, size was an independent predictor for adenomas to have features of ACN. 
Adenomas of 6–9 mm and >9 mm in size were 3.5 and 15 times, respectively, more likely to 
have ACN features than adenoma of <6 mm size. Female sex also was a significant, 
independent predictor for adenomas to display advanced neoplasia (OR = 1.10; 95% CI = 
1.07–1.14). 
 
5.2.7.4When compared to left-sided adenomas, do most right-sided adenomas with  
  advanced neoplasia belong to the sub-centimetre size categories? 
To answer this question, adenomas with ACN were grouped into three different size 
categories; then, a binary logistic regression analysis was performed where the dependent 
variable was location and the predictor variables were the size categories of adenomas with 
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ACN. ORs were adjusted for age and sex. The distribution of size categories and results of the 
regression analysis are described in Table 5.22. 
 
Table 5.22 Distribution of size category for left- and right-sided ACNs 
 
Size (mm) LACN (N) LACN (%) RACN (N) RACN (%) 
<6 3677 10.9 3236 43.4 
6–9 5238 15.5 1662 22.3 
>9 24 948 73.7 2563 34.4 
Total 33 863 100 7461 100 
Note: LACN = left-sided advanced colorectal neoplasia; RACN = right-sided advanced colorectal 
neoplasia. 
 
The majority of right-sided ACNs (65.7%) were <10 mm, and the majority of left-sided ACNs 
(73.7%) were >9 mm. This difference was statistically significant (χ2 = 764.2; P<0.0001). 
5.2.7.5How did adenomas with advanced neoplastic features differ in the different 
segments of the large bowel? 
Adenomas were categorized according to their location in the colon. The proportion of 
advanced neoplasia in each segment was measured (Table 5.23 and Figure 5.9). 
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Table 5.23 Proportion of advanced neoplasia in the different colonic segments 
 
Adenoma 
type 
Rectum 
N (%) 
Sigmoid 
colon 
N (%) 
DC&SF 
N (%) 
TC 
N (%) 
HF&AC 
N (%) 
Caecum 
N (%) 
Without 
AN 
8564 
(57.7) 
29 636 
(55.0) 
13 575 
(80.0) 
16 405 
(88.3) 
17 776 
(84.3) 
9693 
(83.0) 
With ACN 6266 
(42.3) 
24 199 
(45.0) 
3398 
(20.0) 
2175 
(11.7) 
3300 
(15.7) 
1986 
(17.0) 
Total 14 830 53 835 16 973 18 580 21 076 11 679 
Note: AN = advanced neoplasia; ACN = advanced colorectal neoplasia; DC&SF = descending colon and 
splenic flexure; TC = transverse colon; HF&AC = hepatic flexure and ascending colon. 
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Figure 5.9 Advanced neoplasia in adenomas located in different segments of the colon. 
Note: ACN = advanced colorectal neoplasia; DC&SF = descending colon and splenic flexure; HF&AC = 
hepatic flexure and ascending colon. 
 
Adenomas in the sigmoid colon had the highest proportion of advanced neoplasia. The 
proportion of advanced neoplasia was lowest in adenomas located in the TC. The proportion 
of advanced neoplasia in adenomas declined from the sigmoid up to the TC and then 
showed a rise through the rest of the two proximal segments. 
 
          Advanced colorectal neoplasia 
          Non-advanced adenoma 
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5.2.7.6How did the location of an adenoma predict the presence of advanced  
  neoplastic features? 
Multivariate logistic regression was performed where the dependent factor was the 
presence or absence of advanced neoplasia, and the predictor variables were segmental 
location, sex, age and size of the adenoma. Location and sex were modelled into the 
regression analysis as categorical variables. Location in the caecum and male sex were 
considered as references for this analysis. Participants age and size of the adenoma were 
entered into the regression analysis as continuous variables, to measure changes in ORs for 
advanced neoplasia with each unit increase of age (years) and size (mm). 
The results of the regression analysis are shown in Table 5.24. 
 
Table 5.24 Results of logistic regression: advanced neoplasia versus segmental location 
Location B 
(coefficient) 
z (Wald 
test) 
P OR 95% CI OR 
Rectum 0.714 461.76 <0.0001 2.04 1.91–2.18 
Sigmoid 0.405 187.53 <0.0001 1.49 1.41–1.58 
DC&SF  −0.091 6.83 0.009 0.91 0.85–0.97 
TC −0.394 116.79 <0.0001 0.67 0.62–0.72 
HF&AC −0.112 10.95 0.001 0.89 0.83–0.95 
Caecum (ref)      
Female sex 0.093 34.05 <0.0001 1.09 1.06–1.13 
Age (years) 0.002 1.109 <0.0001 1.003 1.001–1.005 
Adenoma size 
(mm) 
0.192 1895 <0.0001 1.21 1.20–1.21 
Note: OR = odds ratio; CI = confidence interval; DC&SF = descending colon and splenic flexure; TC = 
transverse colon; HF&AC = hepatic flexure and ascending colon. 
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An adenoma located in the rectum was twice as likely to have advanced neoplasia compared 
to an adenoma located in the caecum. Compared to adenomas located in the caecum, 
adenomas located in the AC, HF, TC, SF and DC showed lower ORs for advanced neoplasia 
(the coefficients were negative and the ORs did not exceed the value of 1). An adenoma 
from a female patient had a higher probability of having advanced neoplasia (OR = 1.09). 
Adenomas located in the TC had the lowest odds for advanced neoplasia, when all other 
factors were controlled for. 
5.3 Discussion 
Numerous studies of the natural history of adenomas have shown that only a minor 
proportion of colorectal adenomas develop into CRC [8, 35]. Adenomas that continue to 
grow and become AAs have the highest malignant potential. From the perspective of bowel 
cancer screening, it is important to identify the factors associated with the presence of ACN, 
so that this knowledge helps the screening endoscopist to identify and remove these lesions. 
Several studies have reported on the magnitude of detection of advanced neoplasia in a 
screened population. In a cross-sectional analysis performed on a population- based 
colonoscopy screening programme, Regula et al. [42] reported that 5.6% of participants had 
advanced neoplasia. This study analysed the results of 50 148 screening colonoscopies in 
Poland over a four-year period, from October 2000 to December 2004. Brenner et al. [50] 
also reported the prevalence of AAs in a screened population. They derived their data from a 
national screening colonoscopy database of 840 149 participants. AAs were detected in 7.5% 
of patients aged 60–64 years and in 8.4 and 9.2% of patients aged 65–69 and 70–74 years, 
respectively. A systematic review performed to study the distribution of advanced neoplasia 
in 20 562 screened individuals used data from four different studies and demonstrated that 
AAs were only detected in 1155 individuals (5.6%) [45]. Although these studies performed a 
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‘per-participant’ analysis, it is clear that only a small proportion of participants had advanced 
neoplasia; also, the majority of these studies were based on screening programmes where 
colonoscopy was the screening tool. 
In this thesis, only adenomas that had been resected were analysed where the BCSP had a 
complete data set from a FOBT screening programme. ‘Per-adenoma’ analysis demonstrated 
that the majority of adenomas detected were NAAs (81 846; 58.2%) (see Table 5.5). This is in 
keeping with the findings of the other screening studies. The relatively higher proportion of 
AAs compared to previous studies was because only patients with adenomas were included 
and a per-adenoma analysis  was  performed.  In addition, the population studied was  a  
FOBT-positive cohort. 
The majority of adenomas (50.1%) detected in the BCSP were located in the rectum and 
sigmoid colon and 76.59% of all adenomas were located in the distal colon (see Table 5.3 
and Figure 5.3). The distribution of adenomas in the BCSP population is in keeping with the 
epidemiological studies that have demonstrated similar distributions [33, 112]. The 
distributions of adenomas in the BCSP population follows the pattern described in those 
epidemiological studies describing the natural history of colorectal adenoma and also 
perhaps represent the fact that these are derived from FOBT population and left sided 
adenomas with bleeding would be identified more in during the screening. 
The prevalence of an advanced histology in adenomas of different size categories has also 
been well documented [45, 113–116]. These studies evaluated various patient- and 
adenoma-specific factors that are important determinants for the presence of advanced 
histological features in adenomas. The adenoma data in the NPS was derived from 3371 
adenomas (1867 patients); the size and extent of the villous component of the adenoma 
were the major independent risk factors associated with HGD [112]. The increased detection 
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of HGD in distal adenomas was attributed to increased size and villous component rather 
than location. The sex of the participants was not associated with HGD in this study. The 
multiplicity of factors influencing HGD was also dependent on size and VH. 
Lieberman et al. [113] studied 13 992 asymptomatic individuals who had a screening 
colonoscopy; 45% of them had polyps. The study identified an advanced histology in 1.7% of 
the 1–5-mm group, and in 6.6 and 30.6% of the 6–9-mm and >9-mm groups, respectively. 
Otake et al. [114] studied the cumulative incidence of advanced neoplasia during follow-up 
in patients who had diminutive (<5 mm) adenomas at screening and had been referred for 
polypectomy. Only 2.8% of patients with diminutive polyps demonstrated advanced 
histology, but the incidence was significantly higher in those who had multiple (>3) 
adenomas. 
Gschwantler et al. [115] studied patient and adenoma characteristics associated with HGD 
and invasive carcinoma/colorectal adenomas. Their study included 4216 patients and 7590 
adenomas were removed from them. They concluded that adenoma size was the most 
important risk factor for the presence of advanced histological features. In this study, the 
percentages of advanced histology detected were 3.4, 13.5 and 38.5% for adenomas with a 
diameter <5 mm, 5–10 mm and >10 mm, respectively. No CRC was detected in adenomas 
with a diameter <5 mm. Their multivariate analysis identified size, left-sided location, VH and 
age as risk factors for advanced histology. Sex and multiplicity of adenomas failed to 
demonstrate any influence. 
Nusko et al. [116] studied a number of patient- and adenoma-specific characteristics to 
determine their influence on the risk of developing CRC in all adenomas. They performed a 
‘per-adenoma’ analysis that included a total of 11 188 adenomas removed during the period 
from 1978 to 1993. Adenoma size proved to be the most important factor followed by 
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 left-sided location. They did not find CRC in adenomas <6 mm size (5027 adenomas). They 
also demonstrated that with increasing size there was a right-sided shift (that is, more 
cancers were found in right-sided adenomas) as a result of the interaction between location 
and size. They also demonstrated complex interaction between sex and a multiplicity of 
factors predicting for higher risk of CRC in adenomas. 
Increasing size and distal location were factors associated with advanced histology and 
carcinoma in the studies mentioned here. 
In a complex interaction model, a patient’s age and sex were identified as factors 
determining malignant transformation of the benign colorectal adenomas. In contrast to two 
of the studies mentioned earlier [115, 116], a very small proportion of adenomas <6 mm in 
size (79/72 815; 0.1%) were shown to contain a focus of cancer (see Table 5.4 and Figure 
5.5). This perhaps shows that some of the CRCs developed de novo from the epithelium and 
some developed cancer through a different carcinogenesis pathway than the adenoma–
carcinoma sequence, where increasing size is a driving factor in developing a malignant 
focus. This pathway was described as a de novo pathway; according to this hypothesis, CRC 
can also develop de novo from normal mucosa. This pathway is well described in the 
Western and Japanese literature [117–120]. It is an increasingly recognized entity, with more 
diminutive CRC cases being described recently [121]. In a study from the UK, Rembacken et 
al. [122] looked at flat and depressed colorectal lesions and reported that 6% of flat 
adenomas <10 mm showed early CRC signs. The FOBT-positive screening cohort discussed in 
this thesis represents a population at high risk of developing CRCs; the adenomas detected 
in this population represented adenomas that developed either through the conventional 
adenoma–carcinoma sequence or through the de novo pathway. For this reason, in the 
multivariate analysis, size and HGD were separate independent factors used to identify risk 
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factors associated with malignant adenomas because HGD could be a size-independent risk 
factor for developing CRC. 
Adenoma size appeared to be a crucial factor associated with advanced histology; accurate 
estimation of adenoma size is also important for risk stratification and surveillance planning. 
Wide variation in optical size estimation has been reported among experienced 
endoscopists, which in turn adversely affected surveillance intervals [123, 124]. Histological 
size is the most accurate available estimation of adenoma size; it was used in the BCSP and 
was also used for the analysis in this thesis. The analysis performed in this work was on a 
per-adenoma rather than per-person basis, which helped to develop an understanding of 
the assessment of each individual adenoma from an endoscopist’s perspective. 
The distribution of advanced histology demonstrated that the proportion of adenomas 
containing advanced histological features increased with increasing size of the adenomas up 
to 35 mm, after which it plateaued (see Figure 5.5).  
The proportion of advanced histology in diminutive (<6 mm) and small adenomas (6–9 mm) 
was measured. HGD was present in 0.8 and 3.9% of diminutive and smaller adenomas and 
VH was present in 28.1 and 8.9% of smaller and diminutive adenomas. VH accounted for the 
majority of advanced histology in sub-centimetre adenomas. The proportion of adenomas 
with malignancy was very low in these two groups (0.1% in diminutive and 0.8% in smaller 
adenomas). These findings are similar to those of other studies which measured advanced 
histology in sub-centimetre adenomas and also found that VH accounted for the majority of 
advanced histology [125]. 
This is an important finding because a very low prevalence of advanced histology was  
reported in another study by Gupta et al. [126]; this could have important implications for 
the potential practice of ‘predicting, resecting and discarding’ diminutive colon polyps. This 
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study included 2361 adenomas; their sensitivity analysis revealed that the frequency of 
advanced histological features varied from 0.2 to 0.7% within diminutive polyps, and from 
1.5 to 3.6% within small polyps. The proportion of advanced histology is much greater in the 
adenomas detected in a FOBT-positive population. 
The multivariate analysis described in this thesis demonstrated that HGD, increasing 
adenoma size, distal location and female sex were independent risk factors associated with 
carcinoma (see Table 5.14). Also, the proportion of adenomas containing cancer was higher 
in the adenomas of female patients and the difference in proportion was significant for 
malignant adenomas detected in the left or distal colon. In the BCSP, after the first 1 million 
FOBT tests, more CRC was found in men (men vs. women, 11.6 vs. 7.8%) [107]. The findings 
of more adenomas containing cancer when they are still identifiable as polyps in female 
patients (in this study) perhaps reflect the fact that more CRCs in women were detected in 
the BCSP when lesions were still confined as superficial mucosal lesions and/or locally 
confined as polyps. VH did not achieve any significance as an associated factor for the 
presence of carcinomas in adenomas either in univariate or in multivariate analysis. 
The differences between right- and left-sided AAs have been previously studied. Researchers 
reported that right-sided AAs were smaller that their left-sided counterparts and hence 
easier to miss during colonoscopy. Gupta et al. [127] performed a cross-sectional analysis of 
the histology performed at a single centre providing services to more than 1900 
endoscopists in 43 states in the USA. They studied 233 414 polyps removed from 142 686 
patients. They demonstrated that size distribution was similar in the right and left side of the 
colon for all polyps; however, in the case of AAs and adenomas with HGD or cancer, right-
sided adenomas were significantly smaller in size (adenomas with HGD and CRC: right vs. 
left, 8.2 vs. 12.4, P<0.001; AAs: right vs. left, 7.6 vs. 11.1; P<0.001). Their findings suggested 
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that colonoscopy inconsistently protects against right-sided CRC as smaller AAs were easy to 
miss. This fact was further augmented by the evidence in another study which demonstrated 
a greater likelihood for missed and recurrent adenomas in the proximal colon [128]. 
For this thesis, the author had the opportunity to address these issues and the results have 
demonstrated that diminutive (<6 mm), small (6–9 mm) and larger adenomas (≥10 mm), and 
adenomas detected in the left colon had significantly higher proportions of ACN (see Tables 
5.14 and 5.15, and Figure 5.6). Size distribution and the mean size of left-sided adenomas 
were significantly larger than right-sided adenomas in this cohort and this was true for all 
adenomas and ACN (see Tables 5.16 and 5.17 and Figures 5.6 and 5.7). When ACNs were 
considered, only then did the majority of right-sided ACNs belong to the sub-centimetre 
category (see Table 5.22), in contrast to the left side where the majority of ACNs were of 
≥10 mm. This was purely because all adenomas in the left side were larger and hence had a 
higher proportion of advanced histology in each size category; this further supported the 
fact that the malignant potential of the left-sided colonic epithelium is more than that of the 
right colon. 
The fact that malignant adenomas were detected in different segments of the distal colon in 
varying proportions (see Table 5.6) and the evidence from the existing literature that distal 
segments of the colon were more exposed to carcinogens [81], raise the question about the 
biological differences in different segments of the colon, which could be explained in terms 
of the varied malignant potential of each segment. 
A segmental analysis was performed to answer this question. The distribution of ACNs 
demonstrated that the sigmoid colon had the highest proportion of ACN and the transverse 
had the lowest (see Table 5.23 and Figure 5.8). The multivariate analysis performed with a 
valid model confirmed that segmental locations were significant and independent risk 
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factors determining the presence of advanced histological features in adenomas, along with 
adenoma size and sex of the patient (see Table 5.24). These findings suggest that left sided 
colonic epithelium is biologically different and more tumorigenic and further studies 
including cytogenetic analysis into right and left sided colorectal adenomas could answer 
this question. NHS BCSP provides a unique opportunity to perform this which in turn can 
lead into individualistic management and surveillance protocol depending on different 
cytogenetic abnormalities in different segments of colon.   
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Chapter 6: Surveillance follow-up 
6.0 Introduction 
In the BCSP, the BSG guidelines for adenoma surveillance are followed except that the LR 
group is called back for biennial FOBT screening instead of having surveillance colonoscopy 
after five years. The HR and IR groups, who underwent continuing surveillance in the BCSP 
for the study period between June 2006 and August 2012, are analysed in this chapter.  
6.1 Aims and objectives 
The main aims included: 
 detecting the proportion of patients diagnosed with CRC and adenomas at surveillance 
with particular emphasis on the results at first surveillance; 
 determining the proportion of patients with AAs at screening and assessing any 
significant difference in prevalence between the HR and IR groups; 
 detecting the proportion of patients with adenomas ≥10 mm size at screening and 
evaluating any significant difference in prevalence between the two groups; 
 assessing any differences in outcomes between the HR and IR groups at first surveillance 
and determining whether any difference was significant; 
 determining the yield of colorectal neoplasia at second and third surveillance for the HR 
and IR groups; 
 comparing the incidence of patients developing AAs between screening and first 
surveillance and between first and second surveillance to demonstrate the changing 
pattern and determine whether any differences are statically significant. 
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6.2 Methods 
Three data sets were obtained from the national database. They contained all the 
participant information, the procedure used and polyp details. The information obtained has 
been discussed in Chapter 3 (Methodology). The data were processed to create two 
separate data sets, the first set containing the participant- and procedure-specific data on 
the screening episodes, and the second set containing similar participant- and procedure-
specific data on the surveillance episodes. The data sets containing the polyp details were 
further divided into two separate data sets. The first set had all the information for the 
polyps detected and resected during the screening episodes; the second set contained 
similar polyp data at screening and surveillance. The data sets containing the participant and 
procedure details were merged with the polyp data sets to obtain two comprehensive, 
workable data sets that contained relevant information about each participant, procedure 
and polyps for both screening and surveillance episodes. The surveillance episodes were 
chronologically sequenced for each and every participant to identify multiple surveillances 
against each participant. The comprehensive screening and surveillance data sets were then 
merged to obtain the final data set. This contained all the data required for each participant 
with regard to their screening and subsequent surveillance episodes. 
For the analyses of the yield of AAs at screening, and at first and second surveillance, 
participants with available histology for their adenomas were included and the HR and IR 
groups were combined to assess the difference in yield of AAs between screening and first 
surveillance episodes and also between first and second surveillance. 
The data were processed and merged using the Stata Statistical Software, Release 12.1 
(StataCorp LP, College Station, TX, USA) and the analyses were performed with IBM SPSS 
Statistics for Windows, Version 20.0 (IBM Corporation, Armonk, NY, USA). The differences of 
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proportions were statistically evaluated by performing a Pearson’s chi-square test and 
McNemar’s test whenever appropriate, and the results are shown in tables in this chapter. 
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6.3 Data processing 
6.3.1 Participant and procedure data 
These are summarized in Figure 6.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Participant- and procedure-specific data. 
Note: HR = high-risk; IR = intermediate-risk. 
 
Details available for 
24 161 participants 
Details available for 22 801 
participants and 36 563 procedures 
Details available for 22 801 
participants and 36 563 procedures 
22 375 participants with 
24 391 screening episodes 
10 755 participants with 12 172 surveillance 
procedures in 11 817 surveillance episodes 
14 HR and 10 IR participants 
had cancerous polyps and 
hence were excluded 
 8056 HR and 14 295 
IR participants 
Data are 
merged 
8070 HR participants with 9455 
procedures and 14 305 IR participants 
with 14 936 procedures at screening 
10 755 participants had a first surveillance 
1027 participants had a second surveillance 
34 participants had a third surveillance 
1 participant had a fourth surveillance 
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6.3.2  Polyp data 
The database was interrogated for all polyps detected at screening and surveillance for 
participants who were stratified as HR and IR groups during the study period. The data sets 
of the polyps detected at screening and surveillance were integrated with the data sets 
containing the participant- and procedure-specific data, and then analysed to obtain the 
final results. 
6.4 Results 
6.4.1 Outcome of surveillance of high-risk participants 
Participants identified as belonging to the HR group at the screening colonoscopy, who 
underwent surveillance during the study period, were included. The path of HR participants 
during their surveillance episodes is shown in Figures 6.2 and 6.3. 
For the analysis of the yield of ACN at surveillance, participants with CRC and participants 
with histology data were included, combined and used as the denominator. 
Of the HR group at first surveillance, 39 had CRC. A total of 3361 participants in the HR group 
had adenomas and 2953 of them had histology data. In the IR group, 20 had CRC at first 
surveillance; 1896 had adenomas of which 1782 had histology data. Serrated adenomas 
were detected in a very small number of participants (31 in the HR group and 14 in the IR 
group) at first surveillance; they were excluded from the analysis because they represent a 
very small group  and has a different pathways for polyp development and progression. 
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   First surveillance 
 
 
 
 
 
 
 
 
Greatest risk outcome at first surveillance (N = 5579) 
Cancer HR IR LR Abnormal Normal No result 
39 441 1085 1835 1167 989 23 
(0.7%) (7.90%) (19.45%) (32.89%) (20.92%) (17.73%) (0.41%) 
Note: HR = high-risk; IR = intermediate-risk; LR = low-risk. 
 
 
 
(Continued on the next page) 
5579 participants completed first surveillance (August 2007–August 2012) 
Male: 4240; female: 1339 
Age, years: mean: 66.48; median: 66.41; SD: 3.56; range: 60.75– 84.79 
Time lag surveillance–screening, years: mean: 1.2; median: 1.05; range: 0.15–5.05 
Percentile of screening–first surveillance lags, years: 25%: 1.00; 50%: 1.05; 75%: 1.17; 99%: 3.51 
4507/5579 (80.78%) had surveillance within three months (±) of expected date 
Histology available for 3763 participants with adenomas: 2922 
Participants with ≥10-mm adenomas: 120 (4.11%) (N = 2922) 
Participants with <10-mm and ≥10-mm adenomas: 217 (7.43%) (N = 2922) 
Participants with <10-mm adenomas: 2585 (88.46%) (N = 2922) 
AAs: 738 (19.61%); non-AAs: 2184 (58.04%); serrated adenomas: 31 (0.83%); others: 810 
(21.52%) (hyperplastic, inflammatory, non-polyp, other polyp) N = 3763 
 
8046 participants at screening 
(August 2006–August 2012) 
Male: 6138; female: 1908 
Age, years: mean: 65.79; median: 65.29; SD: 4.44; range: 60.05–88.38 
Histology available: 7879 participants 
Participants with three or more ≥10-mm adenomas: 1026 (13.11%) (N = 7826) 
Participants with <10-mm and ≥10-mm adenomas: 5590 (71.43%) (N = 7826) 
Participants with five or more <10-mm adenomas: 1210 (15.46%) (N = 7826) 
AAs: 7140 (90.62%); non-AAs: 686 (8.70%); serrated adenoma: 21 (0.27%); incomplete 
data: 32 (0.41%) (N = 7879) 
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Greatest risk at first surveillance (N = 5579) 
 
 
 
 
 
 
                                                                   Second surveillance 
 
 
 
 
 
 
 
 
Greatest risk at second surveillance (N = 279) 
Cancer HR IR LR Abnormal Normal No result 
2 43 59 101 43 28 3 
(0.72%) (15.41%) (21.15%) (36.2%) (15.41%) (10.04%) (1.07%) 
Note: HR = high-risk; IR = intermediate-risk; LR = low-risk. 
 
(Continued on the next page) 
441 HR participants 
Surveillance after one year (7.90%) 
 
5099 non-HR participants 
Surveillance after three years (91.4%) 39 treated 
for cancer  
 (0.7%) 
 
414 HR participants  
Complete histology available for: 
229 (55.31%) with five or more <10-mm adenomas 
153 (36.96%) with three or more >10-mm adenomas 
32 (7.73%) with <10- and >10-mm adenomas 
279 patients 
Male: 221; female: 58 
Age, years: mean: 67.90; median: 68.14; SD: 3.27; range: 62.02–73.31 
Surveillance 2–surveillance 1 lag, years: mean: 1.12; median: 1.05; range: 0.30–3.08 
Percentile of screening–surveillance 1 lags, years: 25%: 1.01; 50%: 1.05; 75%: 1.14; 99%: 2.34 
241/279 (86.38%) had surveillance within three months (±) of expected date 
Histology available for 228 participants with adenomas: 190 
Participants with ≥10-mm adenomas: 5 (2.63%) (N = 190) 
Participants with <10-mm and ≥10-mm adenomas: 15 (7.89%) (N = 190) 
Participants with <10-mm adenomas: 170 (89.47%) (N = 190) 
AAs: 41 (17.98%); non-AAs: 149 (65.35%); serrated adenomas: 2 (0.88%); others: 36 (15.79%) 
(hyperplastic, inflammatory, not polyp, other polyp) (N = 228) 
 
128 
 
                                               Greatest risk at second surveillance (N = 279) 
 
 
 
 
 
 
                                                                       Third surveillance 
 
 
 
 
 
 
 
 
 
                                                                         Third surveillance 
 
Greatest risk outcome at third surveillance (N = 23) 
HR IR LR Abnormal No result 
6 3 11 1 2 
(26.09%) (13.04%) (47.83%) (4.34%) (8.70) 
Note: HR = high-risk; IR = intermediate-risk; LR = low-risk. 
 
(Continued on the next page) 
Non-HR group = 234 
Surveillance after three years (83.87%) 
 
23 patients 
Male: 17; Female: 6 
Age, years: mean: 69.77; median: 69.60; SD: 3.15; range: 63.37–74.00 
Surveillance 3–surveillance 2 lag, years: mean: 1.07; median: 1.03; range: 0.93–1.4 
Percentile of screening–surveillance 1 lags, years: 25%: 0.99; 50%: 1.03; 75%: 1.11; 99%: 1.4 
21/23 (91.30%) had surveillance within three months (±) of expected date 
Histology available for 22 participants  
Participants with adenomas: 22 
Participants with ≥10-mm adenomas: 0 (N = 22) 
Participants with <10-mm and ≥10-mm adenomas: 0 (N = 22) 
 Participants with <10-mm adenoma: 22 (N = 22) 
AA: 1 (4.55%); non-AAs: 21 (95.45%) 
(N = 22) 
42 HR participants: complete histology available 
27 (64.29%) with five or more <10-mm adenomas 
1 (2.38%) with three or more >10-mm adenomas 
14 (33.33%) with <10- and >10-mm adenomas 
HR group = 43 
Surveillance after one 
year (15.41%) 
Two participants 
treated for 
cancer 
(0.72%) 
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   Fourth surveillance 
 
 
 
 
 
 
                                                                             Second surveillance 
 
 
 
 
 
 
 
 
 
 
(Continued on the next page) 
Six HR group participants 
Surveillance after one year 
(26.09%) 
17 non-HR group participants for 
surveillance after three years 
(73.91%) 
One participant 
74-years-old female 
Greatest risk outcome: HR adenoma 
Surveillance 4–surveillance 3 lag, years: 1.05 
Non-AAs 
Had more than five <10-mm adenomas 
5099 HR participants, non-HR at first surveillance 
Surveillance after three years  
638 participants 
Male: 464; female: 174 
Age, years: mean: 69.71; median: 69.64; SD: 3.4; range: 62.11–75.14 
Surveillance 2–Surveillance 1 lag, years: mean: 3.02; median: 3.03; range: 0.95–3.79 
Percentile of screening–surveillance 1 lags, years: 25%: 3.00; 50%: 3.03; 75%: 3.10; 99%: 3.46 
575/638 (90.12%) of participants had surveillance within three months (±) of expected date 
Histology available for 388 participants 
Participants with adenomas: 329 
Participants with ≥10-mm adenomas: 11 (3.35%) (N = 329) 
Participants with <10- and ≥10-mm adenomas: 20 (6.07%) (N = 329) 
Participants with <10-mm adenomas: 298 (90.58%) (N = 329) 
AAs: 74 (19.07%); non-AAs: 255 (65.72%) 
Others: 59 (15.21%) (hyperplastic, inflammatory, not polyp, other polyp) (N = 388) 
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Greatest risk outcome at second surveillance (N = 638) 
Cancer HR IR LR Abnormal Normal No result 
5 34 67 224 165 131 12 
(0.78%) (5.33%) (10.4%) (35.11%) (25.76%) (20.43%) (1.88%) 
Note: HR = high-risk; IR = intermediate-risk; LR = low-risk. 
                                       Greatest risk outcome (second surveillance) 
 
 
 
 
 
 
 
 
                                                             Third surveillance 
 
 
 
 
 
Figure 6.2 HR group surveillance outcome: per-participant analysis.  
 599 non-HR participants 
Surveillance after three years 
(93.88%) 
 
10 (29.41%) with five or more <10-mm adenomas 
 Three (8.82%) with three or more >10-mm adenomas  
21 (61.77%) with <10- and >10-mm adenomas 
Participants did not qualify for 
surveillance during the study period 
 
Two participants had third surveillance 
Sex: male 
Greatest risk: IR and LR group 
Surveillance 3–surveillance 2 lag, years for both participants: 1.01 
Age: 70 and 68 years 
Both had non-AAs  
Five 
participants 
treated for 
cancer 
(0.78%) 
34 HR participants  
Surveillance after one year (5.33%) 
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  Third surveillance 
 
 
 
 
 
 
Greatest risk outcome at third surveillance 
HR IR LR 
1 1 5 
(14.29%) (14.29%) (71.42%) 
Figure 6.3 HR group at screening and first surveillance, and non-HR group at second 
surveillance. 
Note: Participants did not qualify for further surveillance during the study period. HR = high-risk; IR = 
intermediate-risk; LR = low-risk. 
 
6.4.2 Outcome of surveillance for IR participants 
Participants identified as IR at the screening colonoscopy, and who underwent surveillance 
procedures during the study period and had a complete data set with regard to their 
screening, surveillance and adenomas, were included. The screening data sets were merged 
with the surveillance data set to identify individuals who had a complete data set for both 
screening and surveillance colonoscopies. All were included in the analysis. The pathway of 
IR participants during their surveillance episodes is shown in Figure 6.4. 
Non-HR group = 234 
Surveillance after three years 
Seven participants 
Male: 4; female: 3 
Age, years: mean: 69.71; median: 69.64; SD: 3.4; range: 62.11–75.14 
Surveillance 2–surveillance 1 lag, years: mean: 2.23; median: 3.03; range: 0.73–3.27 
Histology available for seven participants  
Seven participants with adenomas 
Participants with ≥10-mm adenoma: 0 (N = 7) 
Participants with <10-mm and ≥10-mm adenomas: 0 (N = 7) 
Participants with <10-mm adenomas: 7 (N = 7) 
Non-AAs: 7 (100%) 
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   4723 IR participants completed their first surveillance 
 
 
 
 
 
 
 
 
 
Greatest risk outcome at first surveillance (N = 4723) 
Cancer HR IR LR Abnormal Normal No result 
20 144 368 1384 1729 1042 36 
(0.42%) (3.05%) (7.79%) (29.3%) (36.61%) (22.06%) (0.77%) 
Note: HR = high-risk; IR = intermediate-risk; LR = low-risk. 
 
 
 
(Continued on the next page) 
14 295 IR participants at screening 
Male: 9177; female: 5118 
Age, years: mean: 65.43; median: 65.15; SD: 4.39; range: 59.94–88.73 
(August 2006–August 2012) 
Histology available for 13 925 
Participants with one or two ≥10-mm adenomas: 8087 (58.80%) (N = 13 753) 
Participants with <10-mm and ≥10-mm adenomas: 3336 (24.26%) (N = 13 753) 
Participants with three or four <10-mm adenomas: 2330 (16.94%) (N = 13 753) 
AAs: 12 202 (87.63%); non-AAs: 1551 (11.28%); serrated lesions: 119 (0.85%);  
incomplete data sets: 53 (0.24%)  
(N = 13 925) 
 
4723 participants completed their first surveillance (August 2007–August 2012) 
Male: 3029; female: 1694 
Age, years: mean: 68.36; median: 68.32; SD: 3.47; range: 61.03–81.61 
Screening–surveillance 1 lag, years: mean: 2.98; median: 3.04; range: 0.51–5.07 
Percentile of screening–surveillance 1 lags, years: 25%: 3.00; 50%: 3.04; 75%: 3.11; 99%: 3.78 
3967/4723 (83.99%) had surveillance within three months (±) of expected date 
Histology available for 2456 participants  
Participants with adenomas: 1778 
 Participants with ≥10-mm adenomas: 121 (6.8%) (N = 1778) 
Patients with <10-mm and ≥10-mm adenomas: 87 (4.89%) (N = 1778) 
Participants with <10-mm adenomas: 1570 (88.31%) (N = 1778) 
AAs: 385 (15.67%); non-AAs: 1393 (56.72%); serrated adenomas: 14 (0.58%); others: 664 (27.03%) 
(hyperplastic, inflammatory, not polyp, other polyp) (N = 2456) 
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Greatest risk outcome at first surveillance (N = 4723) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Greatest risk outcome at second surveillance (N = 46) 
Cancer HR IR LR Abnormal Normal No Result 
1 5 6 17 9 7 1 
(2.17%) (10.87%) (13.04%) (36.96%) (19.57%) (15.22%) (2.17%) 
Note: HR = high-risk; IR = intermediate-risk; LR = low-risk. 
 
 
(Continued on the next page) 
 
20 treated for 
cancer 
(0.42%) 
144 HR participants 
Surveillance after one year 
(3.05%) 
4559 non-HR participants 
(96.53%) 
Surveillance after three years 
141 HR participants: complete histology available 
68 (48.23%) with five or more <10-mm adenomas 
56 (39.71%) with three or more >10-mm adenomas 
17 (12.06%) with <10- and >10-mm adenomas 
Should N = 2456 be 
shown here? 
46 participants had second surveillance 
Male: 36; female: 10 
Age, years: mean: 70.30; median: 71.29; SD: 3.72; range: 64.15–74.55 
Surveillance 2–surveillance 1 lag, years: mean: 1.12; median: 1.08; range: 0.77–2.04 
Percentile of screening–surveillance 1 lags, years: 25%: 1.01; 50%: 1.08; 75%: 1.15; 99%: 2.04 
39/46 (84.78%) had surveillance within three months (±) of expected date 
Histology available for 46 participants 
Participants with adenoma: 44 
Participants with ≥10-mm adenomas: 4 (9.1%) (N = 44) 
Participants with <10-mm and ≥10-mm adenomas: 18 (40.90%) (N = 44) 
Participants with <10-mm adenomas: 22 (50%) (N = 44) 
AAs: 23 (50%); non-AAs: 21 (45.65%); hyperplastic: 2 (4.35%) 
N = 46 
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Greatest risk outcome at second surveillance (N = 46) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Greatest risk outcome at second surveillance (N = 20) 
HR LR Abnormal Normal 
1 6 8 5 
(5%) (30%) (40%) (25%) 
Note: HR = high-risk; LR = low-risk. 
 
 
Figure 6.4 HR group surveillance outcome: per-participant analysis. 
One 
participant 
treated for 
cancer 
(2.17%) 
Five HR participants 
Surveillance after one year (10.87%) 
Three with five or more <10-mm adenomas 
Two with three or more >10-mm adenomas 
40 non-HR participants 
Surveillance after three years 
(86.96%) 
One male participant had third surveillance 
Age: 70 years 
Surveillance 3–surveillance 2 lag: 1.07 year 
Outcome: IR  
Had <10-mm AA 
4559 IR participants who had LR adenomas and normal and abnormal 
findings at first surveillance 
Surveillance after three years 
20 participants had second surveillance 
Male: 13; female: 7 
Age, years: mean: 70.39; median: 71.91; SD: 3.49; range: 64.22–74.53 
Surveillance 2–surveillance 1 lag, years: mean: 2.15; median: 3.00; range: 0.80–3.21 
Percentile of screening–surveillance 1 lags, years: 25%: 1.03; 50%: 3.00; 75%: 3.08; 99%: 3.21 
11/20 (55%) had surveillance within three months (±) of expected date 
Histology available for nine participants 
Participants with adenomas: 7 
Participants with ≥10-mm adenomas: 0 (N =7) 
Participants with <10-mm and ≥10-mm adenomas: 0 (N =7) 
Participants with <10-mm adenoma: 7 (N =7) 
AA: 1 (11.1%); non-AAs: 6 (66.7%); hyperplastic: 2 (22.29%) (N = 9) 
 
Participants after their second surveillance did not qualify for third surveillance within the study period. 
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6.4.3 Demography of the population studied 
A total of 8056 HR individuals participated in the screening. Mean age was 65.7 years; the 
majority of participants were male (76.2%). Overall, 5579 completed their surveillance 
during the study period and the mean age at first surveillance was 66.4 years. With regard to 
the surveillance procedures, 75% were performed within one year of the screening 
colonoscopy; 99% of participants completed their surveillance by 3.5 years after screening. A 
delay in timing the surveillance colonoscopy could be due to a variety of reasons, including 
delayed participation during surveillance and change of residence. 
For the IR group, 14 295 participants were identified during the screening colonoscopy. 
Mean age at screening was 65.4 years, and the majority of participants were male (64.2%). A 
total of 4723 IR participants completed their first surveillance during the study period and 
the mean age at surveillance was 68.3 years. Of these, 75% completed their first surveillance 
3.11 years after screening and 99% completed first surveillance 3.78 years after screening. 
6.4.4 Detection of advanced adenomas at screening 
The total number and proportion of HR and IR participants who had AAs at screening were 
measured. A chi-square test was then performed to evaluate whether there was any 
significant difference in the detection of AAs at screening between the two groups. The 
results are shown in Tables 6.1 and 6.2. 
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Table 6.1 Detection of AAs at screening 
 
Risk group With 
histology 
AA 
n (%) 
NAA 
n (%) 
Serrated 
adenoma 
n (%) 
Partial 
data set 
n (%) 
HR 7879 7140 (90.62) 686 (8.70) 21 (0.27) 32 (0.41) 
IR 13 925 12 202 (87.63) 1551 (11.28) 119 (0.85) 53 (0.24) 
Note: AA = advanced adenoma; NAA = non-advanced adenoma; HR = high-risk; IR = intermediate-risk. 
 
Table 6.2 Pearson’s chi-square test result showing the difference in proportion of patients 
in the HR and IR groups having AA at screening 
χ2  df P 
44.74 1 <0.001 
Note: HR = high-risk; IR = intermediate-risk; AA = advanced adenoma; df = degrees of freedom. 
In the HR group, there was a higher proportion of participants with AAs compared to the IR 
group at screening (90.62 vs. 87.63%), and the difference in proportion was statistically 
significant. BCSP participants in the HR group had significantly more AAs than participants in 
the IR group. 
6.4.5 Detection of adenomas ≥10 mm 
Adenomas ≥10 mm were AAs by definition. The proportion and number of participants with 
adenomas ≥10 mm at screening were detected, and are described in the Table 6.3. 
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Table 6.3 Number of patients with ≥10-mm adenomas 
 
Risk group Patients with histology 
available 
Patients with ≥10-mm adenomas 
n (%) 
HR 7879 6616 (84.54) 
IR 13 925 11 423 (83.06) 
Note: HR = high-risk; IR = intermediate-risk. 
Most participants in both HR and IR groups had adenomas ≥10 mm at screening, but a 
higher proportion of HR participants had larger adenomas (84.54 vs. 83.06%) and this 
difference was statistically significant (χ2 = 13.03; P = 0.002). 
6.4.6 Detection of colorectal neoplasia and CRC 
6.4.6.1 Detection of colorectal neoplasia and CRC at first surveillance 
The number of HR and IR participants attending their first surveillance colonoscopy were 
studied and the proportion with CRC, adenomas and other findings was measured. 
Participants included in the ‘Other’ category were those whose surveillance colonoscopy did 
not detect any adenomas (normal/abnormal findings like diverticulosis, haemorrhoids, 
outcome not yet recorded in the system). The results are shown in Table 6.4. 
Table 6.4 Outcome of first surveillance 
 
Risk group at 
screening 
Total no. patients at  
first surveillance 
CRC 
n (%) 
Adenoma 
n (%) 
Other 
n (%) 
HR 5579 39 
(0.7) 
3361 
(60.24) 
2179 
(39.06) 
IR 4723 20 
(0.42) 
1896 
(40.14) 
2807 
(59.98) 
Total 10 323 (100) 59 
(0.57) 
5257 
(50.92) 
4986 
(48.51) 
Note: CRC = colorectal cancer; HR = high-risk; IR = intermediate-risk. 
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A very small proportion of participants were detected as having CRC. There was no 
significant difference in the detection of CRC between HR and IR participants at their first 
surveillance (χ2 = 137.5; P = 0.08). The majority of HR participants had adenomas at first 
surveillance (60.24%), whereas the majority of IR participants did not have a colorectal 
adenoma at first surveillance (59.98).  
A higher proportion of HR participants had adenomas (60.24 vs. 40.14%) at first surveillance 
compared to the IR group, and this difference was statistically significant (χ2 = 413.5; 
P<0.001). A higher proportion of IR participants did not have any adenomas compared to HR 
participants (59.98 vs. 39.06%) and the difference was statistically significant (χ2 = 425.2; P = 
<0.001). 
6.4.6.2 Detection of colorectal neoplasia and CRC at second surveillance 
HR and IR participants were stratified into different risk categories according to the findings 
of their first surveillance procedure; they then went on to have their second surveillance 
procedure. This is illustrated in Figures 6.3 and 6.4. The results are summarized in Table 6.5. 
Table 6.5 Outcome of second surveillance 
 
Risk group at screening Total no. patients at  
second surveillance 
CRC 
n (%) 
Adenoma  
n (%) 
Other 
n (%) 
HR 917 7 (0.76) 528 (57.58) 382 (41.66) 
IR 66 1 (1.56) 35 
(53.03) 
20 
(45.41) 
Total 983 (100) 8 (0.81) 563 (57.27) 402 (41.92) 
Note: CRC = colorectal cancer; HR = high-risk; IR = intermediate-risk. 
The majority of participants (57.27%) had colorectal adenomas after the second surveillance. 
Only a very small proportion of participants had CRC at second surveillance (0.81%). There 
was no significant difference in the proportion of participants with adenomas at second 
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surveillance between participants stratified as HR or IR at screening (57.58 vs. 53.03%; χ2 = 
108.6; P = 0.52). 
6.4.6.3 Detection of colorectal neoplasia at third surveillance 
Table 6.6 summarizes the detection of colorectal dysplasia at third surveillance. 
Table 6.6 Detection of colorectal neoplasia at third surveillance 
 
Risk group at 
screening 
Total no. patients at 
second surveillance 
CRC 
n (%) 
Adenoma 
n (%) 
Others 
n (%) 
HR 33 0 29 (87.8) 4 (12.2) 
IR 1 0 1 0 
Note: CRC = colorectal cancer; HR = high-risk; IR = intermediate-risk. 
 
6.4.7 Reduction of advanced adenoma 
AAs were recognized as the potent precursor pathology that could develop into colorectal 
carcinoma. Detection of participants with AAs was measured at screening and also at first 
and second surveillance.  
The significance of the reduction of participants with AAs was analysed with the McNemar’s 
test. The findings of the analyses are described in the next sections. 
6.4.7.1 Advanced adenoma detection at screening vs. first surveillance (HR and IR 
groups combined) 
Table 6.7 shows the distribution of participants with AAs at screening and first surveillance. 
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Table 6.7 Distribution of patients with AAs at screening and first surveillance 
 
Screening 
n (%) 
AAs at first 
surveillance 
n (%) 
AAs at first 
surveillance (%) 
Total 
AAs: 5474 (89.9) 1080 (19.73) 4394 (80.27) 5474 (100%) 
NAAs: 611 (10.1) 107 (17.51) 504 (82.49) 611 (100%) 
Total: 6085 (100) 1087 (19.51) 4890 (80.49) 6085 
Note: AA = advanced adenoma; NAA = non-advanced adenoma. 
There was a significant reduction in the number of participants with AAs at screening (89.9 
vs. 19.73%; McNemar’s test; P<0.001). 
Polypectomies performed during screening had a sustained effect on the reduction of AAs. 
 
6.4.7.2 Advanced adenoma detection in first vs. second surveillance 
Table 6.8 shows the distribution of participants with AAs at first and second surveillance. 
Table 6.8 Distribution of patients with AAs at first and second surveillance 
Note: AA = advanced adenoma; NAA = non-advanced adenoma. 
There was a reduction in the proportion of participants with AAs from second to third 
surveillance (35.3 vs. 19.71%) and the reduction was significant (McNemar’s test; P<0.001). 
Continuing surveillance is effective in reducing the number of patients with AAs. 
 
 
First surveillance 
n (%) 
AAs at second 
surveillance 
n (%) 
No. AAs at second 
surveillance (%) 
Total 
AAs: 197 (35.3) 39 (19.8) 158 (80.2) 197 (100%) 
NAAs: 361 (64.7) 71 (19.67) 290 (80.33) 361 (100%) 
Total: 558 (100) 110 (19.71) 448 (80.29) 558 
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6.5 Discussion 
6.5.1 Yield of CRC at surveillance 
The detection and resection of colorectal adenomas during colonoscopy is an effective and 
powerful tool to reduce the incidence of CRC. There are several long-term follow-up studies 
that support this view.  
Winawer et al. [46] followed a cohort of 1418 patients with sporadic colorectal adenoma for 
an average period of 5.9 years. These were the participants of the NPS, an RCT evaluating 
the effectiveness of surveillance on patients discovered to have one or more colorectal 
adenomas. The incidence of CRC during the follow-up period was compared with three 
reference groups; in two of them, colorectal adenomas were not removed, while the third 
reference group was derived from a population-based registry. Although 1210 patients were 
followed up until the end of the study period, only five (0.41%) asymptomatic, early-stage 
CRCs were detected during follow-up. The number of CRCs expected with regard to the 
three reference groups were 48.3, 43.4 and 20.7; thus, a significant reduction in CRC 
incidence (90, 80 and 76% compared to the three groups; P<0.001) was achieved. 
Zauber et al. [10] followed up the NPS patients further (median follow-up period = 
15.8 years) and noted a significant reduction in mortality from CRC compared to the general 
population. This study demonstrated an even longer-term protective effect of colonoscopy 
and polypectomy. 
Brenner et al. [82] performed a population-based case-control study and showed that a 
colonoscopy performed within the preceding 10 years was associated with a 77% lower risk 
of developing CRC. 
This evidence suggests that colonoscopy and polypectomy should reduce the incidence of 
CRC during follow-up and also confer a protective effect from mortality from CRC. Thus, the 
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protective effect of the high-quality colonoscopy offered by the BCSP at surveillance should 
in turn translate into a lower incidence of CRC and AAs. There should be a subsequent and 
significant gradual reduction in the incidence of AAs and CRC in the cohort undergoing 
ongoing surveillance. 
In the BCSP follow-up, a very small proportion of participants were diagnosed with CRC at 
first surveillance (0.7% in the HR group and 0.42% in the IR group) and there was no 
significant difference between the two groups. Considering the two groups together, there 
were only 39 CRCs among the 10 323 participants (0.57%) who completed first surveillance. 
These results reflect the protective effect of polypectomy with regard to developing future 
CRC in HR and IR groups. The small number of cases of CRC after one and three years of 
screening could either represent missed lesions during screening or de novo CRC that did not 
develop along the adenoma–carcinoma sequence. 
6.5.2 Yield of advanced colorectal neoplasia and advanced adenoma 
Lee et al. [129] reported the results of a 12-month surveillance of the HR group in the BCSP 
(August 2006–April 2010). Their study included 1760 HR participants; of these 1340 
completed their first surveillance during that period. There were 14 CRCs (0.8%) detected at 
surveillance, which is similar to the findings of this thesis. Their ACN yield was 6.6% 
(116/1760). 
In the current study, histology was available for 2922 HR participants with adenomas at 
surveillance of which 25.2% (738/2922) had AAs. Considering that 39 HR participants had 
CRC at surveillance and 2179 HR participants had no colorectal neoplasia, the proportion of 
HR participants with ACN in this study was 15.1% (777/5140). This higher detection of ACN 
compared to the study by Lee et al. [129] could be because a larger cohort was studied over 
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a longer period of time and also because histology data were available for 87.9% 
(2953/3361) of patients with adenomas, but not for all participants.  
For the IR group in this study, histology results were available for 1778 participants with 
adenomas at first surveillance and 21.6% (385/1778) of them had AAs. In this group, at first 
surveillance 20 participants had CRC and 2807 participants did not have any colorectal 
neoplasia. The proportion of the IR group who had ACN at first surveillance was 8.8% 
(405/4605). Combining the HR and IR groups together, the proportion of patients with ACN 
at surveillance was 12.1% (1182/9745).  
AA formation is an important intermediate point in the natural history of adenomas before 
they develop into CRC. Detection and removal of these lesions are of prime importance to 
reduce the incidence of CRC. Many studies have estimated the risk of developing AAs during 
adenoma surveillance. In a meta-analysis, Martínez et al. [65] studied the risk of developing 
AAs and CRC after polypectomy. Their study included 9167 participants with sporadic 
colorectal adenomas from eight different prospective North American studies. Participants 
were followed up for a long period, with a median follow-up of 47.2 months. The mean age 
of participants was 62 years and 71.2% were male. Six of the studies involved were RCTs. All 
the adenomas detected during the initial colonoscopies were removed. ACN was detected in 
11.8% (1082/9167) of patients and CRC was detected in 58 (0.6%) patients at their first 
surveillance. Although the study population differed from the FOBT-positive screened 
population and the surveillance procedures were performed at different intervals, these 
results provide some insight into the occurrence of ACN after polypectomy during follow-up 
in a study setting where all the participants had a complete baseline clearing colonoscopy 
and then underwent a specific surveillance schedule. In this study, the detection of ACN 
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during surveillance (11.8%) is not very different to the detection of ACN for the combined HR 
and IR groups at first surveillance (12.1%) in the BCSP. 
In 2012, Martínez et al. [99] performed another pooled analysis to evaluate the risk of 
developing ACN at one year after initial colonoscopy and polypectomy. The study was 
originally set up to compare the ACN yield for the same cohort of patients with the American 
and British surveillance guidelines. The study included data from four North American 
prevention trials, where a colonoscopy was included in the surveillance protocol one year 
after the initial examination. Overall, 3226 participants were included in the final analysis; 
their median age was 64 years (range = 50–70 years). The follow-up colonoscopy was 
performed at a median of 12.8 months. In the group that fulfilled the BSG HR group criteria 
at baseline examination, 18.7% had ACN at surveillance after one year (95% CI = 14.8–22.5). 
The detection of ACN in the HR group in the BCSP was 15.1%. Although according to the 
baseline risk factors both studies represent similar groups, the procedures were not carried 
out within the setting of a screening programme. Colonoscopy quality indicator data were 
not part of the North American study and were not collected, whereas the examinations 
performed in the BCSP were more demonstrably high-quality colonoscopies. The lower 
detection of ACN in the BCSP cohort is probably because of complete clearance of adenomas 
at baseline. Hence, reducing the probability of missed lesions leads to a lower incidence of 
ACN at surveillance at one year in this HR group. 
More recently, Vemulapalli et al. [130] evaluated the effect of using the British guidelines on 
a cohort of patients with adenomas in North America. This included 1414 patients with 
colorectal adenomas who had a follow-up colonoscopy more than 200 days after the 
baseline examination; 377 patients could be stratified as the UK HR group and, at first 
surveillance, 36 (9.54%) had ACN and two (0.5%) had CRC. The ACN yield is lower than in the 
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BCSP in this HR group. However, this was a single-centre study and did not include patients 
who underwent surveillance procedures elsewhere. This limitation would result in a 
restricted view of the outcome. Also, colonoscopy quality indicator data were not 
mentioned and therefore outcomes may not match the higher yield of BCSP surveillance.  
Saini, Kim and Schoenfeld [89] performed a meta-analysis and systematic review to evaluate 
the incidence of AAs at the three-year surveillance in patients who had been categorized as 
either HR or LR during their baseline colonoscopy according to the American guidelines. 
Although the group under study was different compared to the different risk groups in the 
BCSP, it did provide some insight about AA incidence at the three-year surveillance. They 
selected 15 trials for the meta-analysis and found a variable AA incidence rate during 
surveillance. Four of the studies included in this meta-analysis provided the data on the 
incidence of adenomas at surveillance. 
One of these four studies was performed by Noshirwani et al. [88]. They tried to evaluate 
the need for a three-year surveillance after baseline colonoscopy and polypectomy. This was 
a retrospective study from the Cleveland Clinic Foundation Adenoma Registry database. In 
the study, there were two groups equivalent to the UK HR group. One of these groups were 
patients with three adenomas (along with one >10-mm adenoma) and 21.3% of them had 
AAs at the three-year surveillance. The other group consisted of patients with more than 
three adenomas (along with one >10-mm adenoma) and 34.5% of them had AAs at the 
three-year surveillance. These two groups were equivalent to the HR group in the BCSP. AA 
incidence at the first-year surveillance for the BCSP HR group was 14.4% (738/5140). The 
higher incidence in the North American study was because surveillance was performed after 
a longer duration in the HR group and possibly also because of higher-quality procedures 
performed in the BCSP, where a better clearance could be achieved. There were also groups 
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equivalent to the UK IR group in that study. The first group had three small adenomas and 
the second group had two adenomas, one of them being >10 mm. Overall, 8.5% of the first 
and 10.3% of the second group had AAs at the three-year surveillance. In the BCSP, 8.4% 
(385/4605) of IR patients had AAs at their first surveillance, three years from their initial 
screening, and the AA yield between the UK and the North American groups was not 
significantly different. 
6.5.3 Difference in outcome between HR and IR groups at first surveillance 
Only a very small proportion of participants were diagnosed with CRC at first surveillance in 
both groups (HR group = 0.7%; IR group = 0.42%) and there was no significant difference in 
the detection of cancer. A significantly higher proportion of HR participants had adenomas 
at   first   surveillance   compared   to   the   IR   group   (60.24   vs.  40.14%;   P<0.001).     The  
non-neoplastic yield was significantly higher in the IR group compared to the HR group 
(59.98 vs. 39.06%; P<0.001). 
These findings suggested that the current risk stratification strategy, which relies on 
population-based studies, often involving symptomatic patients, is effective in categorizing 
the FOBT-positive screened population into different risk groups. This model is effective in 
stratifying the HR and IR groups in the BCSP population with the HR group demonstrating a 
significantly higher yield of colorectal adenomas at follow-up. 
The CRC yield in the IR group at first surveillance was very low and the majority of 
participants (59.98%) did not have any colorectal neoplasia. Therefore, the interval between 
screening and first surveillance for this group could be safely prolonged. 
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6.5.4 Detection of advanced adenomas during continuing surveillance 
Colonoscopy and polypectomy have been associated with a reduced mortality risk from CRC 
during prolonged follow-up in a number of studies. This is primarily because of the 
identification and removal of AAs that have the highest potential to develop into CRC. 
Adenoma surveillance provides the opportunity to identify and remove subsequent AAs and 
NAAs and thereby reduce the incidence and mortality from CRC. 
The reduction in incidence and mortality from CRC during surveillance was demonstrated in 
the studies that followed up the cohort from the NPS [10, 46]. In the initial follow-up study, 
1418 patients were followed up for an average period of 5.9 years with a total follow-up 
period of 8401 person-years and a significant reduction in the incidence of CRC achieved at 
the third, sixth and seventh year – 90, 88 and 76%, respectively (P<0.001) – compared to the 
reference group [46]. The long-term study followed up a larger cohort of 2602 patients from 
the NPS for a total of 37 073 person-years (median = 15.8 years); there was a 53% reduction 
in mortality from CRC [10]. 
A colonoscopy-associated reduction in CRC incidence and mortality was also reported in 
population-based studies. A population-based, case-controlled study from Germany 
demonstrated that a colonoscopy performed within a 10-year period was associated with a 
77% lower risk of developing CRC [97] The study also demonstrated the protective effect on 
left- and right-sided CRC. A large population-based study from Norway followed up 40 826 
patients with colorectal adenomas (median follow-up = 7.7 years) and demonstrated that 
colorectal mortality was lower in patients with NAAs and moderately higher in patients with 
AAs compared to the general population [83]. 
An effective adenoma surveillance programme that reduces the incidence and mortality 
from CRC ideally should be effective in demonstrating a significant reduction in the incidence 
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of AAs during the sequential stages of continuing surveillance. This thesis provided a unique 
opportunity to demonstrate this reduction. 
The outcome of the first surveillance has been discussed previously. During the study period, 
917 HR and 66 IR participants underwent second surveillance examinations in the BCSP (see 
Table 6.5). They underwent second surveillance at different time intervals depending on 
their latest risk categorization and based on the findings at the first surveillance 
colonoscopy. The majority of these individuals (563/983; 57.3%) had adenomas at second 
surveillance and a very small proportion had CRC (8/983, 0.81%). This higher yield of 
colorectal adenomas at the second surveillance colonoscopy reflected the fact that a 
significant proportion of participants in this cohort were categorized as HR at first 
surveillance. During the study period, only 34 participants underwent their third 
surveillance; this did not reflect the overall outcome of third surveillance because the 
majority of IR participants, who were categorized as the non-HR group at their first 
surveillance, were scheduled to have their second surveillance after three years from their 
first surveillance; this was beyond the limit of the time frame of the current study. 
The AA yield was compared between screening and first surveillance and also between first 
and second surveillance. The HR and IR groups were combined and participants with 
histology data were included in this analysis. The majority of participants with adenomas at 
screening had AAs (5474/6085; 89.9%), whereas the majority of participants at first 
surveillance had NAAs (4890/6085; 80.4%). The reduction in the proportion of participants 
with AAs was significant (89.9 vs. 19.51%; P<0.001; see Table 6.7). 
Similar comparative analyses were performed between the outcomes of first and second 
surveillance. A total of 558 participants were included; after their first surveillance, they 
completed their second surveillance and had adenomas with histology data available. The 
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majority of these participants had NAAs at first (361/558; 64.7%) and second surveillance 
(448/558; 80.3%); there was a significant reduction in the proportion of participants with 
AAs at second surveillance (19.71 vs. 35.3%; P<0.001; see Table 6.8). These results 
demonstrate that continuing surveillance with colonoscopy and polypectomy was successful 
in reducing the burden of AAs in the screened population, which is crucial to the effort of 
reducing the incidence and mortality from CRC in this population. 
The effects of continuous surveillance and the yield of advanced neoplasia have been 
studied by Imperiale et al. [131] who followed up a cohort of 945 patients with colorectal 
adenomas to evaluate the predictive risk factors for developing ACN at second surveillance. 
It was a single-centre retrospective study that included patients with colorectal adenomas. 
At the index colonoscopy, 36.9% (349/945) of patients had AAs; however, at first and second 
surveillance only 8.9% (84/945) and 5.9% (56/945) patients were found to have AA. The 
study involved a symptomatic population but demonstrated a reduction in AAs at 
subsequent surveillances. 
6.6 Summary and conclusion 
This thesis has demonstrated the outcome of continuing adenoma surveillance in the BCSP. 
A very small proportion of patients presented with CRC at first surveillance. The current 
adenoma surveillance guidelines were effective for stratifying a screening cohort, 
demonstrating a higher AA yield in the HR group at first surveillance. The majority of the IR 
group had a non-neoplastic yield at first surveillance, indicating that the surveillance interval 
for this group could be safely prolonged. Continuing surveillance demonstrated a significant 
reduction in the proportion of patients with AAs, indicating the long-term effectiveness of 
polypectomy for the screening cohort. 
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Chapter 7: Surveillance strategy 
7.0 Introduction 
This chapter focuses on the different key characteristics studied and then established as 
significant factors in predicting the detection of ACN at surveillance in patients with 
colorectal adenoma; their relevance in predicting advanced neoplasia in the BCSP population 
are evaluated. 
7.1 Aims and objectives 
These included: 
 determining the magnitude of advanced neoplasia detected in HR and IR patients at 
screening; 
 determining the magnitude of advanced neoplasia detected at surveillance;  
 identifying the factors at screening that could predict outcome at surveillance; 
 identifying the effects of alternative surveillance intervals on the outcomes of 
surveillance of IR and HR patients. 
7.2 Methodology 
7.2.1 Analysis 
The data for all the HR and IR participants who had their screening and surveillance 
procedures done during the study period were included. For participants at screening, only 
those where all adenomas were retrieved and histological results were available were 
included for final analysis because the number and histological features of adenomas at 
screening were included for analysis. Participants who had completed their first surveillance 
were included because during the study period the majority of surveillance procedures were 
first surveillance procedures. Participants who had polyp data at first surveillance were 
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included as the available data were sufficient for categorization of surveillance outcome. The 
outcomes of the first surveillance procedures were categorized into four different groups: 
normal (no adenoma detected); participants with NAAs; participants with AAs; and 
participants with CRC. 
The intervals between screening and surveillance were measured. The HR group was 
categorized into two different subgroups. In the first subgroup, first surveillance was 
performed within two years of screening; in the second group the surveillance interval was 
longer than two years. Similar categorization was done for the IR group according to a 
surveillance interval of four or more years. The effects of different surveillance intervals on 
the outcomes were determined for both HR and IR groups. 
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7.2.2 Data cleaning flow chart 
Figure 7.1 describes the data cleaning process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Flow chart showing the data cleaning process. 
Note: HR = high-risk; IR = intermediate-risk. 
 
 
 
 
 
24 174 participants with 
polyp data at screening 
 
screening 
12 056 participants with polyp 
data for all surveillances 
4984 had incomplete 
polyp data and were 
excluded  
4604 participants 
had no polyp data 
and were excluded 
19 190 participants with 
complete polyp data at screening 
7452 participants with polyp 
data for all surveillances 
19 166 participants with complete 
polyp data at screening 
24 had cancerous polyp 
and were excluded 
8085 participants with procedure and 
polyp details at first surveillance 
 
 Participant and 
procedure data for 
22 375 HR and IR at 
screening 
 Participant and 
procedure data for 
10 755 at first 
surveillance (IR + HR) 
Data sets merged: 7015 participants with complete adenoma data at screening 
and valid data at first surveillance for categorization and analysis 
17 694 participants at screening with 
complete procedure and polyp data 
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7.3 Predictive factors for analysis 
The adenoma- and patient-specific factors associated with the detection of colorectal 
adenomas and ACN during surveillance have been discussed in details in the literature 
review (Chapter 2, Section 2.8) and will be briefly mentioned here. 
The NPS demonstrated that age, number of adenomas and size of the largest adenoma at 
enrolment were independent risk factors for predicting any adenoma detected during the 
first surveillance colonoscopy; however, the only factor predicting the detection of 
adenomas with advanced pathological features was the number of adenomas at onset (≥3 
adenomas: OR = 6.9; 95% CI = 2.6–18.3; P<0.001) [48]. 
Noshirwani et al. [88] showed that the number and size of baseline adenomas were 
significantly associated with the detection of ACN at surveillance (having ≥4 adenomas or 
any adenoma with advanced pathological features; P<0.001). 
In their pooled analysis, Martínez et al. [65] identified male sex, increasing age, number and 
size of adenomas, proximal location and villous architecture at baseline as independent risk 
factors for metachronous advanced neoplasia. 
The number and size of adenomas, the presence of HGD and VH, and proximal location of 
adenomas at the index colonoscopy were shown in different studies to be important factors 
associated with the detection of AAs at surveillance [77, 89, 91, 100, 132]. 
Along with adenoma- and patient-specific factors, procedure-related factors were also 
shown to be associated with the detection of AAs at surveillance. Poor bowel preparation 
and poor colonoscopy reach (cecal intubation) have been shown to be important factors 
associated   with  the  detection  of  AAs  at  surveillance  [100].   In a recent population-
based, case-control study from Germany, Brenner et al. [96] showed that procedure-related 
factors were more important than polyp characteristics for the stratification of CRC risk after 
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colonoscopic polyp detection in the community setting. In a study performed in a tertiary 
centre, Seo et al. [133] looked at the practice factors important for local recurrence and 
detection of metachronous AAs after polypectomy. In this study, 917 patients with 1206 AAs 
were followed up for a median duration of 28.5 months. Piecemeal resection and the 
presence of two or three of the diagnostic criteria for AAs (≥10 mm, HGD, VH) were 
significantly associated with local recurrence (adjusted hazard ratio = 2.46; 95% CI = 1.11–
5.48; P = 0.027 for the presence of 2/3 criteria of AAs and piecemeal resection) vs. en bloc 
resection (adjusted hazard ratio = 6.96; 95% CI = 1.58–30.71; P = 0.010). Male sex, the 
number of adenomas (>3) and the presence of all three diagnostic AA criteria were 
significantly associated with AA detection at surveillance.  
Therefore, in this thesis, the sex of participants, the number of adenomas at the screening 
colonoscopy and the presence of advanced histology (VH and HGD) were studied to identify 
their importance with regard to the detection of AAs at first surveillance. 
The dependent variable was the outcome at first surveillance, which was categorized into 
four different groups: participants with normal results; participants with NAAs; participants 
with AAs; and participants with CRC. Participants with normal results were the reference 
group for the multinomial logistic regression. 
7.4 Results 
7.4.1 Patient demographics  
In total, 5001 (71.3%) of the 7015 participants were male, and the mean age was 65.27 years 
(SD = 3.45; range = 60.06–80.04; median = 65.21). Overall, 3672 (52.3%) participants were 
HR at screening and the rest were IR at screening. 
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7.4.2 Distribution of advanced neoplasia at screening 
The distribution of advanced neoplasia is shown in Table 7.1. 
Table 7.1 Distribution of advanced neoplasia at screening 
 
Advanced 
neoplasia 
Participants with 
HGD 
N (%) 
Participants 
with VH 
N (%) 
Participants with adenoma 
>10 mm 
N (%) 
Present 1028 (14.7) 4057 (57.8) 5508 (78.5) 
Absent 5881 (83.8) 2985 (42.2) 1287 (18.3) 
Missing values 106 (1.5) 0 220 (3.1) 
Proximal 
location 
958 (13.6) 6045 (86.2) 12 (0.2) 
Note: 14.7% participants had HGD at screening; 57.8% had VH at screening; 78.5% had adenomas 
≥10 mm size during screening; and 13.6% had an adenoma in proximal colon during screening. HGD = 
high-grade dysplasia; VH = villous histology. 
 
7.4.3 Distribution of the number of adenomas at screening  
Table 7.2 shows the number of adenomas per participant at screening. 
Table 7.2 Adenomas per participant at screening 
 
Number of adenomas Number of participants % 
1 1418 20.2 
2 1388 19.8 
3 1393 19.9 
4 1025 14.6 
≥5 1791 25.5 
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Just over one quarter of participants (25.5%) had five adenomas at screening; 20.2% had one 
adenoma; 19.9% had three adenomas; and 19.8% had two adenomas. Participants with four 
adenomas at screening had the lowest proportion (14.6%). 
7.4.4 Outcomes at first surveillance 
Participants were categorized into four groups according to the outcomes at surveillance. 
The groups were those with a normal result, those with a NAA, those with an AA and those 
with CRC. The group with normal results was chosen as the reference group for logistic 
regression analysis. Table 7.3 shows the distribution of outcome at first surveillance. 
Table 7.3 Distribution of outcome at first surveillance 
Outcome at first surveillance Number of participants % 
Normal 620 8.8 
NAA 5566 79.3 
AA 786 11.2 
CRC 43 0.6 
Note: NAA = non-advanced adenoma; AA = advanced adenoma; CRC = colorectal cancer. 
At first surveillance, the majority of participants had NAAs (79.3%) and the lowest 
proportion of participants had CRC (0.6%). 
7.4.5 Univariate regression analysis: the effect of predictive factors 
Univariate multinomial logistic regression analysis was performed to evaluate the individual 
effect of each predictor. The results of the analysis are shown in Table 7.4. 
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Table 7.4 Results of the univariate multinomial regression analysis 
Predictor  Reference NAA 
OR 
(95% 
CI) 
NAA 
P 
AA 
OR  
(95% CI) 
AA 
P 
CRC 
OR 
(95% CI) 
CRC 
P 
Male gender Present 0.94 
(0.78–
1.13) 
0.55 1.55 
(1.2–
1.9) 
<0.001 0.92(0.4
7–1.8) 
0.83 
Female gender 
(Ref) 
Ref – – – – – – 
VH Present 0.88 
(0.74–
1.05) 
0.16 0.90 
(0.72–
1.13) 
0.164 0.63 
(0.31–
1.3) 
0.2 
No VH (Ref) Ref  – – – – – 
HGD – 1.05(0.
76–
1.45) 
0.73 0.87 
(0.57–
1.31) 
0.5 0.91 
(0.27–
3.09) 
0.89 
No HGD (Ref) Ref – – – – – – 
 
Number of 
adenomas (1-
Ref)
a 
Ref – – – – – – 
5 – 1.1 
(0.84–
1.43) 
0.47 1.7 
(1.2–
2.5) 
0.002 2.4 
(0.9–
6.06) 
0.05 
4 – 0.92 
(0.69–
1.2) 
0.6 1.74 
(1.21–
2.5) 
0.002 1.72 
(0.6–
4.9) 
0.3 
3 – 1.06 
(0.8–
1.3) 
0.6 1.2 
(0.91–
1.6) 
0.01 1.8 
(0.7–
4.5) 
0.21 
2 – 0.96 
(0.7–
1.1) 
0.7 1.2 
(0.91–
1.6) 
0.16 1.02 
(0.38–
2.7) 
0.96 
Adenoma 
≥10 mm 
Present 0.92 
(0.77–
1.1) 
0.37 0.68 
(0.55–
0.85) 
0.001 0.62(0.3
2–1.2) 
0.16 
Adenoma 
<10 mm (Ref) 
Ref – – – – – – 
Proximal 
location  
Present 1.2 
(0.9–
1.6) 
0.06 2.1 
(1.5–
2.9) 
<0.001 1.9 
(0.86– 
4.3) 
0.1 
Note: 
a
1-Ref = participants with one adenoma. OR = odds ratio; CI = confidence interval; NAA = non-
advanced adenoma; AA = advanced adenoma; CRC = colorectal cancer; VH = villous histology; HGD = 
high-grade dysplasia. 
158 
 
According to the univariate analysis, male sex increased the odds of having an AA at first 
surveillance. Having three or more adenomas at screening or having an adenoma ≥10 mm at 
screening also increased the odds of having an AA at first screening. 
7.4.6       Multivariate regression analysis: the effect of predictive factors 
A multivariate analysis was performed to determine the main effects of the predictor 
variables on the surveillance outcomes, by using forced entry of factors into the regression 
analysis. The results are shown in Table 7.5. (The significant findings are shown in bold). 
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Table 7.5 Results of the multivariate analysis 
Predictor factor Normal NAA 
OR  
(95% CI) 
NAA 
P 
AA 
OR 
(95% CI) 
AA 
P 
CRC 
OR (95% 
CI) 
CRC 
P 
Male gender Present 0.94 (0.77–
1.14) 
0.56 1.39 
(1.07–1.8) 
0.01 0.84 
(0.41–
1.7) 
0.64 
Female gender 
(Ref) 
Ref – – – – – – 
VH Present 0.83 (0.67–
1.02) 
0.08 1.06 
(0.81–1.4) 
0.63 0.62 
(0.26–
1.4) 
0.27 
No VH (Ref) 
 
–  – – – – – 
HGD Present 1.14 (0.82–
1.6) 
0.42 1.08 (0.7–
1.68) 
0.71 1.3 
(0.37–
4.7) 
0.66 
No HGD (Ref) – – – – – – – 
Number of 
adenomas (1-
Ref) 
Ref – – – – – – 
5 Present 1.16 (0.85–
1.59) 
0.32 2.9 (2.05–
4.3) 
<0.001 2.2 
(0.81–
6.2) 
0.11 
4 Present 1.01 (0.73–
1.3) 
0.95 1.74 (1.1–
2.6) 
0.007 1.7 
(0.59–
5.4) 
0.3 
3 Present 1.05 (0.8–
1.3) 
0.7 1.4 (0.99–
2.03) 
0.05 1.3 
(0.46–
3.7) 
0.6 
2 Present 0.93 (0.7–
1.1) 
0.5 1.2 (0.91–
1.7) 
0.15 1.02 
(0.38–
2.7) 
0.96 
Adenoma 
≥10 mm 
Present 0.98 (0.79–
1.2) 
0.88 0.85 
(0.64–1.3) 
0.2 0.86 
(0.38–
1.9) 
0.73 
Adenoma 
<10 mm (Ref) 
Ref – – – – – – 
Proximal 
location  
Present 1.2 
(1.9–2.7) 
0.1 1.8 
(1.3–2.6) 
<0.001 1.8 
(0.74–
4.3) 
 
0.18 
Note: OR = odds ratio; CI = confidence interval; NAA = non-advanced adenoma; AA = advanced 
adenoma; CRC = colorectal cancer; VH = villous histology; HGD = high-grade dysplasia. 
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Male sex and the detection of 3–5 adenomas, and any adenoma in the proximal colon, were 
significant predictors for detecting advanced adenomas at first surveillance. 
7.5 Effect of surveillance interval on outcomes at first surveillance 
In the data set used to analyse predictor factors at surveillance, 3107 participants were 
stratified as HR at screening. The surveillance interval for them varied beyond one year in 
the programme. Any deviations from the BSG guidelines were because of practical reasons 
related to: communicating with participants; participant compliance; participants changing 
residence; and developing a workforce in the early stages of the screening programme. 
HR participants were divided into three different groups according to the surveillance 
intervals of <1.5 year, 1.5–3 years and >3 years. The group with the surveillance interval of 
<1.5 year was the group where surveillance procedures could be performed according to the 
BSG guidelines. This group was used as the reference group in the regression analysis when 
evaluating whether increasing the surveillance interval would have any effect on the 
surveillance outcomes. The results are shown in Tables 7.6–7.8. 
Table 7.6 Distribution of surveillance interval for HR participants  
Surveillance interval (years) Number (%) 
<1.5 3107 (84.6) 
1.5–3 286 (7.8) 
>3 278 (7.6) 
 
The majority of HR participants had their surveillance within one and a half years. 
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Table 7.7 Distribution of surveillance outcome in the three HR groups  
 
Surveillance <1.5 years Surveillance 1.5–
3 years 
Surveillance >3 years 
Outcome 
 
Count % Count % Count % 
Normal 
 
279 9.0 14 5.0 13 4.5 
NAA 2405 77.4 195 70.1 218 76.2 
AA 399 12.8 67 24.1 55 19.2 
CRC 24 0.8 2 0.7 0 0.0 
Total 3107 100% 278 100% 286 100% 
Note: NAA = non-advanced adenoma; AA = advanced adenoma; CRC = colorectal cancer. 
The majority of HR participants had NAAs in all three surveillance interval groups. 
Table 7.8 Results of the regression analysis 
Outcome Surveillance 
interval (years) 
Coefficient Z  P OR 95% CI 
NAA >3 0.665 5.179 0.023 1.94 1.09–3.4 
NAA 1.5–3 0.48 2.858 0.091 1.61 0.92–2.8 
NAA Reference (<1.5) – – – – – 
AA >3 1.085 11.62
5 
0.001 2.958 1.59–5.5 
AA 1.5–3 1.208 15.78
2 
<0.001 3.346 1.84–6.07 
AA Reference (<1.5) – – – – – 
CRC >3 −19.428 – – – – 
CRC 1.5–3 0.507 0.417 0.518 1.661 0.36–7.74 
CRC Reference (<1.5) – – – – – 
Note: OR = odds ratio; CI = confidence interval; NAA = non-advanced adenoma; AA = advanced 
adenoma; CRC = colorectal cancer. 
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Compared to standard surveillance, when surveillance took place after three years for a HR 
participant the odds for the detection of AAs and NAAs increased significantly without 
increasing the odds for CRC. 
Compared to standard surveillance, when surveillance took place between one and a half 
and three years for a HR participant, the odds for detection of AAs increased significantly 
without increasing the odds for CRC. 
These results provide an opportunity to reassess and possibly increase the surveillance 
interval and use the colonoscopy workforce more appropriately. Surveillance procedures 
could safely be reduced, thus allowing the use of a finite, skilled workforce in a cost-effective 
manner. 
The majority of the IR group had a non-neoplastic yield at first surveillance, signifying that 
the surveillance interval for this group could be safely prolonged. 
Continuing surveillance showed a significant reduction in the proportion of patients with 
AAs, thereby indicating the long-term effectiveness of polypectomy in the screening cohort. 
7.6 Discussion 
In the BCSP population, male sex, the number of the adenomas and the proximal location of 
any adenoma at screening were associated with an increased risk of detecting AAs at first 
surveillance in the HR and IR groups. Increasing adenoma size and the presence of advanced 
histological features were not associated with increased detection of AAs at first 
surveillance. 
In the univariate analysis, multiple adenomas (≥3), proximal location, male sex and 
increasing size (≥10 mm) were associated with the detection of AAs at first surveillance; 
however, in the multivariate analysis, adenoma size failed to reach significance. The 
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association between the number of adenomas at screening and the detection of AAs at 
surveillance is similar to the findings of the NPS [48] and the other studies mentioned 
previously. The evidence derived from population-based studies is valid when stratifying the 
BCSP population into different risk groups according to the number of adenomas detected at 
screening. The BCSP population belongs to the 60–74-year age group, where colorectal 
adenomas are common and patients with multiple adenomas could continue to develop 
metachronous adenomas in the future [46, 77, 134]. Also, the presence of multiple 
adenomas at baseline increases the likelihood of AAs detected at surveillance because of 
missed lesions at the initial colonoscopy; this has been proved by tandem colonoscopy 
studies [78, 135]. 
Proximal location of adenomas at screening was associated with the detection of AAs at 
surveillance, which has also been demonstrated by other studies [65, 101, 135]. This 
association in the BCSP population may represent a cohort of patients with adenomas of 
different tumour biology with the potential for developing metachronous lesions at 
surveillance. 
In contrast to other studies, the presence of advanced histological features did reach a 
significant association with the detection of AAs at surveillance, which indicates that the 
current BSG strategy of risk stratification without histological characteristics is valid for the 
BCSP population. It also demonstrates that the subjective variations that have been reported 
and studied when assessing HGD and VH [136, 137] are often associated with a lack of 
definite objectivity and hence have failed to demonstrate any significant ORs for AAs at 
surveillance. 
The HR group, who had their first surveillance after one and a half or three years after 
screening, did not show any higher OR for CRC at first surveillance; this reinforced the 
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established protective role of polypectomy [46]. The OR for CRC did not increase in any of 
the delayed surveillance HR groups, but the OR for AAs and NAAs increased. This means that 
the surveillance interval can be safely increased in this group without any additional 
increased risk of CRC. The fact that the time required for developing invasive carcinoma from 
an adenoma requires 5–20 years [30] illustrates that increasing the surveillance interval after 
a clearing colonoscopy is safe. Also, the high-quality colonoscopy that was delivered within 
the setting of the BCSP provides better examination and clearance; hence, the surveillance 
interval could safely be prolonged in the HR group. The current European guidelines 
recommended a surveillance interval of three years for HR patients within the setting of 
high-quality colonoscopy [16]. An increase in the interval would allow the cost-effective use 
of a skilled resource. 
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Chapter 8: Discussion and conclusions 
8.0 Introduction 
This chapter summarizes the major findings of this thesis and their relevance in the 
background of existing evidence in the literature and their implications. It also discusses any 
improvements that could be incorporated in future work of a similar nature and the 
direction of future research in the field of colorectal adenoma surveillance. Finally, it 
includes personal reflections from the experience gained during the period of the work. 
8.1 Main findings 
The main findings are enumerated below. 
1.  In the BCSP population, the majority of the adenomas were located in the combined 
regions of the rectum and sigmoid colon (50.13%) and most were detected in the distal 
colon (62.52%) (see Table 5.3 and Figure 5.3). The distribution of adenomas in the BCSP 
population is in keeping with the epidemiological studies that have demonstrated similar 
distributions [33, 112]. The distributions of adenomas in the BCSP population follows the 
pattern described in those epidemiological studies describing the natural history of 
colorectal adenomas. Also, it is important to remember that these data represented subjects 
who were derived from a FOBT-positive population and thus left sided adenomas with 
bleeding are more likely to be picked up than from an undifferentiated, unscreened 
population.  
2. The proportion of adenomas containing advanced histological features increased with 
increasing size of the adenoma up to 35 mm, which was followed by a plateauing trend 
signifying the increasing neoplastic potential with increasing size. The prevalence of  
advanced histology in adenomas of different size categories has also been well documented 
[45, 113–116]. These studies evaluated various patient and adenoma-specific factors that 
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are important determinants of the presence of advanced histological features in adenomas. 
One of the consistent findings is the increased prevalence of advanced histological features 
with increasing adenoma size, reflecting progressive tumorigenesis of colorectal adenomas.  
3. Segmental location of the adenomas was associated with a significant different potential 
to have ACN. An adenoma located in the rectum was twice as likely to have advanced 
neoplasia compared to an adenoma located in the caecum; adenomas located in the 
caecum, AC, HF, TC, SF and DC demonstrated lower ORs for advanced neoplasia. Adenomas 
located in the TC demonstrated the lowest odds for having advanced neoplasia.  
There are several studies [115, 116] which have identified that left sided location is an 
independent risk factor for adenomas to acquire advanced histological features. The results 
in this thesis indicated that even in the left sided colon different segments of the large bowel 
had different potentials for adenomas to develop ACN. This signifies that in the FOBT 
positive BCSP cohort of subjects, the different segments of colon have different tumorigenic 
potential. This could be due to complex interaction of faecal loading, differential segmental 
gut microbiota, differential exposure of carcinogens to different segment of bowel [81] 
leading to different carcinogenic mutations. This would need further evaluation with studies 
involving histological and cytogenetic assessment of the colorectal adenomas from different 
segments of large bowel. These facts emphasised that the adenomas in the different 
segments of the left side of the large bowel would need more thorough examination and 
evaluation during screening colonoscopies due to a higher probability of harbouring CAN. 
4. All left-sided adenomas were larger than right-sided adenomas and this was also true for 
adenomas with advanced neoplasia. The differences in size were statistically significant. The 
proportions of adenomas with advanced neoplasia were located more in the left side of the 
colon than the right side in all size categories and the difference was statistically significant. 
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This illustrates the fact that, in the BCSP population, left-sided adenomas had more 
advanced histological features.  
The differences between right- and left-sided AAs have been previously studied. Researchers 
reported that right-sided AAs were smaller that their left-sided counterparts and hence 
easier to miss during colonoscopy. Gupta et al. [127] performed a cross-sectional analysis of 
the histology performed at a single centre providing services to more than 1900 
endoscopists in 43 states in the USA. They studied 233 414 polyps removed from 142 686 
patients. They demonstrated that size distribution was similar in the right and left side of the 
colon for all polyps; however, in the case of AAs and adenomas with HGD or cancer, right-
sided adenomas were significantly smaller in size (adenomas with HGD and CRC: right vs. 
left, 8.2 vs. 12.4, P<0.001; AAs: right vs. left, 7.6 vs. 11.1; P<0.001). Their findings suggested 
that colonoscopy inconsistently protects against right-sided CRC as smaller AAs were easy to 
miss. This fact was further augmented by the evidence in another study which demonstrated 
a greater likelihood for missed and recurrent adenomas in the proximal colon [128]. 
We addressed these issues and the results have demonstrated that diminutive (<6 mm), 
small (6-9 mm) and larger adenomas (≥10 mm), and adenomas detected in the left colon 
had significantly higher proportions of ACN (see Tables 5.14 and 5.15, and Figure 5.6). Size 
distribution and the mean size of left-sided adenomas were significantly larger than right-
sided adenomas in this cohort and this was true for all adenomas and ACN (see Tables 5.16 
and 5.17 and Figures 5.6 and 5.7). When ACNs were considered, only then did the majority 
of right-sided ACNs belong to the sub-centimetre category (see Table 5.22), in contrast to 
the left side where the majority of ACNs were of ≥10 mm. This was purely because all 
adenomas in the left side were larger and hence had a higher proportion of advanced 
histology in each size category; this further supported the fact that the malignant potential 
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of the left-sided colonic epithelium is more than that of the right colon. The probability of a 
missed lesion in the right colon would be similar for all right sided adenomas (AAs and NAAs) 
as they are generally smaller than the left sided adenomas. The risk of missed lesions in 
right-sided colonic adenomas is not a phenomenon in isolation for advanced adenomas only 
in BCSP population. This implies a careful examination of right sided bowel during screening 
colonoscopy. Further research is needed in this field by studying various protected time slots 
for extubation times in different segment of bowel to identify the optimal time to enhance 
the detection of advanced adenoma in BCSP in right side of the large bowel. 
 
5. The presence of HGD, distal/left sided location, increasing size and female sex 
represented significantly higher ORs for the presence of carcinomas in adenomas which had 
been detected as polyps during colonoscopy in the BCSP, thereby demonstrating important 
factors associated with cancerous polyps. 
There are several studies which have looked into the important determinants for the 
presence of advanced histological features in adenomas. Increased prevalence of advanced 
histology with increasing size of the adenoma is reported I several studies [45, 113-116].  
Gschwantler et al. [115] has demonstrated size, left-sided location, VH and age as risk factors 
for advanced histology. But gender and multiplicity of adenomas failed to demonstrate any 
influence in that study.  
In the National Polyp Study (examined 3371 adenomas from 1867 patients) the size and 
extent of the villous component of the adenoma were the major independent risk factors 
associated with HGD [112]. The increased detection of HGD in distal adenomas was 
attributed to increased size and villous component rather than location. The sex of the 
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participants was not associated with HGD in this study. The multiplicity of factors influencing 
HGD was also dependent on size and VH.  
In another study Nusko et al. [116] performed a ‘per-adenoma’ analysis that included a total 
of 11 188 adenomas removed during the period from 1978 to 1993. Adenoma size proved to 
be the most important factor followed by left-sided location. They also demonstrated 
complex interaction between sex and a multiplicity of factors predicting for higher risk of 
CRC in adenomas. 
In contrast to In contrast to two of the studies mentioned earlier [115, 116], a very small 
proportion of adenomas <6 mm in size (79/72 815; 0.1%) were shown to contain a focus of 
cancer (see Table 5.4 and Figure 5.5). This perhaps shows that some of the CRCs developed 
de novo from the epithelium and some developed cancer through a different carcinogenesis 
pathway than the adenoma–carcinoma sequence, where increasing size is a driving factor in 
developing a malignant focus. This pathway was described as a de novo pathway; according 
to this hypothesis, CRC can also develop de novo from normal mucosa. This pathway is well 
described in the Western and Japanese literature [117–120]. 
Adenoma size appears to be a crucial factor associated with advanced histology in the 
current literature which is also the finding of this current study. The distribution of advanced 
histology demonstrated that the proportion of adenomas containing advanced histological 
features increased with increasing size of the adenomas up to 35 mm, after which it 
plateaued (see Figure 5.5). The left sided location and HGD is also found to be important 
factors as in other studies. The importance of female gender in NHS BCSP is perhaps 
reflecting the fact of increased life expectancy of female population in UK, but this area 
needs more research among the NHS BCSP population.  
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6. A very small proportion of patients had CRC at first surveillance and in subsequent 
surveillance procedures and hence, the current screening interval is safe.  
Winawer et al. [46] followed a cohort of 1418 patients with sporadic colorectal adenoma for 
an average period of 5.9 years. These were the participants of the NPS, an RCT evaluating 
the effectiveness of surveillance on patients discovered to have one or more colorectal 
adenomas. The incidence of CRC during the follow-up period was compared with three 
reference groups; in two of them, colorectal adenomas were not removed, while the third 
reference group was derived from a population-based registry. A significant reduction in CRC 
incidence (90, 80 and 76% compared to the three groups; P<0.001) was achieved. 
Similar results were demonstrated with continuing follow up with NPS study patient cohort 
over a longer period of time (median follow-up period = 15.8 years) and a significant 
reduction in mortality from CRC compared to the general population. Brenner et al. [82] 
performed a population-based case-control study and showed that a colonoscopy 
performed within the preceding 10 years was associated with a 77% lower risk of developing 
CRC. 
This evidence suggests that colonoscopy and polypectomy is leading to the reduction of 
incidence of CRC during follow-up and also confers a protective effect from mortality from 
CRC. Thus, the protective effect of the high-quality colonoscopy offered by the BCSP at 
during screening and surveillance is translating in to a low incidence of CRC and AAs during 
surveillance.  
Ongoing surveillance demonstrated a significant reduction in the proportion of patients with 
AAs indicating the long-term effectiveness of polypectomy in the screened cohort. Advanced 
neoplasia detected at second surveillance was of a very small magnitude. 
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7. The results during the first surveillance in this thesis demonstrated a higher yield of AAs in 
the HR group at first surveillance compared to the IR group and thus establishing the fact 
that the current surveillance stratification strategy is effective. The majority of the IR group 
had a non-neoplastic yield at first surveillance, signifying that the surveillance interval for 
this group could be safely prolonged. 
8. The risk stratification analysis has demonstrated in this thesis that the number of 
adenomas (≥3), proximal location and male sex demonstrated higher ORs for detection of 
AAs at first surveillance in both HR and IR groups. This supports the validity of the current 
guidelines for the BCSP cohort. 
These findings are similar to the findings of others.  Martínez et al. [65] studied the risk of 
developing AAs and CRC after polypectomy. Their study included 9167 participants with 
sporadic colorectal adenomas from eight different prospective North American studies. 
Participants were followed up for a long period, with a median follow-up of 47.2 months. 
Male gender, number and size of prior adenomas the presence of villous features, and 
proximal location were the factors which were found to be significantly associated with an 
increased risk for metachronous advanced neoplasia.  
Similar findings of multiplicity and size of the adenoma being the significant factors were 
also identified in other studies [88, 48, 78, 135]. 
Proximal location of adenomas at screening was associated with the detection of AAs at 
surveillance, which has also been demonstrated by other studies [65, 101, 135]. This 
association in the BCSP population may represent a cohort of patients with adenomas of 
different tumour biology with the potential for developing metachronous lesions at 
surveillance. 
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Thus the evidence derived from population-based studies is valid when stratifying the BCSP 
population into different risk groups according to the number of adenomas detected at 
screening. 
9. An increased surveillance interval (up to three years) in the HR group was not associated 
with any risk of increased detection of CRC at surveillance but was associated with increased 
detection of AAs; hence, the surveillance interval in this group can safely be prolonged. 
The small number of HR group patients who had their surveillance after three years did not 
reveal any significant increased detection of CRC. This reflects the protective effect of the 
polypectomy and also suggests that the surveillance interval could be safely increased 
beyond 12 months. However, the increased detection of AAs in the group with surveillance 
interval more than three years suggests new onset metachronous lesions and hence, 
increasing surveillance interval in this group would need participant involvement in shared 
decision making prior to plan for future surveillance. 
8.2 Opportunities and limitations 
The BCSP database provided a unique opportunity to capture the data and information that 
were collected contemporaneously. Epidemiological risk factors (for example, 
smoking/alcohol consumption, family history of CRC) and metabolic factors (for example, 
body mass index, diabetes) associated with colorectal adenomas could have been 
incorporated in the current study to evaluate their importance in the screened population. If 
the data regarding acetylsalicylic acid and non-steroidal anti-inflammatory drug use in this 
population were available and incorporated, then their protective effect in the screened 
population could have been assessed.  
Detection and removal of colorectal adenomas require high-quality colonoscopy, and good 
bowel preparation is an important part of that. Although the colonoscopies performed in the 
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BCSP are of a high quality and delivered in a quality control setting with continuing 
governance, there were variations in performance and the performance indicators and 
variability in bowel preparations could have been included in the model to assess their 
importance in risk stratification analysis.  
The data collected for this thesis is a reflection of practice amongst the screening 
colonoscopists practising during the time period of this study.  Alhough they all achieved 
certain performance indicators, there are likely to have been performance differences and a 
further study including their adenoma detection rates and withdrawal times for each 
colonoscopy procedure would help to make the analysis more robust and could quantify and 
equilibrate for such differences. 
The missing data about the polyp histology led to loss of 40.3% polyps, which could not be 
included for analysis for descriptive part of the study (chapter 5). This is a weakness of this 
work, but was an unavoidable strategy for analysis and statistical imputation could not 
account for complex biological factors responsible for development and progression of 
polyps. A comparison between adenomas detected in screening and surveillance could have 
demonstrated the true prevalence and incidence of colorectal adenoma in the NHS BCSP 
population and any fundamental difference among screening and surveillance polyps.  
Furthermore the quality of the data in any database research depends in the accuracy of the 
data. Missing data in the database for this research accounts for an unknown degree of 
variation in the results; ideally prospective further research is needed to re-inforce the 
findings of this work. 
 
There could have been patients in NHS BCSP diagnosed with interval cancers during the 
study period who were not included in the surveillance database due to lack of participation 
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in adenoma surveillance. Incorporation of interval cancer data could have demonstrated 
strength or weakness of the quality of the screening colonoscopies in BCSP and could have 
also demonstrated valid risk factors in screening population indicative of interval cancer. 
The overall numbers of participants in their second surveillance, particularly with respect to 
IR group are low in this study, restricting the ability to reach valid conclusions about the 
need of continuing surveillance. This could have been possible by extending the study period 
for at least three more years but this this was beyond the academic duration of this research 
and could not be done. The overall observation of the adenoma surveillance in this 
retrospective study demonstrated gradual diminished incidence of advanced adenomas and 
detection of very small numbers of colorectal cancers. This provides the reassurance to 
perform future randomised controlled trials with different surveillance intervals among HR 
and IR group to identify new evidenced based guidance for NHS BCSP which could be safe, 
and cost effective. This could also lead to a new era where surveillance intervals can be 
decided by shared decision making with more participation from the people screened. The 
current recommendations are didactic and not based on patient participation. These 
approaches would also require qualitative research looking into decision making processes 
involving the participants in NHS BCSP. 
8.3 Personal reflection 
This was a fascinating journey for me over a period of almost four years. It improved my 
understanding of database management and the rigorous methods of data processing and 
the transformation of a raw database to analysable data sets. The various courses and 
modules I took taught me to use a range of statistical software packages and their particular 
usefulness at various stages of data processing and analysis. My experience of working 
continuously with an expert statistician demonstrated the effectiveness and the need of 
175 
 
collaboration between clinicians and scientists to perform useful clinical research that can 
improve patient care. The continuous time struggle between my clinical and research 
workload and deadlines highlighted the need for protected academic time to perform a 
research activity. 
Overall, this study was very satisfactory and demonstrated the safety of current practice in 
the BCSP, the validity of the current surveillance guidelines for the BCSP population and the 
safety of increasing surveillance intervals for both IR and HR groups, which will be more cost-
effective. 
8.4 Future research 
The results from this study demonstrate that the surveillance interval could probably be 
safely prolonged in both HR and IR groups. This assures the safety of performing a 
prospective RCT for different surveillance intervals both for HR and IR groups. The 
magnitude of detection of advanced neoplasia was minimal at second surveillance and the 
number of patients reaching their third surveillance was minimal.  
To address the problematic knowledge gap, and wide variability in adenoma surveillance in 
guidelines in different countries, a large group of investigators in Sweden, Norway, Poland, 
the Netherlands and Spain have decided to undertake a large-scale multicentre randomized 
trials for colorectal adenoma surveillance and the project is named as “European Polyp 
Surveillance Trials (EPoS)” (138). This study has three arms. This study has started to recruit 
patients in April 2015, constitute two parallel-group randomized controlled trials: EPoS I for 
patients with low-risk adenomas; EPoS II for patients with high-risk adenomas. EPoS III is an 
observational study for patients with serrated polyps. The primary end point in EPoS I, II, and 
III will beCRC incidence over 10 years. CRC incidence will be compared in the different arms 
in EPoS I and II, as well as across EPoS I and II, and compared with EPoS III. The secondary 
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end points will also be compared in the different arms in EPoS I and II, across EPoS I and II, 
and compared with EPoS III, and these will include cost effectiveness, yield of adenomas and 
serrated polyps with different subtypes during follow up period and  major adverse events in 
surveillance colonoscopy. This study in future will provide further evidence to develop a new 
cost effective and safe surveillance guideline. 
Continuing adenoma surveillance programmes and their success will need participation from 
the BCSP population. Research is needed focussing on shared decision making for 
surveillance planning. Though the programme is based on available evidence, new onset co-
morbidities could be an important issue in this age group of (60 to 74 years) subjects and 
hence their perspectives need to be included, and hence share decision making tools need 
to developed through qualitative research in NHS BCSP, involving the participants. 
A further study of the BCSP population is needed to capture a sufficient number of HR and IR 
patients completing their second and third surveillances. Since the programme was started 
in 2006, the second half of 2016 would provide sufficient data to perform that study; if the 
advanced neoplastic yield is minimal, then the BCSP population can safely be assessed with a 
screening tool after first surveillance rather than undergoing second surveillance, and that 
would be safe and cost-effective. 
There are opportunities and a need to evaluate the epidemiological and metabolic factors 
and assess their association with advanced neoplasia during index screening procedures and 
during surveillance to weigh their importance in risk stratification, and including the 
cytogenetic factors in it could led to develop a new era in adenoma surveillance where 
individualistic evidence based surveillance guideline formulation is a possibility. 
Another limitation of this study was that results derived the FOBT positive NHS BCSP 
population of a defined age group and hence the results would not be translated in real 
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terms to adenoma surveillance for non-BCSP, symptomatic populations. Further research 
looking into the adenoma surveillance into a symptomatic population would be needed to 
validate that. 
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